[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 372
1. Foo FJ, Gill U, Verbeke CS, Guthrie JA, Menon KV: Ampullary carcinoma associated with an annular pancreas. JOP; 2007;8(1):50-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ampullary carcinoma associated with an annular pancreas.
  • CASE REPORT: We present a case report of a 78-year-old woman with jaundice due to an ampullary carcinoma associated with an annular pancreas treated by pancreaticoduodenectomy.
  • [MeSH-minor] Aged. Ampulla of Vater / surgery. Female. Humans. Pancreaticoduodenectomy

  • Genetic Alliance. consumer health - Annular Pancreas.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17228134.001).
  • [ISSN] 1590-8577
  • [Journal-full-title] JOP : Journal of the pancreas
  • [ISO-abbreviation] JOP
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Italy
  • [Number-of-references] 21
  •  go-up   go-down


2. Milsmann C, Füzesi L, Werner C, Becker H, Horstmann O: [Significance of occult lymphatic tumor spread in pancreatic cancer]. Chirurg; 2005 Nov;76(11):1064-72
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Significance of occult lymphatic tumor spread in pancreatic cancer].
  • PURPOSE: The aim of this study was to determine the frequency and effect on prognosis of occult tumor cells in regional lymph nodes judged to be tumor-free in conventional histopathology of pancreatic cancer patients.
  • PATIENTS AND METHODS: Among 115 patients who underwent pancreatic resection for pancreatic (n=84) or distal common bile duct malignancy (n=12) or carcinoma of the papilla (n=19), 48 (42%) were staged pN0.
  • However, those cells were encountered more frequently in common bile duct carcinomas (100%) than in pancreatic (36%) or papilla (20%) carcinomas (P=0.009).
  • CONCLUSION: Occult tumor cells are frequent in apparently tumor-free lymph nodes of pancreatic cancer patients and often overlooked in conventional histopathology.
  • Occult tumor cells in lymph nodes of pancreatic cancer patients could be used to stratify adjuvant therapy.
  • [MeSH-major] Ampulla of Vater / surgery. Carcinoma, Ductal / surgery. Common Bile Duct Neoplasms / surgery. Lymph Node Excision. Lymphatic Metastasis / pathology. Pancreatectomy. Pancreatic Neoplasms / surgery
  • [MeSH-minor] Aged. Disease Progression. Female. Humans. Lymph Nodes / pathology. Male. Middle Aged. Neoplasm Staging. Prognosis. Survival Analysis

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Pancreas. 1997 Aug;15(2):154-9 [9260200.001]
  • [Cites] J Cancer Res Clin Oncol. 2004 Dec;130(12):733-40 [15378353.001]
  • [Cites] J Hematother. 1994 Fall;3(3):165-73 [7530132.001]
  • [Cites] Acta Cytol. 1992 Mar-Apr;36(2):241-5 [1371897.001]
  • [Cites] J Thorac Cardiovasc Surg. 1997 Sep;114(3):339-46 [9305185.001]
  • [Cites] Br J Cancer. 1999 Nov;81(5):870-3 [10555760.001]
  • [Cites] Pancreas. 2003 May;26(4):315-21 [12717261.001]
  • [Cites] Langenbecks Arch Surg. 1998 Apr;383(2):116-20 [9641883.001]
  • [Cites] Clin Cancer Res. 1997 Nov;3(11):2143-9 [9815608.001]
  • [Cites] Cancer. 2001 Aug 15;92(4):753-60 [11550144.001]
  • [Cites] Cancer. 1999 Dec 15;86(12):2668-73 [10594862.001]
  • [Cites] Am J Surg Pathol. 1999 Mar;23(3):263-7 [10078915.001]
  • [Cites] J Clin Oncol. 1994 Sep;12(9):1827-32 [8083707.001]
  • [Cites] Ann Surg. 1997 Sep;226(3):248-57; discussion 257-60 [9339931.001]
  • [Cites] Ann Surg. 2004 Dec;240(6):993-1000; discussion 1000-1 [15570205.001]
  • [Cites] Pancreas. 1997 Nov;15(4):374-8 [9361091.001]
  • [Cites] Cancer Res. 1987 Jun 1;47(11):2883-91 [3552208.001]
  • [Cites] J Clin Pathol. 1990 Mar;43(3):213-9 [1692040.001]
  • [Cites] Am J Surg. 1993 Jan;165(1):68-72; discussion 72-3 [8380315.001]
  • [Cites] Cancer. 1993 Oct 1;72 (7):2118-23 [8104092.001]
  • [Cites] N Engl J Med. 1997 Oct 23;337(17):1188-94 [9337377.001]
  • [Cites] Am J Gastroenterol. 2000 Aug;95(8):1939-45 [10950039.001]
  • [Cites] Eur J Surg. 1996 Aug;162(8):637-42 [8891622.001]
  • [Cites] Am J Surg Pathol. 2002 Dec;26(12):1578-87 [12459624.001]
  • [Cites] Am J Pathol. 1993 Apr;142(4):1111-8 [7682761.001]
  • [Cites] Int J Oncol. 2000 Jun;16(6):1165-71 [10811991.001]
  • [Cites] Chirurg. 2001 Aug;72(8):920-6 [11554137.001]
  • [Cites] Dis Colon Rectum. 1997 Dec;40(12):1465-71 [9407986.001]
  • [Cites] Surgery. 1998 Oct;124(4):663-9 [9780986.001]
  • (PMID = 15971035.001).
  • [ISSN] 0009-4722
  • [Journal-full-title] Der Chirurg; Zeitschrift fur alle Gebiete der operativen Medizen
  • [ISO-abbreviation] Chirurg
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


3. Fu H, Gao MK, Qu XL, Sun GF, Shen L: [Periampullary carcinoma with situs inversus totalis: case report and review of the literature]. Zhonghua Wei Chang Wai Ke Za Zhi; 2007 Mar;10(2):134-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Periampullary carcinoma with situs inversus totalis: case report and review of the literature].
  • OBJECTIVE: To explore the diagnosis and surgical treatment of patients with periampullary carcinoma and situs inversus totalis.
  • METHODS: The data of a patient with periampullary carcinoma and complete situs inversus totalis, a rare disease treated in our hospital on Mar.
  • RESULTS: This patient was diagnosed with stage I to II of periampullary carcinoma.
  • From 1936 to 2006, 15 malignant tumors with situs viscerum inversus totalis were reported, only 5 periampullary carcinomas with situs viscerum inversus totalis were reported.
  • CONCLUSIONS: Surgical operation should be considered for malignant tumor patients with situs inversus totalis without contraindication.
  • [MeSH-major] Ampulla of Vater. Duodenal Neoplasms / complications. Situs Inversus / complications
  • [MeSH-minor] Humans. Middle Aged. Pancreatic Neoplasms / complications

  • Genetic Alliance. consumer health - Situs inversus.
  • MedlinePlus Health Information. consumer health - Intestinal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17380452.001).
  • [ISSN] 1671-0274
  • [Journal-full-title] Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  • [ISO-abbreviation] Zhonghua Wei Chang Wai Ke Za Zhi
  • [Language] chi
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


Advertisement
4. Sheehan MM, Fraser A, Ravindran R, McAteer D: Bile duct brushings cytology--improving sensitivity of diagnosis using the ThinPrep technique: a review of 113 cases. Cytopathology; 2007 Aug;18(4):225-33
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bile duct brushings cytology--improving sensitivity of diagnosis using the ThinPrep technique: a review of 113 cases.
  • OBJECTIVE: Common bile duct (CBD) brushings have been recognized as a technique of moderate sensitivity and high specificity in identifying carcinoma of the ampulla and pancreatico-biliary regions.
  • Five categories of reporting were used: inadequate, negative, atypia, suspicious and malignant.
  • Sensitivity of diagnosis of malignancy increased from 39% in conventional smears to 53% in the ThinPrep group.
  • CONCLUSIONS: ThinPrep technique was associated with increased sensitivity of diagnosis, in part due to improved specimen fixation and reduced artefact.
  • It may therefore provide the only opportunity for tissue diagnosis of carcinoma from these sites, hence the importance of optimizing sensitivity.
  • [MeSH-major] Common Bile Duct Neoplasms / diagnosis. Histocytological Preparation Techniques / methods. Pancreatic Neoplasms / diagnosis
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Ampulla of Vater / pathology. Biopsy / methods. Cell Nucleus / pathology. Cholangiopancreatography, Endoscopic Retrograde. Cytodiagnosis / methods. Female. Humans. Male. Middle Aged. Predictive Value of Tests. Reproducibility of Results. Sensitivity and Specificity

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17488259.001).
  • [ISSN] 0956-5507
  • [Journal-full-title] Cytopathology : official journal of the British Society for Clinical Cytology
  • [ISO-abbreviation] Cytopathology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


5. Alsaif F: Pylorus preserving pancreaticoduodenectomy for peri-ampullary carcinoma, is it a good option? Saudi J Gastroenterol; 2010 Apr-Jun;16(2):75-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pylorus preserving pancreaticoduodenectomy for peri-ampullary carcinoma, is it a good option?
  • Pancreaticoduodenectomy (PD) is the standard surgical treatment for resectable peri-ampullary tumors.
  • [MeSH-major] Carcinoma / mortality. Carcinoma / surgery. Pancreatic Neoplasms / mortality. Pancreatic Neoplasms / surgery. Pancreaticoduodenectomy / methods. Pylorus
  • [MeSH-minor] Ampulla of Vater / pathology. Ampulla of Vater / surgery. Anastomosis, Surgical / adverse effects. Anastomosis, Surgical / methods. Blood Loss, Surgical. Blood Transfusion. Female. Follow-Up Studies. Gastric Emptying / physiology. Hospital Mortality / trends. Humans. Intraoperative Complications / mortality. Length of Stay. Male. Neoplasm Recurrence, Local / mortality. Neoplasm Recurrence, Local / pathology. Postoperative Complications / mortality. Postoperative Complications / prevention & control. Randomized Controlled Trials as Topic. Survival Analysis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] World J Surg. 2000 Jan;24(1):66-70; discussion 70-1 [10594206.001]
  • [Cites] Surg Gynecol Obstet. 1946 Jun;82:623-31 [20983134.001]
  • [Cites] J Hepatobiliary Pancreat Surg. 2000;7(2):193-7 [10982613.001]
  • [Cites] World J Surg. 2000 Oct;24(10):1236-41; discussion 1242 [11071469.001]
  • [Cites] Dig Dis Sci. 2000 Oct;45(10):1907-12 [11117559.001]
  • [Cites] J Gastroenterol. 2002;37(8):596-603 [12203074.001]
  • [Cites] J Am Coll Surg. 2003 Jun;196(6):859-65 [12788421.001]
  • [Cites] Surgery. 2003 Jun;133(6):647-55 [12796733.001]
  • [Cites] J Gastrointest Surg. 2003 Sep-Oct;7(6):758-65 [13129553.001]
  • [Cites] Am J Surg. 2004 Jun;187(6):743-6 [15191869.001]
  • [Cites] Surg Gynecol Obstet. 1978 Jun;146(6):959-62 [653575.001]
  • [Cites] Ann Surg. 1980 Sep;192(3):306-10 [7416828.001]
  • [Cites] Surgery. 1989 May;105(5):645-53 [2650006.001]
  • [Cites] Am J Surg. 1991 Jan;161(1):120-4; discussion 124-5 [1987845.001]
  • [Cites] Ann Surg. 1993 Feb;217(2):144-8 [8094952.001]
  • [Cites] Surgery. 1997 Sep;122(3):553-66 [9308613.001]
  • [Cites] J Am Coll Surg. 1997 Oct;185(4):373-9 [9328386.001]
  • [Cites] Am J Surg. 1998 Nov;176(5):467-70 [9874435.001]
  • [Cites] World J Surg. 1999 Sep;23(9):920-5 [10449821.001]
  • [Cites] Langenbecks Arch Surg. 1999 Aug;384(4):354-9 [10473855.001]
  • [Cites] J Hepatobiliary Pancreat Surg. 1999;6(3):303-11 [10526067.001]
  • [Cites] Ann Surg Oncol. 2005 Mar;12(3):222-7 [15827814.001]
  • [Cites] Cancer Treat Rev. 2005 Jun;31(4):328-31 [15905037.001]
  • [Cites] World J Surg. 2005 Jul;29(7):873-9; discussion 880 [15951944.001]
  • [Cites] World J Surg. 2005 Jul;29(7):881-4 [15951940.001]
  • [Cites] World J Surg. 2005 Oct;29(10):1319-24 [16284796.001]
  • [Cites] Langenbecks Arch Surg. 2006 Jun;391(3):195-202 [16491403.001]
  • [Cites] Ann Surg Oncol. 2007 Jun;14(6):1825-34 [17342566.001]
  • [Cites] World J Surg. 2007 Aug;31(8):1606-15 [17566824.001]
  • [Cites] J Hepatobiliary Pancreat Surg. 2008;15(3):262-9 [18535763.001]
  • [Cites] J Med Assoc Thai. 2008 May;91(5):693-8 [18672634.001]
  • [Cites] Eur J Surg Oncol. 2008 Nov;34(11):1237-45 [18242943.001]
  • [CommentIn] Saudi J Gastroenterol. 2010 Apr-Jun;16(2):65 [20339172.001]
  • (PMID = 20339174.001).
  • [ISSN] 1998-4049
  • [Journal-full-title] Saudi journal of gastroenterology : official journal of the Saudi Gastroenterology Association
  • [ISO-abbreviation] Saudi J Gastroenterol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Review
  • [Publication-country] Saudi Arabia
  • [Number-of-references] 36
  • [Other-IDs] NLM/ PMC3016509
  •  go-up   go-down


6. Lygidakis NJ, Jain S, Sacchi M, Vrachnos P: Reappraisal of a method of reconstruction after pancreatoduodenectomy. Hepatogastroenterology; 2005 Jul-Aug;52(64):1077-82
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND/AIMS: After pancreatoduodenectomy (PD), pancreatic leak and the functional pancreatic and gastrointestinal disorders are the most important complications.
  • The shortterm and long-term results assessed were mortality rate, morbidity rate, early reoperation, survival, steatorrhea, pancreatic enzyme supplementation requirement, occurrence of bile gastritis, dumping, new onset of diabetes, marginal ulcers, cholangitis, postoperative weight trends and frequency of hospital readmission for symptom management.
  • Follow-up was done 6 monthly in all the patients with the aim of diagnosis of recurrence and assessment of long-term gastrointestinal and pancreatic function and nutritional status.
  • In addition, in 15 patients, upper gastrointestinal endoscopy (UGIE) with gastric and jejunal biopsy, 99Tc-HIDA scan, determination of fecal fat loss after a standard 100-g fat diet for three days, fecal elastase-1 measurement (ELISA) and MRCP were done to objectively document the changes in gastrointestinal and pancreatic function.
  • Of all the PD cases 57 were for ampullary, 70 were for lower end cholangiocarcinoma and 98 were for pancreatic head cancer.
  • The overall 5-year survival for ampullary, lower end cholangio- and pancreatic head carcinoma were 65%, 25% and 20% respectively.
  • [MeSH-major] Ampulla of Vater / surgery. Bile Ducts, Intrahepatic / surgery. Cholangiocarcinoma / surgery. Common Bile Duct Neoplasms / surgery. Pancreatic Neoplasms / surgery. Pancreaticoduodenectomy / methods

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16001633.001).
  • [ISSN] 0172-6390
  • [Journal-full-title] Hepato-gastroenterology
  • [ISO-abbreviation] Hepatogastroenterology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


7. Sato Y, Ohwada S, Oyama T, Kashiwabara K, Totsuka O, Yamada T, Morishita Y: Ampullary carcinoma associated with protein-losing gastropathy due to diffuse varioliform gastritis. Hepatogastroenterology; 2005 Jul-Aug;52(64):1143-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ampullary carcinoma associated with protein-losing gastropathy due to diffuse varioliform gastritis.
  • Protein-losing gastropathy due to diffuse varioliform gastritis is a rare condition, and its occurrence accompanying ampullary carcinoma is particularly rare.
  • We report here a case of ampullary carcinoma accompanied with protein-losing gastroenteropathy due to diffuse varioliform gastritis.
  • Upper gastrointestinal endoscopic examination showed diffuse varioliform gastritis and carcinoma of the papilla of Vater.
  • A diagnosis of protein-losing gastropathy was made based on the results of scintigraphy using technetium 99m-labeled human albumin.
  • Continuous bleeding from ampullary carcinoma caused anemia and deteriorated hypoproteinemia.
  • Pancreaticoduodenectomy was performed for ampullary carcinoma prior to Helicobacter pylori eradication.
  • [MeSH-major] Adenocarcinoma, Papillary / complications. Ampulla of Vater. Common Bile Duct Neoplasms / complications. Gastritis, Hypertrophic / pathology. Protein-Losing Enteropathies / etiology
  • [MeSH-minor] Adult. Female. Helicobacter Infections / diagnosis. Helicobacter Infections / therapy. Helicobacter pylori. Humans. Pancreaticoduodenectomy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16001648.001).
  • [ISSN] 0172-6390
  • [Journal-full-title] Hepato-gastroenterology
  • [ISO-abbreviation] Hepatogastroenterology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


8. Terasawa H, Uchiyama K, Tani M, Kawai M, Tsuji T, Tabuse K, Kobayashi Y, Taniguchi K, Yamaue H: Impact of lymph node metastasis on survival in patients with pathological T1 carcinoma of the ampulla of Vater. J Gastrointest Surg; 2006 Jun;10(6):823-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Impact of lymph node metastasis on survival in patients with pathological T1 carcinoma of the ampulla of Vater.
  • To determine the prognostic factors for patients with pathological T1 (pT1) carcinoma of the ampulla of Vater, 36 consecutive patients with carcinoma of the ampulla of Vater who underwent surgery were retrospectively analyzed in terms of clinicopathological features.
  • [MeSH-major] Ampulla of Vater. Common Bile Duct Neoplasms / mortality. Common Bile Duct Neoplasms / pathology. Lymphatic Metastasis
  • [MeSH-minor] Aged. Chemotherapy, Adjuvant. Female. Humans. Japan / epidemiology. Lymph Node Excision. Male. Middle Aged. Multivariate Analysis. Neoplasm Staging. Prognosis. Proportional Hazards Models. Retrospective Studies. Survival Analysis

  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] World J Gastroenterol. 2004 Feb 15;10(4):614-6 [14966929.001]
  • [Cites] Am J Surg Pathol. 2004 Jul;28(7):875-82 [15223956.001]
  • [Cites] Ann Surg. 1998 Jun;227(6):821-31 [9637545.001]
  • [Cites] Ann Surg. 1997 May;225(5):590-9; discussion 599-600 [9193186.001]
  • [Cites] Surgery. 2004 Nov;136(5):994-1002 [15523392.001]
  • [Cites] Hepatogastroenterology. 2004 Sep-Oct;51(59):1275-7 [15362731.001]
  • [Cites] Eur J Surg Oncol. 2005 Mar;31(2):158-63 [15698732.001]
  • [Cites] Ann Surg. 1996 Nov;224(5):621-7 [8916877.001]
  • [Cites] World J Surg. 1996 Jul-Aug;20(6):707-12 [8662157.001]
  • [Cites] Arch Surg. 1993 May;128(5):515-20 [8098205.001]
  • [Cites] Am J Surg. 2000 Jul;180(1):13-7 [11036132.001]
  • [Cites] Surgery. 1995 Mar;117(3):247-53 [7878528.001]
  • [Cites] Ann Surg Oncol. 2003 Dec;10(10):1176-83 [14654474.001]
  • [Cites] Arch Surg. 2003 Sep;138(9):941-8; discussion 948-50 [12963649.001]
  • [Cites] Hepatogastroenterology. 1994 Feb;41(1):73-8 [8175122.001]
  • [Cites] Arch Surg. 1991 Mar;126(3):353-7 [1998478.001]
  • [Cites] Arch Surg. 2001 Jan;136(1):65-9 [11146780.001]
  • [Cites] Br J Surg. 1995 Dec;82(12):1693-6 [8548244.001]
  • [Cites] Dig Surg. 2003;20(6):511-5 [14506332.001]
  • (PMID = 16769538.001).
  • [ISSN] 1091-255X
  • [Journal-full-title] Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
  • [ISO-abbreviation] J. Gastrointest. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


9. Botsios D, Zacharakis E, Lambrou I, Tsalis K, Christoforidis E, Kalfadis S, Zacharakis E, Betsis D, Dadoukis I: Our local experience with the surgical treatment of ampullary cancer. Int Semin Surg Oncol; 2005 Aug 30;2:16
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Our local experience with the surgical treatment of ampullary cancer.
  • BACKGROUND: The aim of this study is to report the outcome after surgical treatment of 32 patients with ampullary cancers from 1990 to 1999.
  • METHODS: Twenty-one of them underwent pancreaticoduodenectomy and 9 local excision of the ampullary lesion.
  • RESULTS: When the final histological diagnosis was compared with the preoperative histological finding on biopsy, accurate diagnosis was preoperatively established in 24 patients.
  • Following local excision of the ampullary cancer, the survival rate at 3 and 5 years was 77.7% and 33.3% respectively.
  • CONCLUSION: In this series, local resection was a safe option in patients with significant co-morbidity or small ampullary tumors less than 2 cm in size, and was associated with satisfactory long-term survival rates.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Surg. 1995 Dec;82(12):1693-6 [8548244.001]
  • [Cites] Cancer. 2002 Oct 15;95(8):1685-95 [12365016.001]
  • [Cites] Hepatogastroenterology. 1999 May-Jun;46(27):1973-9 [10430380.001]
  • [Cites] Arch Surg. 1999 May;134(5):526-32 [10323425.001]
  • [Cites] Ann Surg. 1990 Apr;211(4):447-58 [2322039.001]
  • [Cites] Am J Surg. 1989 Dec;158(6):593-6; discussion 596-7 [2589595.001]
  • [Cites] Br J Surg. 1987 Oct;74(10):957-61 [3664230.001]
  • [Cites] Surgery. 1995 Mar;117(3):247-53 [7878528.001]
  • [Cites] Br J Surg. 1994 May;81(5):668-71 [7913860.001]
  • [Cites] Ann Surg. 1993 Apr;217(4):356-68 [7682052.001]
  • [Cites] Arch Surg. 1994 Oct;129(10):1075-80 [7944938.001]
  • [Cites] Surg Gynecol Obstet. 1993 Jan;176(1):33-8 [8093983.001]
  • [Cites] Chirurg. 1993 Jun;64(6):476-82 [8359060.001]
  • [Cites] Leber Magen Darm. 1993 Jan;23(1):13-8, 21-3 [8445972.001]
  • [Cites] Surgery. 2000 Jun;127(6):628-33 [10840357.001]
  • [Cites] Ann Surg. 1996 Feb;223(2):134-40 [8597506.001]
  • [Cites] Arch Surg. 1996 Apr;131(4):366-71 [8615720.001]
  • [Cites] Eur J Surg Oncol. 1996 Aug;22(4):366-71 [8783654.001]
  • [Cites] World J Surg. 1997 May;21(4):379-83 [9143568.001]
  • [Cites] Ann Surg. 1998 Jun;227(6):821-31 [9637545.001]
  • [Cites] Surgery. 1986 Oct;100(4):716-23 [3764694.001]
  • [Cites] Acta Chir Scand. 1986 Aug-Sep;152:537-9 [3788399.001]
  • [Cites] Cancer. 1987 Feb 1;59(3):506-15 [3791159.001]
  • [Cites] Br J Surg. 1987 Feb;74(2):116-8 [3815026.001]
  • [Cites] Br J Surg. 1986 Jan;73(1):72-3 [3947884.001]
  • [Cites] Am J Surg. 1985 Jan;149(1):46-52 [3966641.001]
  • [Cites] J R Coll Surg Edinb. 1982 May;27(3):154-7 [7108832.001]
  • [Cites] Endoscopy. 1981 Jul;13(4):154-6 [7250083.001]
  • (PMID = 16131399.001).
  • [ISSN] 1477-7800
  • [Journal-full-title] International seminars in surgical oncology : ISSO
  • [ISO-abbreviation] Int Semin Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1215507
  •  go-up   go-down


10. Balsells-Valls J, Olsina-Kissler JJ, Bilbao-Aguirre I, Solans-Doménech A, Margarit-Creixell C, Armengol-Carrasco M: [Surgical treatment of pancreatic and periampullary carcinoma in a specialized unit: a decade later]. Gastroenterol Hepatol; 2006 Feb;29(2):66-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Surgical treatment of pancreatic and periampullary carcinoma in a specialized unit: a decade later].
  • [Transliterated title] Tratamiento quirúrgico de la neoplasia de páncreas y región periampular en una unidad especializada: una década después.
  • INTRODUCTION: Results of surgical treatment for pancreatic and periampullary carcinoma have improved in recent years owing to several factors, particularly the concentration of these patients in specialised surgical units.
  • MATERIAL AND METHODS: Retrospective-prospective comparative study of results in 2 groups of patients treated over 2 different periods of time and with different surgical policy: group A, which included 80 patients treated from 1982 to 1992 in a general surgery unit, and group B, which comprised 151 patients treated from 1998 to 2003 in a specialised hepato-biliary-pancreatic surgery unit.
  • CONCLUSIONS: Pancreatic and periampullary carcinoma should be surgically treated in specialised pancreatic surgery units in order to offer the best outcome to patients.
  • [MeSH-major] Ampulla of Vater. Common Bile Duct Neoplasms / surgery. Pancreatic Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16448606.001).
  • [ISSN] 0210-5705
  • [Journal-full-title] Gastroenterología y hepatología
  • [ISO-abbreviation] Gastroenterol Hepatol
  • [Language] spa
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


11. Murakami Y, Uemura K, Sasaki M, Morifuji M, Hayashidani Y, Sudo T, Sueda T: Duodenal cancer arising from the remaining duodenum after pylorus-preserving pancreatoduodenectomy for ampullary cancer in familial adenomatous polyposis. J Gastrointest Surg; 2005 Mar;9(3):389-92
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Duodenal cancer arising from the remaining duodenum after pylorus-preserving pancreatoduodenectomy for ampullary cancer in familial adenomatous polyposis.
  • We herein report a rare occurrence of duodenal cancer arising from the remaining duodenum after pylorus-preserving pancreatoduodenectomy for ampullary cancer in familial adenomatous polyposis (FAP).
  • During the current admission, the patient was diagnosed with adenocarcinoma in the Vater's ampulla using imaging and pathological examinations.
  • [MeSH-minor] Adult. Ampulla of Vater / pathology. Cholangiopancreatography, Endoscopic Retrograde / methods. Duodenoscopy / methods. Female. Follow-Up Studies. Humans. Neoplasm, Residual / pathology. Neoplasm, Residual / surgery. Pylorus. Risk Assessment. Treatment Outcome

  • Genetic Alliance. consumer health - Familial Adenomatous Polyposis (FAP).
  • Genetic Alliance. consumer health - Familial Polyposis.
  • MedlinePlus Health Information. consumer health - Intestinal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Surg. 1993 Feb;217(2):101-8 [8382467.001]
  • [Cites] Dis Colon Rectum. 1990 Aug;33(8):639-42 [2165452.001]
  • [Cites] Lancet. 1995 Apr 1;345(8953):855-6 [7898240.001]
  • [Cites] J R Soc Med. 1991 Aug;84(8):476-8 [1653358.001]
  • [Cites] Lancet. 1988 May 21;1(8595):1149-51 [2896968.001]
  • [Cites] Int J Colorectal Dis. 1998;13(1):39-42 [9548099.001]
  • [Cites] J Clin Pathol. 1994 Aug;47(8):709-10 [7962621.001]
  • [Cites] Br J Surg. 1998 May;85(5):665-8 [9635818.001]
  • [Cites] J Gastrointest Surg. 2000 Jan-Feb;4(1):13-21, discussion 22-3 [10631358.001]
  • [Cites] Lancet. 1989 Sep 30;2(8666):783-5 [2571019.001]
  • [Cites] Gut. 1997 Jun;40(6):716-9 [9245923.001]
  • [Cites] J Gastrointest Surg. 2002 Sep-Oct;6(5):671-5 [12399055.001]
  • [Cites] Ann Surg. 1993 May;217(5):430-5; discussion 435-8 [8098202.001]
  • (PMID = 15749602.001).
  • [ISSN] 1091-255X
  • [Journal-full-title] Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
  • [ISO-abbreviation] J. Gastrointest. Surg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


12. Milson A, Abdellaoui A, Fraser C, Watkinson AF: Transhepatic assisted transoral placement of a duodenal stent in malignant gastric outlet obstruction. J Vasc Interv Radiol; 2010 Apr;21(4):590-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Transhepatic assisted transoral placement of a duodenal stent in malignant gastric outlet obstruction.
  • Gastric outlet obstruction is a well- recognized complication of locally advanced carcinoma of the head of the pancreas.
  • The authors report a transoral placement of a duodenal stent over a percutaneous guide wire, inserted retrogradely through a transhepatic approach via the ampulla of Vater, in a patient in whom traditional stent placement was technically not possible.
  • This technique allows safe duodenal stent placement for different malignant gastric outlet obstruction such as pancreatic, gastric, duodenal, and metastases to the peripancreatic region.
  • [MeSH-major] Gastric Outlet Obstruction / etiology. Gastric Outlet Obstruction / therapy. Liver / surgery. Mouth. Pancreatic Neoplasms / complications. Prosthesis Implantation / methods. Stents

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 SIR. Published by Elsevier Inc. All rights reserved.
  • (PMID = 20149689.001).
  • [ISSN] 1535-7732
  • [Journal-full-title] Journal of vascular and interventional radiology : JVIR
  • [ISO-abbreviation] J Vasc Interv Radiol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


13. Srinarmwong C, Luechakiettisak P, Prasitvilai W: Standard whipple's operation versus pylorus preserving pancreaticoduodenectomy: a randomized controlled trial study. J Med Assoc Thai; 2008 May;91(5):693-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • MATERIAL AND METHOD: Between January 2000 and December 2004, 27 patients with pancreatic or periampullary adenocarcinoma were enrolled into the study.
  • Both surgical procedures were equally effective for the treatment of pancreatic and periampullary carcinoma.
  • [MeSH-major] Adenocarcinoma / surgery. Ampulla of Vater / surgery. Pancreatic Neoplasms / surgery. Pancreaticoduodenectomy / methods. Perioperative Care. Pylorus / surgery

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18672634.001).
  • [ISSN] 0125-2208
  • [Journal-full-title] Journal of the Medical Association of Thailand = Chotmaihet thangphaet
  • [ISO-abbreviation] J Med Assoc Thai
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Randomized Controlled Trial
  • [Publication-country] Thailand
  •  go-up   go-down


14. Morise Z, Sugioka A, Tokoro T, Tanahashi Y, Okabe Y, Kagawa T, Takeura C: Surgery and chemotherapy for intrahepatic cholangiocarcinoma. World J Hepatol; 2010 Feb 27;2(2):58-64
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • However, locoregional extension of these tumors is usually advanced with intrahepatic and lymph-node metastases at the time of diagnosis.
  • Only a small number of ICC cases, accompanied with ECC, gall bladder carcinoma, and ampullary carcinoma, have been reported in the studies of chemotherapy due to the rarity of the disease.
  • However, in some reports, significant anti-cancer effects were achieved with a response rate of up to 40% and a median survival of one year.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21160974.001).
  • [ISSN] 1948-5182
  • [Journal-full-title] World journal of hepatology
  • [ISO-abbreviation] World J Hepatol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  • [Other-IDs] NLM/ PMC2998957
  • [Keywords] NOTNLM ; Chemotherapy / Intrahepatic cholangiocarcinoma / Surgery
  •  go-up   go-down


15. Valeri S, Caricato M, Ripetti V, Crucitti P, Ausania F, Garberini A, Giarratano G, Gullotta G, Coppola R: [Signet-ring cell carcinoma of the Vater's ampulla: report of a clinical case]. Suppl Tumori; 2005 May-Jun;4(3):S61
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Signet-ring cell carcinoma of the Vater's ampulla: report of a clinical case].
  • [Transliterated title] Carcinoma a cellule ad anello con castone dell'ampolla di vater: osservazione di un caso clinico.
  • We report the case of a sixty-six year-old man admitted at our hospital with a suspected malignant tumor of the ampulla of Vater.
  • Histology showed a signet-ring cell carcinoma of the ampulla of Vater.
  • This case is the 13th report in the literature of a signet-ring cell carcinoma of the ampulla of Vater.
  • [MeSH-major] Ampulla of Vater. Carcinoma, Signet Ring Cell / surgery. Common Bile Duct Neoplasms / surgery

  • Genetic Alliance. consumer health - Signet ring cell carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16437905.001).
  • [ISSN] 2283-5423
  • [Journal-full-title] I supplementi di Tumori : official journal of Società italiana di cancerologia ... [et al.]
  • [ISO-abbreviation] Suppl Tumori
  • [Language] ita
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Italy
  • [Number-of-references] 4
  •  go-up   go-down


16. Yao HS, Wang Q, Wang WJ, Hu ZQ: Intraoperative allogeneic red blood cell transfusion in ampullary cancer outcome after curative pancreatoduodenectomy: a clinical study and meta-analysis. World J Surg; 2008 Sep;32(9):2038-46
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intraoperative allogeneic red blood cell transfusion in ampullary cancer outcome after curative pancreatoduodenectomy: a clinical study and meta-analysis.
  • BACKGROUND: Allogeneic blood transfusion (ABT) containing packed red blood cells (RBCs) has a known immunosuppressive effect that may affect cancer metastases and recurrence.
  • This study examined whether intraoperative allogeneic RBC transfusion is an independent risk factor of adverse outcome in patients with ampullary carcinoma after curative pancreatoduodenectomy.
  • METHODS: The clinical data of 67 patients with carcinoma of the ampulla of Vatar underwent pancreatoduodenectomy between 1999 and 2004 were analyzed, and long-term follow-up visits were made for all patients.
  • For the meta-analysis, all English-language studies regarding blood transfusion from carcinoma of the ampulla of Vatar or ampullary carcinoma and prognostic factors or factors for survival from 1995 to 2007 were reviewed, and contingency tables were constructed from which a summary relative risk was calculated.
  • After multivariate analysis, except for presence of lymph node metastasis (P = 0.023) and pancreatic invasion (P = 0.024), the intraoperative ABT > or =3 units was found to be an independent poor prognostic factor for those with ampullary cancer after curative pancreatoduodenectomy either (relative risk, 2.082; 95% confidence interval (CI), 1.048-4.135; P = 0.036).
  • CONCLUSIONS: The amount of intraoperative ABT is one of the important factors that adversely influenced survival in patients with ampullary cancer after curative pancreatoduodenectomy.
  • [MeSH-major] Ampulla of Vater / surgery. Erythrocyte Transfusion. Pancreatic Neoplasms / surgery. Pancreaticoduodenectomy
  • [MeSH-minor] Adult. Aged. Blood Loss, Surgical. Blood Transfusion, Autologous. Chi-Square Distribution. Female. Humans. Intraoperative Care. Male. Middle Aged. Neoplasm Staging. Prognosis. Proportional Hazards Models. Risk Factors. Survival Analysis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Surg. 1997 May;225(5):590-9; discussion 599-600 [9193186.001]
  • [Cites] Am J Surg. 1991 Jan;161(1):120-4; discussion 124-5 [1987845.001]
  • [Cites] J Clin Epidemiol. 1991;44(2):127-39 [1995774.001]
  • [Cites] Ann Surg. 1998 Jul;228(1):87-94 [9671071.001]
  • [Cites] Surgery. 1985 Feb;97(2):225-30 [3969625.001]
  • [Cites] J Surg Oncol. 2000 Dec;75(4):258-63 [11135267.001]
  • [Cites] Surg Today. 1998;28(6):576-9 [9681604.001]
  • [Cites] Blood. 1984 Jul;64(1):308-10 [6234037.001]
  • [Cites] Jpn J Clin Oncol. 1993 Oct;23(5):299-302 [8230754.001]
  • [Cites] Control Clin Trials. 1986 Sep;7(3):177-88 [3802833.001]
  • [Cites] Lancet. 1977 Mar 5;1(8010):506-9 [65609.001]
  • [Cites] Am J Surg. 2003 Mar;185(3):188-93 [12620553.001]
  • [Cites] World J Surg. 2002 Apr;26(4):487-92 [11910485.001]
  • [Cites] Ann Thorac Surg. 1989 Mar;47(3):346-51 [2539064.001]
  • [Cites] Pancreas. 2006 May;32(4):390-5 [16670621.001]
  • [Cites] Dis Colon Rectum. 1990 Feb;33(2):127-30 [2298098.001]
  • [Cites] J Surg Res. 1990 May;48(5):498-503 [2352426.001]
  • [Cites] Cancer. 1987 Feb 1;59(3):506-15 [3791159.001]
  • [Cites] Transfusion. 1999 Jul;39(7):718-23 [10413279.001]
  • [Cites] World J Surg. 2007 Jan;31(1):137-43; discussion 144-6 [17171495.001]
  • [Cites] Lancet. 1982 Sep 18;2(8299):662 [6125797.001]
  • [Cites] Ann Surg Oncol. 2002 Jan-Feb;9(1):5-12 [11829431.001]
  • [Cites] Dis Colon Rectum. 2006 Aug;49(8):1116-30 [16779711.001]
  • [Cites] Br J Urol. 1992 Aug;70(2):135-8 [1393434.001]
  • [Cites] Plast Reconstr Surg. 2007 Jun;119(7):2001-7 [17519691.001]
  • [Cites] Br J Surg. 2003 Sep;90(9):1131-6 [12945082.001]
  • [Cites] Yale J Biol Med. 1988 Nov-Dec;61(6):493-500 [3242314.001]
  • [Cites] Cancer. 1989 Oct 15;64(8):1727-37 [2790686.001]
  • [Cites] Am J Surg. 1988 Nov;156(5):374-80 [3189708.001]
  • [Cites] Ann Surg. 2007 Feb;245(2):187-200 [17245171.001]
  • [Cites] Transplant Proc. 1988 Dec;20(6):1121-4 [3201556.001]
  • [Cites] Transplantation. 1978 Oct;26(4):255-9 [360527.001]
  • [Cites] Ann Surg. 1988 Dec;208(6):679-87 [3196088.001]
  • [Cites] Transplantation. 1997 Apr 15;63(7):964-7 [9112348.001]
  • [Cites] Rev Gastroenterol Mex. 2006 Jul-Sep;71(3):252-6 [17140045.001]
  • [Cites] Ann Surg. 1977 Jan;185(1):52-7 [831636.001]
  • [Cites] World J Surg. 2005 Apr;29(4):513-8 [15776300.001]
  • [Cites] Transplant Proc. 1979 Mar;11(1):127-37 [109959.001]
  • [Cites] Dis Colon Rectum. 2001 Jul;44(7):955-64 [11496075.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 2002 Mar;128(3):308-12 [11886349.001]
  • [Cites] World J Surg. 2007 Oct;31(10):2044-51 [17671807.001]
  • [Cites] Immunol Invest. 1995 Jan-Feb;24(1-2):311-7 [7713592.001]
  • (PMID = 18584239.001).
  • [ISSN] 0364-2313
  • [Journal-full-title] World journal of surgery
  • [ISO-abbreviation] World J Surg
  • [Language] eng
  • [Publication-type] Journal Article; Meta-Analysis
  • [Publication-country] United States
  •  go-up   go-down


17. Dittrick GW, Mallat DB, Lamont JP: Management of ampullary lesions. Curr Treat Options Gastroenterol; 2006 Sep;9(5):371-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Management of ampullary lesions.
  • Adenomatous lesions of the ampulla of Vater are relatively rare neoplasms that raise many questions regarding standard management.
  • Adenocarcinoma often will be found in ampullary lesions and should be treated by pancreaticoduodenectomy (PD).
  • Preoperative endoscopic biopsies should be obtained to identify carcinoma, but they have high false-negative rates and cannot be relied upon to rule out malignancy.
  • Intraoperative frozen section evaluation should be requested routinely during AMP, with conversion to PD if carcinoma is demonstrated.
  • Adjuvant chemoradiation has a very limited role in the treatment of ampullary carcinoma and ideally should be offered in the setting of a clinical trial.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Surg. 1997 May;225(5):590-9; discussion 599-600 [9193186.001]
  • [Cites] Gastrointest Endosc Clin N Am. 2003 Oct;13(4):649-69 [14986792.001]
  • [Cites] Eur J Surg Oncol. 2005 Mar;31(2):158-63 [15698732.001]
  • [Cites] Surg Endosc. 2006 Apr;20(4):608-13 [16508819.001]
  • [Cites] Br J Surg. 2004 Dec;91(12):1600-7 [15515106.001]
  • [Cites] Ann Surg. 1998 Jul;228(1):87-94 [9671071.001]
  • [Cites] Br J Surg. 1997 Jul;84(7):948-51 [9240132.001]
  • [Cites] Br J Surg. 1999 Feb;86(2):189-93 [10100785.001]
  • [Cites] Mod Pathol. 2000 Dec;13(12):1300-7 [11144926.001]
  • [Cites] World J Surg. 1997 May;21(4):379-83 [9143568.001]
  • [Cites] Am Surg. 1999 Nov;65(11):1043-8 [10551754.001]
  • [Cites] Gastrointest Endosc. 1997 Oct;46(4):334-7 [9351037.001]
  • [Cites] Gastrointest Endosc. 1999 Jul;50(1):27-33 [10385718.001]
  • [Cites] Arch Surg. 1990 Aug;125(8):961-5 [2378560.001]
  • [Cites] Surgery. 1995 Mar;117(3):247-53 [7878528.001]
  • [Cites] Ann Surg Oncol. 2005 Dec;12(12):971-80 [16244798.001]
  • [Cites] J Gastrointest Surg. 2005 Dec;9(9):1300-6 [16332486.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2000 Jul 1;47(4):945-53 [10863064.001]
  • [Cites] World J Surg. 2000 Jan;24(1):54-9 [10594204.001]
  • [Cites] Am J Gastroenterol. 1992 Jan;87(1):37-42 [1728122.001]
  • [Cites] Gastrointest Endosc. 2004 Feb;59(2):225-32 [14745396.001]
  • [Cites] Arch Surg. 2005 Jun;140(6):529-32; discussion 532-3 [15967899.001]
  • [Cites] Surgery. 2000 Jun;127(6):628-33 [10840357.001]
  • [Cites] Arch Surg. 2001 Jan;136(1):65-9 [11146780.001]
  • [Cites] Ann Surg. 1986 Mar;203(3):301-6 [3954483.001]
  • [Cites] J Gastrointest Surg. 2000 Jan-Feb;4(1):13-21, discussion 22-3 [10631358.001]
  • [Cites] JAMA. 2004 Mar 3;291(9):1092-9 [14996778.001]
  • [Cites] Gastrointest Endosc. 1992 Nov-Dec;38(6):676-83 [1473669.001]
  • [Cites] Br J Surg. 1994 May;81(5):668-71 [7913860.001]
  • [Cites] Ann Surg. 1988 Mar;207(3):234-9 [3345110.001]
  • [Cites] Gut. 1991 Dec;32(12):1558-61 [1773967.001]
  • [Cites] Arch Surg. 1999 May;134(5):526-32 [10323425.001]
  • [Cites] World J Surg. 2005 May;29(5):649-52 [15827855.001]
  • [Cites] Gastrointest Endosc. 1993 Mar-Apr;39(2):127-31 [8495831.001]
  • [Cites] J Am Coll Surg. 2006 Jan;202(1):112-9 [16377504.001]
  • [Cites] Br J Radiol. 1999 May;72 (857):443-7 [10505006.001]
  • (PMID = 16942661.001).
  • [ISSN] 1092-8472
  • [Journal-full-title] Current treatment options in gastroenterology
  • [ISO-abbreviation] Curr Treat Options Gastroenterol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


18. Uchida H, Shibata K, Iwaki K, Kai S, Ohta M, Kitano S: Ampullary cancer and preoperative jaundice: possible indication of the minimal surgery. Hepatogastroenterology; 2009 Jul-Aug;56(93):1194-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ampullary cancer and preoperative jaundice: possible indication of the minimal surgery.
  • BACKGROUND/AIMS: Obstructive jaundice is common symptom of carcinoma of the ampulla of Vater.
  • Preoperative jaundice, serum carbohydrate antigen 19-9 level, pancreatic invasion, lymphatic invasion, venous invasion, perineural invasion, duodenal invasion, margin status, lymph node metastasis, and T stage were shown to be significant prognostic factors.
  • CONCLUSIONS: Preoperative jaundice may reflect advanced-stage in case of ampullary cancer.
  • [MeSH-major] Adenocarcinoma / surgery. Ampulla of Vater / pathology. Common Bile Duct Neoplasms / surgery. Jaundice, Obstructive / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19760968.001).
  • [ISSN] 0172-6390
  • [Journal-full-title] Hepato-gastroenterology
  • [ISO-abbreviation] Hepatogastroenterology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


19. Riediger H, Makowiec F, Fischer E, Adam U, Hopt UT: Postoperative morbidity and long-term survival after pancreaticoduodenectomy with superior mesenterico-portal vein resection. J Gastrointest Surg; 2006 Sep-Oct;10(8):1106-15
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Between July 1994 and December 2004, 222 PD (78% pylorus preserving, 19% Whipple, and 3% total pancreatectomy) were performed for malignant disease.
  • Long-term survival was analyzed in 165 patients with pancreatic (n = 110), ampullary (n = 33), or distal bile (n = 22) duct cancer using univariate (log-rank) and multivariate (Cox regression) methods.
  • Five-year survival rates were 15% in cancer of the pancreatic head, 22% in ampullary cancer, and 24% in distal bile duct cancer (P = 0.02).
  • Univariate survival analysis of the 110 patients with cancer of the pancreatic head revealed that a histologically undifferentiated tumor (P = 0.05) and positive resection margins (P = 0.02) were associated with a poorer survival.
  • In case of tumor adherence or infiltration, combined resection of the pancreatic head and the vein should always be considered in the absence of other contraindications for resection.
  • [MeSH-major] Mesenteric Veins / pathology. Mesenteric Veins / surgery. Pancreatic Neoplasms. Pancreaticoduodenectomy / methods. Portal Vein / pathology. Portal Vein / surgery. Vascular Surgical Procedures / methods
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Female. Follow-Up Studies. Humans. Male. Middle Aged. Morbidity / trends. Neoplasm Invasiveness. Postoperative Period. Prospective Studies. Survival Rate. Time Factors. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Gastrointest Surg. 2005 Nov;9(8):1080-6; discussion 1086-7 [16269378.001]
  • [Cites] Am J Surg. 2001 Aug;182(2):120-9 [11574081.001]
  • [Cites] J Vasc Interv Radiol. 2002 Aug;13(8):805-14 [12171984.001]
  • [Cites] Ann Surg. 1998 Oct;228(4):508-17 [9790340.001]
  • [Cites] Pancreas. 2004 Apr;28(3):289-92 [15084973.001]
  • [Cites] Surgery. 1995 Jan;117(1):50-5 [7809836.001]
  • [Cites] J Gastrointest Surg. 2004 Dec;8(8):935-49; discussion 949-50 [15585381.001]
  • [Cites] Chirurg. 2000 Jul;71(7):803-7 [10986602.001]
  • [Cites] Surgery. 2001 Feb;129(2):158-63 [11174708.001]
  • [Cites] J Gastrointest Surg. 2003 Dec;7(8):1089-95 [14675720.001]
  • [Cites] J Gastrointest Surg. 2005 Dec;9(9):1191-204; discussion 1204-6 [16332474.001]
  • [Cites] Ann Surg. 1984 Apr;199(4):418-25 [6712317.001]
  • [Cites] Pancreas. 2004 Apr;28(3):219-30 [15084961.001]
  • [Cites] World J Surg. 1999 Sep;23(9):926-9 [10449822.001]
  • [Cites] Am J Surg. 1996 Jan;171(1):170-4; discussion 174-5 [8554135.001]
  • [Cites] Am J Surg. 2004 Feb;187(2):201-8 [14769305.001]
  • [Cites] Br J Surg. 2004 May;91(5):586-94 [15122610.001]
  • [Cites] Am J Surg. 2003 May;185(5):476-80 [12727570.001]
  • [Cites] J Gastrointest Surg. 2000 Nov-Dec;4(6):567-79 [11307091.001]
  • [Cites] Surgery. 1973 Feb;73(2):307-20 [4265314.001]
  • [Cites] Ann Surg. 2004 Aug;240(2):293-8 [15273554.001]
  • [Cites] Ann Surg. 2000 Dec;232(6):786-95 [11088073.001]
  • [Cites] Br J Surg. 1998 May;85(5):611-7 [9635805.001]
  • [Cites] J Am Coll Surg. 1999 Jul;189(1):1-7 [10401733.001]
  • [Cites] Ann Surg. 1996 Feb;223(2):154-62 [8597509.001]
  • [Cites] Eur J Surg Oncol. 2001 Sep;27(6):549-57 [11520088.001]
  • [Cites] Arch Surg. 1989 Jan;124(1):127-32 [2910241.001]
  • [Cites] N Engl J Med. 2004 Mar 18;350(12):1200-10 [15028824.001]
  • [Cites] Br J Surg. 1994 Aug;81(8):1190-3 [7953357.001]
  • [Cites] Surgery. 1991 Apr;109(4):481-7 [1848949.001]
  • [Cites] Ann Surg. 1995 Dec;222(6):711-8 [8526577.001]
  • [Cites] World J Surg. 2001 Aug;25(8):1002-5 [11571964.001]
  • [Cites] J Gastrointest Surg. 2003 Feb;7(2):209-19 [12600445.001]
  • [Cites] Ann Surg. 1996 Sep;224(3):342-7; discussion 347-9 [8813262.001]
  • (PMID = 16966029.001).
  • [ISSN] 1091-255X
  • [Journal-full-title] Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
  • [ISO-abbreviation] J. Gastrointest. Surg.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] United States
  •  go-up   go-down


20. Hao CY, Su XQ, Ji JF, Huang XF, Xing BC: Stomach-interposed cholecystogastrojejunostomy: a palliative approach for periampullary carcinoma. World J Gastroenterol; 2005 Apr 7;11(13):2009-12
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Stomach-interposed cholecystogastrojejunostomy: a palliative approach for periampullary carcinoma.
  • AIM: For patients of periampullary carcinoma found to be unresectable at the time of laparotomy, surgical palliation is the primary choice of treatment.
  • [MeSH-minor] Aged. Ampulla of Vater / pathology. Humans. Laparotomy / methods. Middle Aged. Retrospective Studies

  • Genetic Alliance. consumer health - Stomach carcinoma.
  • MedlinePlus Health Information. consumer health - Palliative Care.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15800996.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  • [Other-IDs] NLM/ PMC4305727
  •  go-up   go-down


21. Peng SY, Hong DF, Liu YB, Tan ZJ, Li JT, Tao F: [Binding pancreaticogastrostomy]. Zhonghua Wai Ke Za Zhi; 2009 Jan 15;47(2):139-42
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: From May 2008 to October 2008, 15 patients were performed with BPG, included pancreatic head cancer in 7 cases, duodenal adenocarcinoma in 2 cases,mass-type chronic pancreatitis with pancreatolithiasis in 1 case, ampullary carcinoma in 1 case, gallbladder cancer in 1 case, islet cell tumor in 1 case and cholangiocarcinoma in 2 cases.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19563012.001).
  • [ISSN] 0529-5815
  • [Journal-full-title] Zhonghua wai ke za zhi [Chinese journal of surgery]
  • [ISO-abbreviation] Zhonghua Wai Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


22. Das P, Wolff RA, Abbruzzese JL, Varadhachary GR, Evans DB, Vauthey JN, Baschnagel A, Delclos ME, Krishnan S, Janjan NA, Crane CH: Concurrent capecitabine and upper abdominal radiation therapy is well tolerated. Radiat Oncol; 2006;1:41
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • These patients included 28 (32%) with pancreatic adenocarcinoma, 18 (20%) with cholangiocarcinoma, 11 (13%) with ampullary carcinoma, 11 (13%) with other primary tumors, 14 (16%) with liver metastases, and 6 (7%) with metastases at other sites.
  • [MeSH-minor] Antimetabolites, Antineoplastic / administration & dosage. Capecitabine. Dose-Response Relationship, Radiation. Drug Administration Schedule. Gastrointestinal Neoplasms / drug therapy. Gastrointestinal Neoplasms / radiotherapy. Humans. Neoplasm Metastasis. Radiotherapy Dosage. Retrospective Studies. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Radiation Therapy.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CAPECITABINE .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2000 Mar;18(6):1337-45 [10715306.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Oct 1;63(2):346-53 [15913913.001]
  • [Cites] J Clin Oncol. 2001 Apr 15;19(8):2282-92 [11304782.001]
  • [Cites] Eur J Cancer. 2002 Feb;38(3):349-58 [11818199.001]
  • [Cites] Ann Oncol. 2002 Apr;13(4):566-75 [12056707.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2002 Jul 1;53(3):675-9 [12062611.001]
  • [Cites] J Clin Oncol. 2002 Oct 1;20(19):3983-91 [12351595.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2004 Jun 1;59(2):454-9 [15145162.001]
  • [Cites] Br J Cancer. 2004 Sep 13;91(6):1019-24 [15305186.001]
  • [Cites] J Clin Oncol. 1997 Jan;15(1):110-5 [8996131.001]
  • [Cites] Eur J Cancer. 1998 Jul;34(8):1274-81 [9849491.001]
  • [Cites] N Engl J Med. 2005 Jun 30;352(26):2696-704 [15987918.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2006 Nov 1;66(3):762-71 [17011451.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Dec 1;63(5):1325-30 [15993549.001]
  • [Cites] J Clin Oncol. 2005 Dec 1;23(34):8679-87 [16314628.001]
  • [Cites] Ann Oncol. 2006 Feb;17(2):246-51 [16282246.001]
  • [Cites] J Clin Oncol. 2006 Mar 1;24(7):1145-51 [16505434.001]
  • [Cites] Eur J Cancer. 2001 Mar;37(5):597-604 [11290435.001]
  • (PMID = 17062148.001).
  • [ISSN] 1748-717X
  • [Journal-full-title] Radiation oncology (London, England)
  • [ISO-abbreviation] Radiat Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0W860991D6 / Deoxycytidine; 6804DJ8Z9U / Capecitabine; U3P01618RT / Fluorouracil
  • [Other-IDs] NLM/ PMC1634749
  • [General-notes] NLM/ Original DateCompleted: 20070808
  •  go-up   go-down


23. Westphalen AC, Coakley FV, Joe BN: Radiological reasoning: 88-year-old man with abdominal pain and dilated biliary tree and pancreatic duct. AJR Am J Roentgenol; 2010 Jun;194(6 Suppl):S46-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Radiological reasoning: 88-year-old man with abdominal pain and dilated biliary tree and pancreatic duct.
  • [MeSH-major] Abdominal Pain / diagnosis. Adenocarcinoma, Mucinous / diagnosis. Carcinoma, Pancreatic Ductal / diagnosis. Carcinoma, Papillary / diagnosis. Pancreatic Neoplasms / diagnosis. Pneumonia / diagnosis
  • [MeSH-minor] Aged, 80 and over. Ampulla of Vater / pathology. Cholangiopancreatography, Endoscopic Retrograde. Cholangiopancreatography, Magnetic Resonance. Diagnosis, Differential. Dilatation, Pathologic. Endoscopy, Gastrointestinal. Endosonography. Humans. Incidental Findings. Magnetic Resonance Imaging. Male. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Abdominal Pain.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • MedlinePlus Health Information. consumer health - Pneumonia.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20489116.001).
  • [ISSN] 1546-3141
  • [Journal-full-title] AJR. American journal of roentgenology
  • [ISO-abbreviation] AJR Am J Roentgenol
  • [Language] eng
  • [Publication-type] Case Reports; Clinical Conference; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


24. Will U, Bosseckert H, Meyer F: Correlation of endoscopic ultrasonography (EUS) for differential diagnostics between inflammatory and neoplastic lesions of the papilla of Vater and the peripapillary region with results of histologic investigation. Ultraschall Med; 2008 Jun;29(3):275-80
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Correlation of endoscopic ultrasonography (EUS) for differential diagnostics between inflammatory and neoplastic lesions of the papilla of Vater and the peripapillary region with results of histologic investigation.
  • PURPOSE: There is currently no imaging procedure that allows precise differentiation between inflammatory and malignant lesions of the papilla of Vater (papilla) in a satisfying manner.
  • The aim was to study whether endoscopic ultrasonography (EUS) as an initial diagnostic step 1. may have the potential to distinguish between different tissue characteristics, such as tumor growth or inflammation of the papilla, because of its high resolution capacity and 2. is superior to the accuracy of histologic investigations of mucosal biopsies by means of a prospective collection and retrospective evaluation of the data.
  • PATIENTS AND METHODS: Between 1995 and 2002, a significant pathologic finding in the papilla and the peripapillary region was revealed using EUS in 311 patients (overall, 4,832 EUS investigations); the comparison of this suspicion with the results of histologic investigation was only possible in 183 subjects.
  • Diagnosis was set up using EUS, which tried to differentiate between benign or malignant lesions of the papilla.
  • Histologic investigation of the 133 tumor lesions of the papilla became possible by taking deep transpapillary biopsies following papillotomy, papillectomy or by obtaining specimens from surgical resections.
  • RESULTS: Using EUS, differentiation between inflammatory and neoplastic lesions of the papilla or the peripapillary region was correct in 109 of 133 cases (82%), while suspected EUS-based diagnosis "papillitis stenosans" (inflammatory lesions of the papilla of Vater) in 4 subjects (3%) was corrected to adenoma and carcinoma, respectively (n=2 each) by histologic investigation.
  • In 20 of 133 patients with suspected neoplastic lesions, inflammatory lesion of the papilla of Vater was detected resulting in an overall sensitivity of 92.3% and specificity of 75.3%.
  • In patients with biliary symptoms, EUS can reliably visualize and characterize a malignant lesion as a first diagnostic tool (detection rate, 82%) and may be considered the basis for subsequent diagnostic steps for verifying diagnosis correctly, e. g., using histologic investigation.
  • [MeSH-major] Ampulla of Vater / pathology. Ampulla of Vater / ultrasonography. Common Bile Duct Diseases / ultrasonography. Common Bile Duct Neoplasms / pathology. Common Bile Duct Neoplasms / ultrasonography. Endosonography. Inflammation / pathology. Inflammation / ultrasonography
  • [MeSH-minor] Diagnosis, Differential. Humans. Retrospective Studies. Sphincter of Oddi / pathology. Sphincter of Oddi / ultrasonography

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18491258.001).
  • [ISSN] 0172-4614
  • [Journal-full-title] Ultraschall in der Medizin (Stuttgart, Germany : 1980)
  • [ISO-abbreviation] Ultraschall Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


25. Wu LH, Zhang W: [Prevention and treatment of complications after duodenopancreatectomy]. Di Yi Jun Yi Da Xue Xue Bao; 2005 Apr;25(4):461-3
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: The clinical data of 36 cases receiving duodenopancreatectomy during the last decade were analyzed, including 13 cases of ampullary carcinoma, 8 cases of carcinoma of the pancreas head, 8 cases of distal cholangiocarcinoma, and 7 cases of carcinoma of the duodenal papilla.
  • RESULTS: Complications occurred in 6 cases after duodenopancreatectomy including pancreatic fistula in 3 cases, bile duct fistula in 1 case, abdominal cavity hemorrhage in 1 case, and alimentary tract hemorrhage in 1 case, with an incidence rate of postoperative complications of 16.7%; and death occurred in 2 cases.
  • CONCLUSION: Adequate measures should be taken to reduce such complications as pancreatic fistula, bile duct fistula, abdominal cavity hemorrhage, alimentary tract hemorrhage and abdominal cavity infection, and these measures include nutritional support, careful operation in the surgery with adequate drainage, and careful observation and nursing after the surgery.
  • [MeSH-major] Pancreatic Neoplasms / surgery. Pancreaticoduodenectomy / adverse effects. Postoperative Complications / prevention & control
  • [MeSH-minor] Adult. Aged. China / epidemiology. Common Bile Duct Neoplasms / surgery. Female. Humans. Male. Middle Aged. Pancreatic Fistula / epidemiology. Pancreatic Fistula / etiology. Pancreatic Fistula / prevention & control

  • MedlinePlus Health Information. consumer health - After Surgery.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15837657.001).
  • [ISSN] 1000-2588
  • [Journal-full-title] Di 1 jun yi da xue xue bao = Academic journal of the first medical college of PLA
  • [ISO-abbreviation] Di Yi Jun Yi Da Xue Xue Bao
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


26. Kawakami H, Zen Y, Kuwatani M, Eto K, Haba S, Yamato H, Shinada K, Kubota K, Asaka M: IgG4-related sclerosing cholangitis and autoimmune pancreatitis: histological assessment of biopsies from Vater's ampulla and the bile duct. J Gastroenterol Hepatol; 2010 Oct;25(10):1648-55
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] IgG4-related sclerosing cholangitis and autoimmune pancreatitis: histological assessment of biopsies from Vater's ampulla and the bile duct.
  • The present study was carried out to examine the usefulness of endoscopic biopsies from Vater's ampulla and the bile duct to diagnose IgG4-SC.
  • METHODS: The present study included 29 IgG4-SC patients (26 with both pancreatitis and cholangitis, and 3 with cholangitis only), 6 PSC patients, and 27 pancreatobiliary carcinoma patients.
  • All patients underwent endoscopic biopsies from Vater's ampulla and the common bile duct.
  • RESULTS: For the ampullary and bile duct biopsies, the IgG4-SC samples had a significantly greater number of IgG4-positive plasma cells than the PSC or pancreatobiliary carcinoma specimens.
  • The bile duct biopsy was significantly valuable for IgG4-SC patients with swelling of the pancreatic head.
  • [MeSH-major] Ampulla of Vater / pathology. Autoimmune Diseases / immunology. Biopsy / methods. Cholangitis, Sclerosing / immunology. Common Bile Duct / pathology. Immunoglobulin G / immunology. Pancreatitis / immunology
  • [MeSH-minor] Adult. Aged. Cholangiopancreatography, Endoscopic Retrograde. Diagnosis, Differential. Humans. Middle Aged. Reproducibility of Results. Retrospective Studies

  • Genetic Alliance. consumer health - Pancreatitis.
  • MedlinePlus Health Information. consumer health - Autoimmune Diseases.
  • MedlinePlus Health Information. consumer health - Biopsy.
  • MedlinePlus Health Information. consumer health - Pancreatitis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2010 Journal of Gastroenterology and Hepatology Foundation and Blackwell Publishing Asia Pty Ltd.
  • (PMID = 20880174.001).
  • [ISSN] 1440-1746
  • [Journal-full-title] Journal of gastroenterology and hepatology
  • [ISO-abbreviation] J. Gastroenterol. Hepatol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Immunoglobulin G
  •  go-up   go-down


27. Watanabe M, Midorikawa Y, Yamano T, Mushiake H, Fukuda N, Kirita T, Mizuguchi K, Sugiyama Y: Carcinoma of the papilla of Vater following treatment of pancreaticobiliary maljunction. World J Gastroenterol; 2009 Dec 28;15(48):6126-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Carcinoma of the papilla of Vater following treatment of pancreaticobiliary maljunction.
  • Pancreaticobiliary maljunction (PBM) is frequently associated with biliary cancer due to reflux of pancreatic enzymes into the choledochus, and even after surgery to correct the PBM such patients still have a risk of residual bile duct cancer.
  • Here, we report the case of a 59-year-old female with carcinoma of the papilla of Vater which developed 2.5 years after choledochoduodenostomy for PBM.
  • As a result, carcinoma of the papilla of Vater was diagnosed at an early stage, followed by surgical cure.
  • For early detection of periampullary cancer in patients undergoing surgery for PBM, careful long-term follow-up is needed.
  • [MeSH-major] Adenocarcinoma / etiology. Ampulla of Vater / pathology. Bile Ducts, Extrahepatic / abnormalities. Common Bile Duct Neoplasms / etiology. Pancreatic Ducts / abnormalities. Postoperative Complications / etiology

  • MedlinePlus Health Information. consumer health - After Surgery.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Surgery. 1999 Nov;126(5):939-44 [10568195.001]
  • [Cites] J Hepatobiliary Pancreat Surg. 2003;10(5):345-51 [14598134.001]
  • [Cites] J Hepatobiliary Pancreat Surg. 2004;11(4):223-31 [15368105.001]
  • [Cites] Br J Surg. 1997 Dec;84(12):1687-91 [9448616.001]
  • [Cites] Ann Surg. 1998 Jul;228(1):87-94 [9671071.001]
  • [Cites] J Hepatobiliary Pancreat Surg. 2008;15(1):15-24 [18274840.001]
  • [Cites] J Hepatobiliary Pancreat Surg. 1999;6(3):207-12 [10526053.001]
  • [Cites] World J Surg. 2005 Apr;29(4):519-23 [15770375.001]
  • [Cites] Dig Liver Dis. 2005 Sep;37(9):705-8 [15925554.001]
  • [Cites] World J Surg. 2007 Jan;31(1):137-43; discussion 144-6 [17171495.001]
  • [Cites] J Hepatobiliary Pancreat Surg. 1998;5(1):113-6 [9683764.001]
  • (PMID = 20027689.001).
  • [ISSN] 2219-2840
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Other-IDs] NLM/ PMC2797673
  •  go-up   go-down


28. Aloysius MM, Lobo DN, Rowlands BJ, Madhusudan S, Ilyas M, Zaitoun AM: HER-2/Neu overexpression is a rare event in peri-ampullary cancer: assessment using the HercepTest. Histopathology; 2009 Aug;55(2):236-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] HER-2/Neu overexpression is a rare event in peri-ampullary cancer: assessment using the HercepTest.
  • [MeSH-major] Adenocarcinoma / metabolism. Ampulla of Vater. Carcinoma, Pancreatic Ductal / metabolism. Pancreatic Neoplasms / metabolism. Receptor, ErbB-2 / analysis

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19694833.001).
  • [ISSN] 1365-2559
  • [Journal-full-title] Histopathology
  • [ISO-abbreviation] Histopathology
  • [Language] eng
  • [Publication-type] Letter
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Reagent Kits, Diagnostic; EC 2.7.10.1 / Receptor, ErbB-2
  •  go-up   go-down


29. Haddad LB, Scatton O, Randone B, Andraus W, Massault PP, Dousset B, Soubrane O: Pancreatic fistula after pancreaticoduodenectomy: the conservative treatment of choice. HPB (Oxford); 2009 May;11(3):203-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pancreatic fistula after pancreaticoduodenectomy: the conservative treatment of choice.
  • BACKGROUND: A pancreatic fistula (PF) is the most common complication after pancreaticoduodenectomy (PD), and its reported incidence varies from 2% to 28%.
  • The main indications for PD were pancreatic duct carcinoma in 52 patients (44.5%), ampullary carcinoma or adenoma in 18 (15.4%) and islet cell tumour in 11 (9.4%).
  • The medium delay between the pancreatic resection and reoperation was 10 days (range, 3-32 days).

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Arch Surg. 2004 Jan;139(1):16-9 [14718268.001]
  • [Cites] Br J Surg. 2000 Jul;87(7):883-9 [10931023.001]
  • [Cites] World J Surg. 2003 Jun;27(6):709-14 [12732998.001]
  • [Cites] Arch Surg. 2006 Jun;141(6):574-9; discussion 579-80 [16785358.001]
  • [Cites] Ann Surg. 2005 Dec;242(6):767-71, discussion 771-3 [16327486.001]
  • [Cites] Br J Surg. 2005 Sep;92(9):1117-23 [15931656.001]
  • [Cites] Arch Surg. 2005 Sep;140(9):849-54; discussion 854-6 [16172293.001]
  • [Cites] Surgery. 2005 Jul;138(1):8-13 [16003309.001]
  • [Cites] World J Surg. 2005 Feb;29(2):212-6 [15654661.001]
  • [Cites] J Gastrointest Surg. 2004 Dec;8(8):951-9 [15585382.001]
  • [Cites] J Gastrointest Surg. 2004 Nov;8(7):766-72; discussion 772-4 [15531229.001]
  • [Cites] World J Surg. 1999 Feb;23(2):164-71; discussion 171-2 [9880426.001]
  • [Cites] Ann Surg. 1997 Sep;226(3):248-57; discussion 257-60 [9339931.001]
  • [Cites] J Am Coll Surg. 1997 Jul;185(1):18-24 [9208956.001]
  • [Cites] Br J Surg. 1996 Feb;83(2):176-9 [8689156.001]
  • [Cites] Ann Surg. 1995 Oct;222(4):580-8; discussion 588-92 [7574936.001]
  • [Cites] Br J Surg. 1995 Sep;82(9):1270-3 [7552016.001]
  • [Cites] Ann Surg. 1995 Jun;221(6):721-31; discussion 731-3 [7794076.001]
  • [Cites] Cancer. 1995 Apr 15;75(8):2069-76 [7697596.001]
  • [Cites] Arch Surg. 1995 Mar;130(3):295-9; discussion 299-300 [7887797.001]
  • [Cites] Br J Surg. 1994 Feb;81(2):265-9 [8156354.001]
  • [Cites] Am J Surg. 1994 Oct;168(4):295-8 [7524375.001]
  • [Cites] Ann Surg. 1993 Sep;218(3):229-37; discussion 237-8 [8103982.001]
  • [Cites] Ann Surg. 1993 May;217(5):430-5; discussion 435-8 [8098202.001]
  • [Cites] Arch Surg. 1992 Aug;127(8):945-9; discussion 949-50 [1353671.001]
  • [Cites] World J Surg. 1992 May-Jun;16(3):521-4 [1350387.001]
  • [Cites] Am J Surg. 1992 Jan;163(1):125-30; discussion 130-1 [1733360.001]
  • [Cites] Ann Surg. 1988 Jan;207(1):39-47 [3276272.001]
  • [Cites] Ann Surg. 1990 Apr;211(4):447-58 [2322039.001]
  • [Cites] Surg Gynecol Obstet. 1978 Jun;146(6):959-62 [653575.001]
  • [Cites] J Am Coll Surg. 2004 Aug;199(2):198-203 [15275873.001]
  • [Cites] Arch Surg. 2004 Jul;139(7):718-25; discussion 725-7 [15249403.001]
  • [Cites] Arch Surg. 2003 Dec;138(12):1310-4; discussion 1315 [14662530.001]
  • [Cites] J Am Coll Surg. 2003 Apr;196(4):556-64; discussion 564-5; author reply 565 [12691930.001]
  • [Cites] Ann Surg. 2003 Jan;237(1):57-65 [12496531.001]
  • [Cites] Br J Surg. 2002 Oct;89(10):1245-51 [12296891.001]
  • [Cites] Dig Surg. 2001;18(6):453-7; discussion 458 [11799295.001]
  • [Cites] J Gastrointest Surg. 2000 Nov-Dec;4(6):567-79 [11307091.001]
  • [Cites] Arch Surg. 2001 Apr;136(4):391-8 [11296108.001]
  • [Cites] Am J Surg. 2000 Aug;180(2):117-20 [11044525.001]
  • [Cites] Ann Surg. 2000 Sep;232(3):419-29 [10973392.001]
  • [Cites] J Gastrointest Surg. 2003 Jul-Aug;7(5):672-82 [12850681.001]
  • (PMID = 19590648.001).
  • [ISSN] 1365-182X
  • [Journal-full-title] HPB : the official journal of the International Hepato Pancreato Biliary Association
  • [ISO-abbreviation] HPB (Oxford)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2697888
  • [Keywords] NOTNLM ; pancreatic fistula / pancreatic resection / pancreaticoduodenectomy / postoperative complications
  •  go-up   go-down


30. Tien YW, Yeh CC, Wang SP, Hu RH, Lee PH: Is blind pancreaticoduodenectomy justified for patients with ampullary neoplasms? J Gastrointest Surg; 2009 Sep;13(9):1666-73
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Is blind pancreaticoduodenectomy justified for patients with ampullary neoplasms?
  • BACKGROUND: Many specialists justify pancreaticoduodenectomy (PD) for pancreatic head neoplasms with suspected but unproven malignance (blind-PD).
  • Our aim in this study was to determine whether blind-PD is also justified for ampullary neoplasms.
  • METHODS: We retrospectively reviewed the records of all patients with presumed resectable ampullary neoplasms treated at the National Taiwan University Hospital from 1998 to 2008.
  • RESULTS: Of the 84 patients without a preoperative tissue diagnosis of malignance, 64 had blind-PD and 20 had ampullectomy (AMP) with intraoperative frozen section.
  • Final pathological diagnosis was benign in ten of 64 blind-PD-treated patients.
  • CONCLUSIONS: Our data support a selective use of blind-PD because (1) a significant portion (65%) of benign ampullary neoplasms can be safely and effectively treated by AMP, (2) blind-PD does not treat ampullary cancer at earlier stage, and (3) blind-PD is associated with significantly more complications and significantly longer hospital stay than AMP.
  • However, blind-PD is strongly recommended for patients with large ampullary neoplasms (>3 cm in diameter), with jaundice, or with malignant endoscopic appearance.
  • [MeSH-major] Ampulla of Vater / pathology. Pancreatic Neoplasms / pathology. Pancreatic Neoplasms / surgery. Pancreaticoduodenectomy / methods
  • [MeSH-minor] Aged. Biopsy, Needle. Cholangiopancreatography, Endoscopic Retrograde / methods. Cohort Studies. Disease-Free Survival. Female. Follow-Up Studies. Hospital Mortality / trends. Humans. Immunohistochemistry. Male. Middle Aged. Neoplasm Invasiveness / pathology. Neoplasm Staging. Postoperative Complications / mortality. Preoperative Care. Probability. Registries. Retrospective Studies. Risk Assessment. Sphincterotomy, Endoscopic. Statistics, Nonparametric. Survival Rate

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Arch Surg. 1996 Apr;131(4):366-71 [8615720.001]
  • [Cites] World J Surg. 1999 Feb;23(2):158-62; discussion 162-3 [9880425.001]
  • [Cites] Curr Opin Gastroenterol. 2008 Sep;24(5):617-22 [19122504.001]
  • [Cites] Ann Surg Oncol. 2005 Dec;12(12):955-6 [16228813.001]
  • [Cites] Br J Surg. 1997 Jul;84(7):948-51 [9240132.001]
  • [Cites] Cancer. 1989 Jul 1;64(1):161-7 [2471581.001]
  • [Cites] South Med J. 1989 Jul;82(7):917-20 [2665132.001]
  • [Cites] Gastrointest Endosc. 2002 Aug;56(2):239-43 [12145603.001]
  • [Cites] J Gastrointest Surg. 2006 Sep-Oct;10(8):1140-3 [16966033.001]
  • [Cites] Pathol Oncol Res. 2003;9(1):32-41 [12704445.001]
  • [Cites] Ann Chir. 2004 Mar;129(2):73-8 [15050176.001]
  • [Cites] Ann Surg Oncol. 2005 Dec;12(12):971-80 [16244798.001]
  • [Cites] Am Surg. 2004 Jan;70(1):6-10; discussion 11-2 [14964538.001]
  • [Cites] Am Surg. 1990 Apr;56(4):214-7 [2194412.001]
  • [Cites] J Gastrointest Surg. 2005 Dec;9(9):1300-6 [16332486.001]
  • [Cites] Ann Surg Oncol. 2008 Jul;15(7):1855-61 [18415651.001]
  • [Cites] Pancreas. 1995 Oct;11(3):283-8 [8577683.001]
  • [Cites] Endoscopy. 2003 May;35(5):402-6 [12701011.001]
  • [Cites] Gastrointest Endosc. 2004 Feb;59(2):225-32 [14745396.001]
  • [Cites] Surgery. 2000 Jun;127(6):628-33 [10840357.001]
  • [Cites] Ann Surg. 1986 Mar;203(3):301-6 [3954483.001]
  • [Cites] Am J Surg Pathol. 1991 Dec;15(12):1188-96 [1746684.001]
  • [Cites] Arch Surg. 1999 May;134(5):526-32 [10323425.001]
  • [Cites] Ann Surg. 2005 Jul;242(1):92-100 [15973106.001]
  • [Cites] Gastrointest Endosc. 1993 Mar-Apr;39(2):127-31 [8495831.001]
  • [Cites] Gastrointest Endosc. 1990 Nov-Dec;36(6):588-92 [2279648.001]
  • [Cites] Endoscopy. 2005 May;37(5):444-8 [15844023.001]
  • (PMID = 19557483.001).
  • [ISSN] 1873-4626
  • [Journal-full-title] Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
  • [ISO-abbreviation] J. Gastrointest. Surg.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


31. Gao JM, Tang SS, Fu W, Fan R: Signet-ring cell carcinoma of ampulla of Vater: contrast-enhanced ultrasound findings. World J Gastroenterol; 2009 Feb 21;15(7):888-91
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Signet-ring cell carcinoma of ampulla of Vater: contrast-enhanced ultrasound findings.
  • Signet-ring cell carcinoma (SRCC) of ampulla of Vater is extremely uncommon, and less than 15 cases have been reported so far in literature.
  • We report a rare case of SRCC of the ampulla of Vater in a 38-year-old woman who presented with a small tumor at the Vater, discovered by the contrast-enhanced ultrasound (CEUS).
  • We also describe the imaging features of SRCC of ampulla of Vater in CEUS.
  • [MeSH-major] Ampulla of Vater / ultrasonography. Carcinoma, Signet Ring Cell / ultrasonography. Common Bile Duct Neoplasms / ultrasonography

  • Genetic Alliance. consumer health - Signet ring cell carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Surg Today. 2003;33(6):467-9 [12768376.001]
  • [Cites] Tohoku J Exp Med. 1998 Oct;186(2):121-30 [10223615.001]
  • [Cites] JOP. 2004 Nov;5(6):495-7 [15536289.001]
  • [Cites] Surg Today. 2007;37(12):1110-4 [18030577.001]
  • [Cites] World J Surg. 2005 Apr;29(4):513-8 [15776300.001]
  • [Cites] Indian J Gastroenterol. 2005 Sep-Oct;24(5):222-3 [16361773.001]
  • [Cites] Am Surg. 2006 Feb;72(2):193-5 [16536256.001]
  • [Cites] Ann Clin Lab Sci. 2004 Autumn;34(4):471-5 [15648791.001]
  • (PMID = 19230055.001).
  • [ISSN] 2219-2840
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Contrast Media
  • [Other-IDs] NLM/ PMC2653376
  •  go-up   go-down


32. Kikuyama M, Itoi T, Sasada Y, Sofuni A, Ota Y, Itokawa F: Large-balloon technique for one-step endoscopic biliary stenting in patients with an inaccessible major papilla owing to difficult duodenal stricture (with video). Gastrointest Endosc; 2009 Sep;70(3):568-72
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Large-balloon technique for one-step endoscopic biliary stenting in patients with an inaccessible major papilla owing to difficult duodenal stricture (with video).
  • BACKGROUND: Marked duodenal stenosis makes endoscopic biliary stenting (EBS) impossible, although it is the most common method for treating obstructive jaundice in patients with benign or malignant biliary strictures.
  • OBJECTIVE: We describe 4 cases of successful EBS combined with the use of a large balloon for the treatment of difficult duodenal strictures in patients with benign and malignant biliary strictures.
  • PATIENTS: Four patients: 1 with hilar carcinoma, 1 with gallbladder carcinoma, and 2 with chronic pancreatitis.
  • INTERVENTIONS: After duodenal dilation, the slightly deflated balloon was pushed with the endoscope into the major papilla through the duodenal stricture (pushing method used in 2 patients).
  • In the cases in which the major papilla was not accessible with the pushing method, a large dilation balloon was deflated completely after dilation, advanced beyond the stricture into the third portion of the duodenum, and reinflated to the maximum size.
  • Pulling the dilation balloon catheter into the working channel while hooking the inflated balloon as the anchor at the anal side of the duodenal stricture, the endoscope was straightened to advance to the major papilla (hooking method used in 2 patients).
  • RESULTS: Reaching the major papilla and EBS was accomplished in all 4 patients.
  • [MeSH-minor] Adult. Aged. Ampulla of Vater. Female. Follow-Up Studies. Humans. Male. Middle Aged. Risk Assessment. Severity of Illness Index. Survival Rate. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19573866.001).
  • [ISSN] 1097-6779
  • [Journal-full-title] Gastrointestinal endoscopy
  • [ISO-abbreviation] Gastrointest. Endosc.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


33. Yildirim N, Oksüzoğlu B, Budakoğlu B, Vural M, Abali H, Uncu D, Zengin N: Primary duodenal diffuse large cell non-hodgkin lymphoma with involvement of ampulla of Vater: report of 3 cases. Hematology; 2005 Oct;10(5):371-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary duodenal diffuse large cell non-hodgkin lymphoma with involvement of ampulla of Vater: report of 3 cases.
  • Periampullary lymphoma or lymphomatous involvement of ampulla of Vater is even rarer.
  • Since, periampullary lymphoma is not easy to differentiate from epithelial carcinoma of these sites clinically and radiologically, accurate histopathological diagnosis is essential to plan optimal treatment strategy.
  • In this report, we present three cases of duodenal diffuse large cell lymphoma with involvement of ampulla of Vater, two of whom presented with the initial signs of obstructive jaundice.
  • One of the icteric patients was only diagnosed histopathologically following an explorative laparotomy with the initial diagnosis of carcinoma.
  • [MeSH-major] Ampulla of Vater / pathology. Common Bile Duct Neoplasms / pathology. Duodenal Neoplasms / pathology. Lymphoma, Large B-Cell, Diffuse / pathology


34. Baumhoer D, Zlobec I, Tornillo L, Dietmaier W, Wuensch PH, Hartmann A, Sessa F, Ruemmele P, Terracciano LM: Immunophenotyping and oncogene amplifications in tumors of the papilla of Vater. Virchows Arch; 2008 Dec;453(6):579-88
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunophenotyping and oncogene amplifications in tumors of the papilla of Vater.
  • Carcinomas of the ampulla of Vater are rare and assumed to generally arise from preexisting adenomas (adenoma-carcinoma sequence).
  • Since pathologists usually receive bioptic tissue samples of ampullary tumors obtained during endoscopy, accurate classification of carcinoma subtypes can sometimes be difficult on morphological criteria alone.
  • We therefore performed immunohistochemistry using a panel of established marker proteins (CK7, CK20, p21, p27, ESA, bax, and ephrin-B2) on 175 carcinoma, 111 adenoma, and 152 normal mucosa specimens of the ampulla of Vater and identified distinct immunoprofiles for every carcinoma subtype.
  • [MeSH-major] Adenoma / metabolism. Ampulla of Vater / metabolism. Common Bile Duct Neoplasms / metabolism. Cyclin D1 / metabolism. Keratin-7 / metabolism. Receptor, ErbB-2 / metabolism. bcl-2-Associated X Protein / metabolism

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Surg. 1997 May;225(5):590-9; discussion 599-600 [9193186.001]
  • [Cites] Cancer. 1990 Aug 15;66(4):702-15 [2167140.001]
  • [Cites] Eur J Cancer. 2007 Apr;43(6):1101-7 [17350821.001]
  • [Cites] Ann Surg. 1998 Jul;228(1):87-94 [9671071.001]
  • [Cites] J Hepatobiliary Pancreat Surg. 2004;11(5):301-9 [15549428.001]
  • [Cites] Mod Pathol. 2000 Dec;13(12):1300-7 [11144926.001]
  • [Cites] J Natl Cancer Inst. 1987 Apr;78(4):653-6 [3470541.001]
  • [Cites] Cancer. 1982 Mar 1;49(5):971-83 [7059931.001]
  • [Cites] Am J Surg. 2000 Jul;180(1):13-7 [11036132.001]
  • [Cites] Hepatogastroenterology. 1997 Jul-Aug;44(16):1157-63 [9261617.001]
  • [Cites] Ann Surg Oncol. 2003 Dec;10(10):1176-83 [14654474.001]
  • [Cites] Cancer. 1981 Aug 1;48(3):799-819 [7248908.001]
  • [Cites] Br J Cancer. 2007 Mar 12;96(5):793-800 [17311026.001]
  • [Cites] Clin Cancer Res. 1998 Oct;4(10):2377-82 [9796968.001]
  • [Cites] Adv Cancer Res. 1996;68:67-108 [8712071.001]
  • [Cites] Endoscopy. 1989 Dec;21 Suppl 1:324-9 [2691236.001]
  • [Cites] BMC Cancer. 2008 Jun 11;8:170 [18547417.001]
  • [Cites] Pathologe. 2003 May;24(3):196-203 [12739053.001]
  • [Cites] Br J Surg. 1987 Oct;74(10):957-61 [3664230.001]
  • [Cites] Ann Surg. 1997 Sep;226(3):248-57; discussion 257-60 [9339931.001]
  • [Cites] Z Gastroenterol. 2002 Nov;40(11):913-20 [12436368.001]
  • [Cites] J Clin Pathol. 2008 May;61(5):561-9 [18326017.001]
  • [Cites] J Clin Pathol. 2007 Jul;60(7):768-72 [16882699.001]
  • [Cites] Oncol Rep. 2005 Oct;14(4):867-72 [16142344.001]
  • [Cites] Cancer Res. 2002 Jun 1;62(11):2993-8 [12036902.001]
  • [Cites] World J Surg. 2005 Apr;29(4):513-8 [15776300.001]
  • [Cites] Jpn J Cancer Res. 1994 Feb;85(2):161-6 [7511574.001]
  • [Cites] Cancer. 1983 Mar 1;51(5):878-81 [6821853.001]
  • [Cites] Br J Surg. 1994 May;81(5):668-71 [7913860.001]
  • [Cites] Lab Invest. 2005 Jul;85(7):921-31 [15864317.001]
  • [Cites] Gut. 1981 Dec;22(12):1031-4 [7319287.001]
  • [Cites] Cancer. 1999 Aug 15;86(4):596-607 [10440687.001]
  • [Cites] Cancer. 1995 Jan 1;75(1 Suppl):154-70 [8000994.001]
  • [Cites] Virchows Arch. 2002 Jul;441(1):19-24 [12111196.001]
  • (PMID = 18936968.001).
  • [ISSN] 0945-6317
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CCND1 protein, human; 0 / Ephrin-B2; 0 / Keratin-20; 0 / Keratin-7; 0 / MYC protein, human; 0 / Proliferating Cell Nuclear Antigen; 0 / Proto-Oncogene Proteins c-myc; 0 / bcl-2-Associated X Protein; 0 / p27 antigen; 136601-57-5 / Cyclin D1; EC 2.7.10.1 / ERBB2 protein, human; EC 2.7.10.1 / Receptor, ErbB-2
  •  go-up   go-down


35. Zhang XM, Shen CY, Li W, Zhang XM: [Surgical treatment of tumor invading important vessel]. Zhonghua Wai Ke Za Zhi; 2007 Aug 1;45(15):1044-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The tumor involving thoraco-abdominal cavity was in one case with malignant neuroblastoma.
  • Tumor located in thoracic cavity were in 13 cases including IVC leiomyosarcoma in 2 cases, thymic carcinoma in 3 cases, malignant thymoma in 4 cases, malignant seminoma of superior mediastinum in 1 case, malignant lymphoma in 1 case, lung cancer in 2 cases.
  • The tumor located in abdominal cavity were in 24 cases including renal carcinoma with tumor thrombi in 11 cases, inflammatory pseudotumor of retro-peritoneum in 4 cases, malignant fibrous histiocytoma of retro-peritoneum in 1 case, non-Hodgkin's disease of retro-peritoneum in 1 case, lymph metastasis of retro-peritoneum in 2 cases, paraganglion tumor of the right adrenal gland in 1 case, ampullary carcinoma in 1 case, leiomyosarcoma of abdominal IVC in 1 case, leiomyosarcoma of pelvic cavity and IVC in 1 cases, fibrosarcoma of pelvic cavity in 1 case.
  • [MeSH-minor] Adolescent. Adult. Aged. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Invasiveness. Retrospective Studies. Treatment Outcome. Vena Cava, Inferior / pathology. Vena Cava, Inferior / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18005586.001).
  • [ISSN] 0529-5815
  • [Journal-full-title] Zhonghua wai ke za zhi [Chinese journal of surgery]
  • [ISO-abbreviation] Zhonghua Wai Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


36. Alvaro D, Cannizzaro R, Labianca R, Valvo F, Farinati F, Italian Society of Gastroenterology (SIGE), Italian Association of Hospital Gastroenterology (AIGO), Italian Association of Medical Oncology (AIOM), Italian Association of Oncological Radiotherapy (AIRO): Cholangiocarcinoma: A position paper by the Italian Society of Gastroenterology (SIGE), the Italian Association of Hospital Gastroenterology (AIGO), the Italian Association of Medical Oncology (AIOM) and the Italian Association of Oncological Radiotherapy (AIRO). Dig Liver Dis; 2010 Dec;42(12):831-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The incidence of Cholangiocellular carcinoma (CCA) is increasing, due to a sharp increase of the intra-hepatic form.
  • Evidence-ascertained risk factors for CCA are primary sclerosing cholangitis, Opistorchis viverrini infection, Caroli disease, congenital choledocal cist, Vater ampulla adenoma, bile duct adenoma and intra-hepatic lithiasis.
  • Obesity, diabetes, smoking, abnormal biliary-pancreatic junction, bilio-enteric surgery, and viral cirrhosis are emerging risk factors, but their role still needs to be validated.
  • Diagnosis of the tumor is often difficult and multiple imaging techniques should be used, particularly for staging.
  • [MeSH-major] Bile Duct Neoplasms / diagnosis. Bile Duct Neoplasms / therapy. Bile Ducts, Intrahepatic. Cholangiocarcinoma / diagnosis. Cholangiocarcinoma / therapy

  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd. All rights reserved.
  • (PMID = 20702152.001).
  • [ISSN] 1878-3562
  • [Journal-full-title] Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
  • [ISO-abbreviation] Dig Liver Dis
  • [Language] eng
  • [Publication-type] Journal Article; Practice Guideline
  • [Publication-country] Netherlands
  • [Investigator] Avuzzi B; Buscarini E; Fornasarig M; Iacono C; Maiero S; Mosconi S; Muto P; Tasca C; Vanin V
  •  go-up   go-down


37. Fujita T, Konishi M, Gotohda N, Takahashi S, Nakagohri T, Kojima M, Kinoshita T: Invasive micropapillary carcinoma of the ampulla of Vater with extensive lymph node metastasis: Report of a case. Surg Today; 2010 Dec;40(12):1197-200
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Invasive micropapillary carcinoma of the ampulla of Vater with extensive lymph node metastasis: Report of a case.
  • Invasive micropapillary carcinoma is characterized by extensive lymph node metastasis and a poor prognosis.
  • This histological variant was first described in breast cancer, with a few subsequent reports of it in the ampullo-pancreato-biliary region.
  • We report a case of invasive micropapillary carcinoma of the papilla of Vater.
  • Detailed investigations revealed a tumor in the periampullary region, and pancreatoduodenectomy was performed for cancer of the ampulla of Vater.
  • Microscopic examination of the resected specimen revealed a tumor composed mainly of carcinoma cells arranged in micropapillary structures, with extensive regional lymph node metastasis.
  • [MeSH-major] Ampulla of Vater / pathology. Ampulla of Vater / surgery. Carcinoma, Papillary / pathology. Carcinoma, Papillary / surgery. Common Bile Duct Neoplasms / pathology. Common Bile Duct Neoplasms / surgery
  • [MeSH-minor] Fatal Outcome. Humans. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Invasiveness

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Mod Pathol. 2005 Nov;18(11):1504-11 [16007065.001]
  • [Cites] Histopathology. 2005 Nov;47(5):479-84 [16241995.001]
  • [Cites] Pancreas. 2007 Aug;35(2):190-2 [17632330.001]
  • [Cites] J Urol. 1999 Jun;161(6):1798-802 [10332438.001]
  • [Cites] Mod Pathol. 1993 Nov;6(6):660-2 [8302807.001]
  • [Cites] Mod Pathol. 2001 Sep;14(9):836-41 [11557778.001]
  • [Cites] BMC Urol. 2009 Jun 17;9:5 [19534791.001]
  • [Cites] Am J Surg Pathol. 1996 Nov;20(11):1319-30 [8898836.001]
  • [Cites] Hum Pathol. 2001 Jun;32(6):583-9 [11431712.001]
  • [Cites] Histopathology. 2009 May;54(6):741-50 [19438749.001]
  • [Cites] Histol Histopathol. 2005 Jul;20(3):791-9 [15944928.001]
  • [Cites] Hum Pathol. 1999 Dec;30(12):1459-63 [10667424.001]
  • [Cites] Histopathology. 2005 Jan;46(1):24-30 [15656882.001]
  • (PMID = 21110170.001).
  • [ISSN] 1436-2813
  • [Journal-full-title] Surgery today
  • [ISO-abbreviation] Surg. Today
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


38. Palanivelu C, Jani K, Senthilnathan P, Parthasarathi R, Rajapandian S, Madhankumar MV: Laparoscopic pancreaticoduodenectomy: technique and outcomes. J Am Coll Surg; 2007 Aug;205(2):222-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: The procedure could be completed laparoscopically with tumor-free margins in all patients, including patients with ampullary carcinoma (n = 24), pancreatic cystadenocarcinoma (n = 4), pancreatic head adenocarcinoma (n = 9), low common bile duct cancer (n = 3), and two patients with chronic pancreatitis with a suspicious mass lesion in the head of pancreas.
  • Five-year actuarial survival rates for all patients with malignancy, ampullary adenocarcinoma, pancreatic cystadenocarcinoma, pancreatic head adenocarcinoma, and common bile duct adenocarcinoma are 32%, 30.7%, 33.3%, 19.1%, and 50%, respectively.
  • Localized malignant lesions, irrespective of histopathology, are particularly amenable to this approach.
  • [MeSH-major] Duodenal Neoplasms / surgery. Laparoscopy. Pancreatic Neoplasms / surgery. Pancreaticoduodenectomy / methods

  • MedlinePlus Health Information. consumer health - Intestinal Cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17660068.001).
  • [ISSN] 1072-7515
  • [Journal-full-title] Journal of the American College of Surgeons
  • [ISO-abbreviation] J. Am. Coll. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


39. Kamisawa T, Tu Y, Egawa N, Tsuruta K, Okamoto A, Funata N: Endocrine cells in ampullary carcinoma. J Hepatobiliary Pancreat Surg; 2009;16(3):322-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endocrine cells in ampullary carcinoma.
  • BACKGROUND/PURPOSE: As ampullary carcinoma originates from four anatomical regions, it may have different behaviors depending on its origin.
  • We documented the presence of endocrine cells found in ampullary carcinoma, and we studied the clinicopathological implications of their presence.
  • METHODS: We immunohistochemically examined the presence of an endocrine component in 62 surgically resected specimens of ampullary carcinoma, and we studied the clinicopathological differences between endocrine component-positive cases and endocrine component-negative cases.
  • The histology of 15 of the 16 endocrine component-positive ampullary carcinomas was the intestinal type.
  • Pancreatic invasion and lymph node involvement were observed less frequently in endocrine component-positive cases (P < 0.01).
  • CONCLUSIONS: Endocrine component-positive ampullary carcinoma seemed to be derived from the ampullopancreaticobiliary common duct or the ampulloduodenum, and to behave less aggressively than endocrine component-negative carcinoma.
  • [MeSH-major] Ampulla of Vater / pathology. Common Bile Duct Neoplasms / pathology. Endocrine Cells / pathology. Neoplasm Invasiveness / pathology. Pancreatic Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19214369.001).
  • [ISSN] 1436-0691
  • [Journal-full-title] Journal of hepato-biliary-pancreatic surgery
  • [ISO-abbreviation] J Hepatobiliary Pancreat Surg
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Carcinoembryonic Antigen
  •  go-up   go-down


40. Sun JH, Chao M, Zhang SZ, Zhang GQ, Li B, Wu JJ: Coexistence of small cell neuroendocrine carcinoma and villous adenoma in the ampulla of Vater. World J Gastroenterol; 2008 Aug 7;14(29):4709-12
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Coexistence of small cell neuroendocrine carcinoma and villous adenoma in the ampulla of Vater.
  • Small cell neuroendocrine carcinoma of the ampulla of Vater is extremely rare and different from the common ampullary adenocarcinoma.
  • The ampullary adenoma is also a rare neoplasm and has the potential to develop an adenocarcinoma.
  • We herein describe an unusual case of a small cell neuroendocrine carcinoma associated with a villous adenoma in the ampulla of Vater with emphasis on computed tomography (CT) and histopathological findings.
  • [MeSH-major] Adenoma, Villous / complications. Ampulla of Vater. Carcinoma, Neuroendocrine / complications. Common Bile Duct Neoplasms / complications

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Hepatogastroenterology. 2001 Nov-Dec;48(42):1588-93 [11813580.001]
  • [Cites] Gastrointest Endosc. 2002 Jun;55(7):870-6 [12024143.001]
  • [Cites] Arch Pathol Lab Med. 2003 Feb;127(2):221-3 [12562240.001]
  • [Cites] J Clin Oncol. 2004 Jul 1;22(13):2730-9 [15226341.001]
  • [Cites] J Hepatobiliary Pancreat Surg. 2004;11(4):232-8 [15368106.001]
  • [Cites] J Natl Cancer Inst. 1981 Sep;67(3):607-12 [6268879.001]
  • [Cites] J Hepatobiliary Pancreat Surg. 2006;13(5):450-3 [17013721.001]
  • [Cites] Am J Surg Pathol. 1990 Aug;14(8):703-13 [1696069.001]
  • [Cites] Gut. 1991 Dec;32(12):1558-61 [1773967.001]
  • [Cites] Cancer. 1992 Sep 15;70(6):1502-4 [1325273.001]
  • [Cites] J Hepatobiliary Pancreat Surg. 2004;11(1):56-60 [15747032.001]
  • [Cites] Am J Surg Pathol. 2005 May;29(5):588-94 [15832081.001]
  • [Cites] Clin Gastroenterol. 1986 Apr;15(2):439-56 [3731520.001]
  • (PMID = 18698690.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] China
  • [Other-IDs] NLM/ PMC2738800
  •  go-up   go-down


41. Baumhoer D, Riener MO, Zlobec I, Tornillo L, Vogetseder A, Kristiansen G, Dietmaier W, Hartmann A, Wuensch PH, Sessa F, Ruemmele P, Terracciano LM: Expression of CD24, P-cadherin and S100A4 in tumors of the ampulla of Vater. Mod Pathol; 2009 Feb;22(2):306-13
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of CD24, P-cadherin and S100A4 in tumors of the ampulla of Vater.
  • Carcinomas of the Vaterian system are rare and presumably arise from preexisting adenomas (adenoma-carcinoma-sequence).
  • Usually, biopsies are obtained to confirm and specify endoscopic findings, but differentiating reactive atypia from dysplasia or dysplasia from invasive carcinoma can sometimes be difficult or even impossible on morphological criteria alone.
  • In case of invasive carcinoma, furthermore, the precise classification of carcinoma subtypes needs to be established since the distinct subtypes differ significantly in terms of clinical outcome.
  • We therefore investigated their expression in 177 carcinoma, 114 adenoma and 152 normal mucosa specimens of the ampulla of Vater.
  • Although the expression of the cell adhesion proteins did not differ between the carcinoma subtypes, marked differences between normal mucosa, adenoma and carcinoma samples were observed.
  • All marker proteins were expressed in less than 7% of normal mucosa samples (S100A4 in only 1% of cases) and showed an increasing expression from adenoma to invasive carcinoma.
  • CD24 and S100A4, furthermore, can assist in the differential diagnosis of dysplasia vs invasive carcinoma.
  • [MeSH-major] Adenoma / chemistry. Ampulla of Vater / chemistry. Antigens, CD24 / analysis. Biomarkers, Tumor / analysis. Cadherins / analysis. Carcinoma / chemistry. Common Bile Duct Neoplasms / chemistry. S100 Proteins / analysis
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Biopsy. Diagnosis, Differential. Europe. Female. Humans. Male. Middle Aged. Mucous Membrane / chemistry. Neoplasm Invasiveness. Young Adult

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19043399.001).
  • [ISSN] 1530-0285
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD24; 0 / Biomarkers, Tumor; 0 / CD24 protein, human; 0 / CDH3 protein, human; 0 / Cadherins; 0 / S100 Proteins; 142662-27-9 / S100A4 protein, human
  •  go-up   go-down


42. Williams KJ, Picus J, Trinkhaus K, Fournier CC, Suresh R, James JS, Tan BR: Gemcitabine with carboplatin for advanced biliary tract cancers: a phase II single institution study. HPB (Oxford); 2010 Aug;12(6):418-26
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Patients with histologically proven BTCs, including cholangiocarcinoma or gallbladder and ampullary carcinomas, were treated with a maximum of nine cycles of intravenous (i.v.) gemcitabine at 1000 mg/m(2) over 30 min on days 1 and 8 with i.v. carboplatin dosed at an area-under-the-curve (AUC) of 5 over 60 min on day 1 of a 21-day cycle.
  • RESULTS: A total of 48 patients with advanced BTCs (35 cholangiocarcinoma, 12 gallbladder and 1 ampullary cancer) were enrolled.

  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Clin Oncol. 2000 Aug;23(4):425-8 [10955877.001]
  • [Cites] N Engl J Med. 2010 Apr 8;362(14):1273-81 [20375404.001]
  • [Cites] Hepatogastroenterology. 2001 May-Jun;48(39):783-9 [11462924.001]
  • [Cites] Eur J Cancer. 2001 Oct;37(15):1833-8 [11576836.001]
  • [Cites] J Clin Oncol. 2001 Oct 15;19(20):4089-91 [11600613.001]
  • [Cites] Cancer. 2002 Oct 15;95(8):1685-95 [12365016.001]
  • [Cites] Invest New Drugs. 2004 Apr;22(2):193-8 [14739669.001]
  • [Cites] Ann Oncol. 2004 Sep;15(9):1339-43 [15319238.001]
  • [Cites] Cancer. 1974 Jan;33(1):193-7 [4272473.001]
  • [Cites] Br J Surg. 1974 Feb;61(2):98-100 [4361236.001]
  • [Cites] Ann Surg. 1982 Mar;195(3):270-3 [7059239.001]
  • [Cites] Cancer. 1984 Sep 15;54(6):965-9 [6235908.001]
  • [Cites] J Clin Oncol. 1984 Nov;2(11):1245-8 [6092556.001]
  • [Cites] Ann Surg. 1988 Feb;207(2):120-5 [2829760.001]
  • [Cites] Control Clin Trials. 1989 Mar;10(1):1-10 [2702835.001]
  • [Cites] Surg Clin North Am. 1990 Dec;70(6):1429-47 [2174191.001]
  • [Cites] Arch Surg. 1993 Aug;128(8):871-7; discussion 877-9 [8393652.001]
  • [Cites] Ann Oncol. 1993 Aug;4(7):607-9 [8363992.001]
  • [Cites] J Surg Oncol. 1994 Apr;55(4):239-45 [8159005.001]
  • [Cites] Am J Clin Oncol. 1994 Jun;17(3):223-6 [8192106.001]
  • [Cites] Ann Oncol. 1996 Aug;7(6):593-600 [8879373.001]
  • [Cites] Oncol Rep. 1998 Jul-Aug;5(4):931-4 [9625849.001]
  • [Cites] Oncology. 1999 Apr;56(3):177-80 [10202270.001]
  • [Cites] Br J Cancer. 2004 Nov 15;91(10):1769-74 [15505626.001]
  • [Cites] Cancer. 2005 Jan 1;103(1):111-8 [15558814.001]
  • [Cites] Jpn J Clin Oncol. 2005 Feb;35(2):68-73 [15709089.001]
  • [Cites] Ann Oncol. 2005;16 Suppl 2:ii93-6 [15958484.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Jul 15;62(4):1030-4 [15990005.001]
  • [Cites] BMC Cancer. 2005;5:61 [15949047.001]
  • [Cites] Cancer Chemother Pharmacol. 2006 May;57(5):647-53 [16142487.001]
  • [Cites] Cancer. 2006 Mar 15;106(6):1339-46 [16475213.001]
  • [Cites] Br J Cancer. 2006 Oct 9;95(7):848-52 [16969352.001]
  • [Cites] J Clin Oncol. 2006 Oct 10;24(29):4699-707 [16966687.001]
  • [Cites] Br J Cancer. 2007 Mar 26;96(6):896-902 [17325704.001]
  • [Cites] Eur Urol. 2007 Jul;52(1):134-41 [17207911.001]
  • [Cites] J Natl Cancer Inst. 2007 Jun 6;99(11):847-57 [17551145.001]
  • [Cites] Cancer. 2007 Sep 15;110(6):1307-12 [17628484.001]
  • [Cites] Dig Dis Sci. 2008 Feb;53(2):564-70 [17597402.001]
  • [Cites] CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96 [18287387.001]
  • [Cites] J Clin Oncol. 2008 Aug 1;26(22):3702-8 [18669455.001]
  • [Cites] Clin Breast Cancer. 2008 Oct;8(5):425-31 [18952556.001]
  • [Cites] Eur J Cancer. 2009 Jan;45(2):228-47 [19097774.001]
  • [Cites] Cancer Chemother Pharmacol. 2009 Jul;64(2):371-7 [19142638.001]
  • [Cites] Ann Oncol. 2001 Feb;12(2):183-6 [11300321.001]
  • (PMID = 20662793.001).
  • [ISSN] 1477-2574
  • [Journal-full-title] HPB : the official journal of the International Hepato Pancreato Biliary Association
  • [ISO-abbreviation] HPB (Oxford)
  • [Language] eng
  • [Databank-accession-numbers] ClinicalTrials.gov/ NCT00660140
  • [Publication-type] Clinical Trial, Phase II; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine; BG3F62OND5 / Carboplatin
  • [Other-IDs] NLM/ PMC3028583
  •  go-up   go-down


43. Nielsen A, Scarlett CJ, Samra JS, Gill A, Li Y, Allen BJ, Smith RC: Significant overexpression of urokinase-type plasminogen activator in pancreatic adenocarcinoma using real-time quantitative reverse transcription polymerase chain reaction. J Gastroenterol Hepatol; 2005 Feb;20(2):256-63
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Significant overexpression of urokinase-type plasminogen activator in pancreatic adenocarcinoma using real-time quantitative reverse transcription polymerase chain reaction.
  • It was hypothesized that uPA would be overexpressed in highly metastatic pancreatic cancer.
  • The aims of this study were to analyze uPA mRNA expression in pancreatic cancer and to correlate this to the expression of uPA protein and to the stage of the disease.
  • METHODS: Twenty-one pancreatic adenocarcinoma, six ampullary carcinoma and 10 benign mucinous cystadenoma samples, all with adjacent normal tissue, were collected. uPA mRNA was measured using real-time quantitative reverse transcription polymerase chain reaction.
  • Localization of uPA within normal and pancreatic tumor sections was subsequently confirmed using immunohistochemistry.
  • RESULTS: The median and range of the ratios of uPA mRNA measures between tumor tissue and non-involved pancreatic tissue was 17.1 (1.4-653.6) for pancreatic adenocarcinoma (P < 0.001), 3.9 (0.7-7.7) for ampullary carcinoma (P = 0.055) and 1.9 (0.6-5.9) for mucinous cystadenoma tissue (P = 0.052).
  • Immunohistochemistry confirmed that uPA protein was more prevalent in pancreatic adenocarcinoma tissue than in normal tissue and that it was membrane-bound. uPA mRNA expression was significantly associated with poorly differentiated pancreatic cancers (P < 0.05) and positively associated with tumor stage.
  • CONCLUSIONS: These observations suggest that significant overexpression of uPA correlates closely to the rapid progression and invasiveness of pancreatic cancer and that uPA may provide a future therapeutic target for pancreatic cancer treatment.
  • [MeSH-major] Adenocarcinoma / genetics. Pancreatic Neoplasms / genetics. Urokinase-Type Plasminogen Activator / genetics

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2004 Blackwell Publishing Asia Pty Ltd.
  • (PMID = 15683429.001).
  • [ISSN] 0815-9319
  • [Journal-full-title] Journal of gastroenterology and hepatology
  • [ISO-abbreviation] J. Gastroenterol. Hepatol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / RNA, Messenger; EC 3.4.21.73 / Urokinase-Type Plasminogen Activator
  •  go-up   go-down


44. Shao YF, Wu TC, Shan Y, Wu JX, Wang X, Zhao P: [Clinico-pathological characteristics of surgical effect on periampullary cancers: report of 631 cases]. Zhonghua Yi Xue Za Zhi; 2005 Mar 2;85(8):510-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: A retrospective study was accomplished on the clinical manifestation, pathological behavior and postoperative survival of 631 patients with periampullary cancer hospitalized from Jan 1980 to Dec 2003.
  • RESULTS: The characteristics of different periampullary cancers, in the order of carcinoma of head of pancreas (n = 352), carcinoma of common bile duct (n = 42), carcinoma of Vater's ampulla (n = 189), and duodenal cancer (n = 48) were as follows:.
  • [MeSH-major] Ampulla of Vater. Common Bile Duct Neoplasms / pathology. Pancreatic Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15949327.001).
  • [ISSN] 0376-2491
  • [Journal-full-title] Zhonghua yi xue za zhi
  • [ISO-abbreviation] Zhonghua Yi Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


45. Kim YK, Han YM, Kim CS: Usefulness of fat-suppressed T1-weighted MRI using orally administered superparamagnetic iron oxide for revealing ampullary carcinomas. J Comput Assist Tomogr; 2007 Jul-Aug;31(4):519-25
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Usefulness of fat-suppressed T1-weighted MRI using orally administered superparamagnetic iron oxide for revealing ampullary carcinomas.
  • OBJECTIVE: To evaluate the value of adding fat-suppressed (FS) T1-weighted magnetic resonance imaging (MRI) with orally administered superparamagnetic iron oxide (SPIO) to the 3-dimensional dynamic MRI for revealing ampullary carcinomas.
  • MATERIALS: Twenty-five patients with ampullary carcinoma who underwent MRI with orally administered SPIO, including a FS T1-weighted fast low-angle shot (FLASH) sequence, a respiratory-triggered turbo spin-echo (RT-TSE) sequence, and the 3-phasic 3-dimensional dynamic images, were enrolled in this study.
  • CONCLUSIONS: Addition of the FS FLASH image using orally administered SPIO to the dynamic MRI is useful for revealing ampullary carcinoma.
  • [MeSH-major] Adenocarcinoma / diagnosis. Ampulla of Vater. Common Bile Duct Neoplasms / diagnosis. Contrast Media. Ferric Compounds. Image Enhancement / methods. Magnetic Resonance Imaging / methods

  • MedlinePlus Health Information. consumer health - MRI Scans.
  • Hazardous Substances Data Bank. FERRIC OXIDE .
  • Hazardous Substances Data Bank. HEMATITE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17882025.001).
  • [ISSN] 0363-8715
  • [Journal-full-title] Journal of computer assisted tomography
  • [ISO-abbreviation] J Comput Assist Tomogr
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Contrast Media; 0 / Ferric Compounds; 1K09F3G675 / ferric oxide
  •  go-up   go-down


46. Hsu HP, Shan YS, Hsieh YH, Yang TM, Lin PW: Predictors of recurrence after pancreaticoduodenectomy in ampullary cancer: comparison between non-, early and late recurrence. J Formos Med Assoc; 2007 Jun;106(6):432-43
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Predictors of recurrence after pancreaticoduodenectomy in ampullary cancer: comparison between non-, early and late recurrence.
  • BACKGROUND/PURPOSE: Ampullary cancer is one of the periampullary cancers with a better prognosis, but relapse still occurs early in some patients.
  • METHODS: Between January 1989 and March 2006, information was gathered on a total of 127 patients undergoing pancreaticoduodenectomy with regional lymphadenectomy for ampullary cancer at National Cheng Kung University Hospital and Tainan Municipal Hospital.
  • The early and late recurrence patients had higher levels of microscopically (R1) or macroscopically (R2) positive margin of resection and more advanced disease (advanced tumor stage, numbers of lymph nodes involved, lymph node status, pancreatic invasion and TNM stage) than the non-recurrence group.
  • After multivariate analysis, positive resection margin, pancreatic invasion and lymph node involvement were significant predictors for disease recurrence.
  • CONCLUSION: Positive resection margin, pancreatic invasion, and lymph node involvement were found to be predictors for disease recurrence and indicators for postoperative treatment.

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17588836.001).
  • [ISSN] 0929-6646
  • [Journal-full-title] Journal of the Formosan Medical Association = Taiwan yi zhi
  • [ISO-abbreviation] J. Formos. Med. Assoc.
  • [Language] ENG
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Singapore
  •  go-up   go-down


47. Cortes A, Sauvanet A, Bert F, Janny S, Sockeel P, Kianmanesh R, Ponsot P, Ruszniewski P, Belghiti J: Effect of bile contamination on immediate outcomes after pancreaticoduodenectomy for tumor. J Am Coll Surg; 2006 Jan;202(1):93-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: The distribution of tumors was comparable except for ampullary carcinoma, which was more frequent in group B+ patients (p = 0.001).
  • During PD for ampullary carcinoma or after interventional biliary endoscopy, a specific antibioprophylaxis should be evaluated.
  • [MeSH-major] Ampulla of Vater. Bile / microbiology. Common Bile Duct Neoplasms / surgery. Pancreaticoduodenectomy. Postoperative Complications

  • MedlinePlus Health Information. consumer health - After Surgery.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16377502.001).
  • [ISSN] 1072-7515
  • [Journal-full-title] Journal of the American College of Surgeons
  • [ISO-abbreviation] J. Am. Coll. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


48. Ni XG, Bai XF, Mao YL, Shao YF, Wu JX, Shan Y, Wang CF, Wang J, Tian YT, Liu Q, Xu DK, Zhao P: The clinical value of serum CEA, CA19-9, and CA242 in the diagnosis and prognosis of pancreatic cancer. Eur J Surg Oncol; 2005 Mar;31(2):164-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The clinical value of serum CEA, CA19-9, and CA242 in the diagnosis and prognosis of pancreatic cancer.
  • AIM: Serum tumour markers carcinoembryonic antigen (CEA), carbohydrate antigen 19-9 (CA19-9) and CA242 were investigated to evaluate the values of single and combined test in the diagnosis and prognosis of pancreatic cancer.
  • METHODS: Pre-operative serum CEA, CA19-9 and CA242 were measured in 105 pancreatic cancers, 70 non-pancreatic malignancies and 30 benign pancreatic diseases.
  • RESULTS: The sensitivity of CA19-9 alone was the highest in pancreatic cancer patients (80%), but the specificity was significantly lower than that of CEA and CA242 (P<0.01).
  • CONCLUSION: The diagnostic rate of CA19-9 in pancreatic cancer is better than that of CEA and CA242.
  • [MeSH-major] Antigens, Tumor-Associated, Carbohydrate / blood. Biomarkers, Tumor / blood. CA-19-9 Antigen / blood. Carcinoembryonic Antigen / blood. Carcinoma, Islet Cell / blood. Carcinoma, Islet Cell / diagnosis. Pancreatic Neoplasms / blood. Pancreatic Neoplasms / diagnosis
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Ampulla of Vater / metabolism. Ampulla of Vater / pathology. Bile Duct Neoplasms / blood. Bile Duct Neoplasms / diagnosis. Bile Duct Neoplasms / surgery. Bile Ducts, Extrahepatic / metabolism. Bile Ducts, Extrahepatic / pathology. Bilirubin / blood. Cholangiocarcinoma / blood. Cholangiocarcinoma / diagnosis. Cholangiocarcinoma / surgery. Female. Humans. Male. Middle Aged. Neoplasm Staging. Pancreaticoduodenectomy. Prognosis. Sensitivity and Specificity. Statistics as Topic. Survival Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15698733.001).
  • [ISSN] 0748-7983
  • [Journal-full-title] European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  • [ISO-abbreviation] Eur J Surg Oncol
  • [Language] eng
  • [Publication-type] Comparative Study; Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, Tumor-Associated, Carbohydrate; 0 / Biomarkers, Tumor; 0 / CA 242 antigen; 0 / CA-19-9 Antigen; 0 / Carcinoembryonic Antigen; RFM9X3LJ49 / Bilirubin
  •  go-up   go-down


49. Artifon EL, Couto D Jr, Sakai P, da Silveira EB: Prospective evaluation of EUS versus CT scan for staging of ampullary cancer. Gastrointest Endosc; 2009 Aug;70(2):290-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prospective evaluation of EUS versus CT scan for staging of ampullary cancer.
  • BACKGROUND: Malignancies of the biliary and pancreatic systems are associated with a poor prognosis.
  • However, ampullary cancer carries a better prognosis and is often diagnosed when curative treatment is still possible.
  • (1) To determine the test performance characteristics of EUS and CT in loco-regional staging of ampullary neoplasms, and (2) to determine the impact of CT scan results on the test performance characteristics of EUS.
  • Further studies to determine the role of specialized CT protocols in patients with ampullary malignancies are needed.
  • [MeSH-major] Adenocarcinoma / pathology. Ampulla of Vater. Common Bile Duct Neoplasms / pathology. Endosonography. Tomography, X-Ray Computed
  • [MeSH-minor] Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Neoplasm Staging. Prospective Studies

  • MedlinePlus Health Information. consumer health - CT Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19523619.001).
  • [ISSN] 1097-6779
  • [Journal-full-title] Gastrointestinal endoscopy
  • [ISO-abbreviation] Gastrointest. Endosc.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


50. Yang YM, Tian XD, Zhuang Y, Wang WM, Wan YL, Huang YT: Risk factors of pancreatic leakage after pancreaticoduodenectomy. World J Gastroenterol; 2005 Apr 28;11(16):2456-61
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Risk factors of pancreatic leakage after pancreaticoduodenectomy.
  • AIM: To analyze the risk factors for pancreatic leakage after pancreaticoduodenectomy (PD) and to evaluate whether duct-to-mucosa pancreaticojejunostomy could reduce the risk of pancreatic leakage.
  • The primary diseases of the patients included pancreas cancer, ampullary cancer, bile duct cancer, islet cell cancer, duodenal cancer, chronic pancreatitis, pancreatic cystadenoma, and gastric cancer.
  • A duct-to-mucosa pancreaticojejunostomy was performed for patients with a hard pancreas and a dilated pancreatic duct, and a traditional end-to-end invagination pancreaticojejunostomy for patients with a soft pancreas and a non-dilated duct.
  • Seven preoperative and six intraoperative risk factors with the potential to affect the incidence of pancreatic leakage were analyzed with SPSS10.0 software.
  • Logistic regression was then used to determine the effect of multiple factors on pancreatic leakage.
  • RESULTS: Of the 62 patients, 10 (16.13%) were identified as having pancreatic leakage after operation.
  • The hospital mortality in this series was 4.84% (3/62), and the mortality associated with pancreatic fistula was 10% (1/10).
  • Sixteen cases underwent duct-to-mucosa pancreaticojejunostomy and 1 case (1/16, 6.25%) developed postoperative pancreatic leakage, 46 cases underwent invagination pancreaticojejunostomy and 9 cases (9/46, 19.6%) developed postoperative pancreatic leakage.
  • General risk factors including patient age, gender, history of jaundice, preoperative nutrition, pathological diagnosis and the length of postoperative stay were similar in the two groups.
  • There was no statistical difference in the incidence of pancreatic leakage between the patients who received the prophylactic use of octreotide after surgery and the patients who did not undergo somatostatin therapy.
  • Moreover, multivariate logistic regression analysis showed that none of the above factors seemed to be associated with pancreatic fistula.
  • Two intraoperative risk factors, pancreatic duct size and texture of the remnant pancreas, were found to be significantly associated with pancreatic leakage.
  • The incidence of pancreatic leakage was 4.88% in patients with a pancreatic duct size greater than or equal to 3 mm and was 38.1% in those with ducts smaller than 3 mm (P = 0.002).
  • The pancreatic leakage rate was 2.94% in patients with a hard pancreas and was 32.1% in those with a soft pancreas (P = 0.004).
  • The incidence of pancreatic leakage was 6.25% (1/16) in patients with duct-to-mucosa anastomosis, and was 19.6% (9/46) in those with traditional invagination anastomosis.
  • Although the difference of pancreatic leakage between the two groups was obvious, no statistical significance was found.
  • By further analyzing with multivariate logistic regression, both pancreatic duct size and texture of the remnant pancreas were demonstrated to be independent risk factors (P = 0.007 and 0.017, OR = 11.87 and 15.45).
  • Although anastomotic technique was not a significant factor, pancreatic leakage rate was much less in cases that underwent duct-to-mucosa pancreaticojejunostomy.
  • CONCLUSION: Pancreatic duct size and texture of the remnant pancreas are risk factors influencing pancreatic leakage after PD.
  • Duct-to-mucosa pancreaticojejunostomy, as a safe and useful anastomotic technique, can reduce pancreatic leakage rate after PD.
  • [MeSH-major] Intraoperative Complications / epidemiology. Pancreatic Diseases / epidemiology. Pancreatic Diseases / surgery. Pancreaticoduodenectomy / adverse effects. Postoperative Complications / epidemiology
  • [MeSH-minor] Adult. Aged. Duodenum / surgery. Female. Humans. Male. Middle Aged. Pancreas / surgery. Pancreatic Ducts / surgery. Risk Factors

  • MedlinePlus Health Information. consumer health - After Surgery.
  • MedlinePlus Health Information. consumer health - Pancreatic Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15832417.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  • [Other-IDs] NLM/ PMC4305634
  •  go-up   go-down


51. Stojsic Z, Brasanac D, Bilanovic D, Mitrovic O, Stevanovic R, Boricic I: Large-cell neuroendocrine carcinoma of the ampulla of Vater. Med Oncol; 2010 Dec;27(4):1144-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Large-cell neuroendocrine carcinoma of the ampulla of Vater.
  • Large-cell neuroendocrine carcinoma is a high-grade neuroendocrine carcinoma, originally described in the lung.
  • The tumor rarely occurs in extrapulmonary sites like the gastrointestinal tract, and only few examples have been described in the ampulla of Vater.
  • A new case of large-cell neuroendocrine carcinoma of the ampulla of Vater in a 60-year-old man is reported.
  • After pancreatoduodenectomy, macroscopic examination revealed ulcerated tumor in the region of the ampulla of Vater.
  • Two months after surgery, liver metastases occurred, confirming highly aggressive behavior of large-cell neuroendocrine carcinoma.
  • [MeSH-major] Ampulla of Vater / pathology. Carcinoma, Large Cell / pathology. Carcinoma, Neuroendocrine / pathology. Common Bile Duct Neoplasms / pathology. Liver Neoplasms / secondary


52. Schirmacher P, Büchler MW: Ampullary adenocarcinoma - differentiation matters. BMC Cancer; 2008;8:251
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ampullary adenocarcinoma - differentiation matters.
  • This fuels the discussion about maintaining ampullary cancer as a separate entity.
  • [MeSH-major] Adenocarcinoma / diagnosis. Ampulla of Vater / pathology. Common Bile Duct Neoplasms / diagnosis
  • [MeSH-minor] Biomarkers, Tumor. Cell Differentiation. Diagnosis, Differential. Epithelium / pathology. Humans. Medical Oncology / methods. Prognosis

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2001 May 1;19(9):2422-32 [11331321.001]
  • [Cites] Jpn J Cancer Res. 1994 Feb;85(2):161-6 [7511574.001]
  • [Cites] Eur J Surg Oncol. 2009 Feb;35(2):187-91 [18343082.001]
  • [Cites] Surgery. 2006 Nov;140(5):764-72 [17084719.001]
  • [Cites] BMC Cancer. 2008;8:170 [18547417.001]
  • [Cites] Arch Surg. 1999 May;134(5):526-32 [10323425.001]
  • (PMID = 18761739.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Editorial
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Other-IDs] NLM/ PMC2553420
  •  go-up   go-down


53. Ruemmele P, Dietmaier W, Terracciano L, Tornillo L, Bataille F, Kaiser A, Wuensch PH, Heinmoeller E, Homayounfar K, Luettges J, Kloeppel G, Sessa F, Edmonston TB, Schneider-Stock R, Klinkhammer-Schalke M, Pauer A, Schick S, Hofstaedter F, Baumhoer D, Hartmann A: Histopathologic features and microsatellite instability of cancers of the papilla of vater and their precursor lesions. Am J Surg Pathol; 2009 May;33(5):691-704
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Histopathologic features and microsatellite instability of cancers of the papilla of vater and their precursor lesions.
  • The prevalence and development of microsatellite instability (MSI) and underlying mismatch repair (MMR) deficiency in the carcinogenesis of adenocarcinomas of the papilla of Vater and their precursor lesions are not well established.
  • We analyzed 120 ampullary adenomas (31 pure adenomas and 89 carcinoma-associated adenomas) and 170 pure adenocarcinomas for MSI, immunohistochemical expression of MMR proteins and specific histopathologic features.
  • Patients with MSI-H carcinoma had a significantly longer overall survival (P=0.0082) than those with MSI-L or MSS tumors.
  • The MMR deficient molecular pathway of carcinogenesis is associated with a histopathologic phenotype in ampullary cancer, similar to the one that has been well described in colon cancer.
  • [MeSH-major] Adenoma / pathology. Ampulla of Vater / pathology. Carcinoma / pathology. Common Bile Duct Neoplasms / pathology. DNA Mismatch Repair. Gene Expression Regulation, Neoplastic. Microsatellite Instability. Precancerous Conditions / pathology
  • [MeSH-minor] Adaptor Proteins, Signal Transducing / genetics. Adenocarcinoma / genetics. Adenocarcinoma / pathology. Adenocarcinoma, Mucinous / genetics. Adenocarcinoma, Mucinous / pathology. Adult. Aged. Aged, 80 and over. Carcinoma, Papillary / genetics. Carcinoma, Papillary / pathology. Cell Differentiation. DNA Methylation. DNA-Binding Proteins / genetics. Europe. Female. Gene Deletion. Genotype. Humans. Immunohistochemistry. Kaplan-Meier Estimate. Male. Middle Aged. MutS Homolog 2 Protein / genetics. Neoplasm Invasiveness. Neoplasm Staging. Nuclear Proteins / genetics. Phenotype. Polymerase Chain Reaction. Promoter Regions, Genetic. Proportional Hazards Models. Risk Assessment. Treatment Outcome

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19252434.001).
  • [ISSN] 1532-0979
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adaptor Proteins, Signal Transducing; 0 / DNA-Binding Proteins; 0 / G-T mismatch-binding protein; 0 / MLH1 protein, human; 0 / Nuclear Proteins; EC 3.6.1.3 / MSH2 protein, human; EC 3.6.1.3 / MutS Homolog 2 Protein
  •  go-up   go-down


54. Ouaïssi M, Sielezneff I, Alves A, Pirro N, Heyries L, Robitail S, Consentino B, Payan MJ, Valleur P, Panis Y, Sastre B: [Long term outcome following 26 surgical ampullectomies]. Ann Chir; 2006 May;131(5):322-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Résultat à long terme de 26 ampullectomies chirurgicales.
  • BACKGROUND: Pancreaticoduodenectomy (PD) is the standard surgical treatment for malignant ampullomas but is still associated with a mortality and morbidity still ranging from 0 to 10% and from 15 to 40%, respectively.
  • Ampullectomy is an alternative to PD for benign ampulloma or, in high-risk patients, for invasive carcinoma.
  • CONCLUSION: Ampullectomy is a good alternative to PD in case of benign or non-invasive malignant ampullary lesion, including in selected cases of FAP.
  • [MeSH-major] Ampulla of Vater / surgery. Common Bile Duct Neoplasms / surgery
  • [MeSH-minor] Adenocarcinoma / surgery. Adenoma / surgery. Adenomatous Polyposis Coli / surgery. Adult. Aged. Carcinoma in Situ / surgery. Cause of Death. Common Bile Duct Diseases / surgery. Female. Follow-Up Studies. Granuloma, Plasma Cell / surgery. Humans. Longitudinal Studies. Male. Middle Aged. Neoplasm Recurrence, Local / pathology. Retrospective Studies. Somatostatinoma / surgery. Survival Rate. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16615931.001).
  • [ISSN] 0003-3944
  • [Journal-full-title] Annales de chirurgie
  • [ISO-abbreviation] Ann Chir
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


55. Franko J, Krasinskas AM, Nikiforova MN, Zarnescu NO, Lee KK, Hughes SJ, Bartlett DL, Zeh HJ 3rd, Moser AJ: Loss of heterozygosity predicts poor survival after resection of pancreatic adenocarcinoma. J Gastrointest Surg; 2008 Oct;12(10):1664-72; discussion 1672-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Loss of heterozygosity predicts poor survival after resection of pancreatic adenocarcinoma.
  • BACKGROUND: American Joint Committee on Cancer (AJCC) staging for pancreatic adenocarcinoma is a validated predictor of prognosis but insufficiently discriminates postresection survival.
  • METHODS: Resected pancreatic ductal and ampullary adenocarcinomas (n = 50) were analyzed for loss of heterozygosity (LOH) at 15 markers including 5q(APC), 6q(TBSP2), 9p(p16), 10q(PTEN), 12q(MDM2), 17p(TP53), and 18q(DCC/SMAD4).
  • CONCLUSION: LOH and KRAS mutations indicate aggressive tumor biology and correlate strongly with survival in resected pancreatic ductal and ampullary carcinomas.
  • [MeSH-major] Adenocarcinoma / genetics. Ampulla of Vater. Common Bile Duct Neoplasms / genetics. Loss of Heterozygosity. Pancreatic Neoplasms / genetics
  • [MeSH-minor] Aged. Aged, 80 and over. Carcinoma, Pancreatic Ductal / genetics. Carcinoma, Pancreatic Ductal / surgery. Female. Genes, Tumor Suppressor. Humans. Male. Middle Aged. Mutation. Pancreatectomy. Pilot Projects. Predictive Value of Tests. Prognosis. Proto-Oncogene Proteins / genetics. Proto-Oncogene Proteins p21(ras). Retrospective Studies. Survival Analysis. ras Proteins / genetics

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Surg. 2006 Jul;244(1):10-5 [16794383.001]
  • [Cites] Pancreas. 1996 May;12(4):373-80 [8740405.001]
  • [Cites] Cancer Res. 1997 Aug 1;57(15):3126-30 [9242437.001]
  • [Cites] J Clin Oncol. 2005 Oct 20;23(30):7529-35 [16234519.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Dec 21;96(26):14888-93 [10611308.001]
  • [Cites] Am J Pathol. 2003 Apr;162(4):1151-62 [12651607.001]
  • [Cites] Am J Gastroenterol. 2000 Aug;95(8):2080-5 [10950061.001]
  • [Cites] Development. 2007 Aug;134(15):2719-25 [17596282.001]
  • [Cites] J Gastrointest Surg. 2004 Dec;8(8):935-49; discussion 949-50 [15585381.001]
  • [Cites] J Clin Oncol. 2007 Feb 10;25(5):587-95 [17290067.001]
  • [Cites] Arch Surg. 2003 Apr;138(4):427-3; discussion 433-4 [12686529.001]
  • [Cites] Ann Surg. 2002 Sep;236(3):355-66; discussion 366-8 [12192322.001]
  • [Cites] Gene. 2000 Jan 25;242(1-2):15-29 [10721693.001]
  • [Cites] World J Gastroenterol. 2005 Apr 14;11(14 ):2162-5 [15810085.001]
  • [Cites] Breast Cancer Res. 2006;8(3):R25 [16737553.001]
  • [Cites] Annu Rev Cell Biol. 1991;7:601-32 [1667084.001]
  • [Cites] Science. 1998 May 15;280(5366):1036-7 [9616081.001]
  • [Cites] Cancer Res. 1995 Oct 15;55(20):4670-5 [7553647.001]
  • [Cites] Cancer Res. 2004 Feb 1;64(3):871-5 [14871814.001]
  • [Cites] Breast Cancer Res Treat. 2007 Jun;103(2):197-208 [17039265.001]
  • [Cites] Cancer. 2001 Aug 1;92(3):488-99 [11505392.001]
  • [Cites] Oncogene. 2007 Jul 19;26(33):4850-62 [17297450.001]
  • [Cites] J Gastrointest Surg. 2004 Nov;8(7):775-84; discussion 784 [15531230.001]
  • [Cites] Cancer Res. 2007 Sep 1;67(17):8121-30 [17804724.001]
  • [Cites] Liver Transpl. 2003 Jul;9(7):664-71 [12827550.001]
  • [Cites] Cancer. 2007 Aug 15;110(4):738-44 [17580363.001]
  • [Cites] Clin Cancer Res. 2006 Jan 1;12(1):235-41 [16397047.001]
  • [Cites] Science. 1987 Jun 26;236(4809):1657-61 [2885916.001]
  • [Cites] Cancer. 1999 Jan 15;85(2):326-32 [10023699.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Mar 11;105(10 ):3933-8 [18316739.001]
  • [Cites] Mol Cell. 2001 Jul;8(1):85-94 [11511362.001]
  • [Cites] Clin Cancer Res. 2000 Aug;6(8):2969-72 [10955772.001]
  • [Cites] Br J Cancer. 2005 Apr 25;92(8):1372-81 [15812554.001]
  • [Cites] Genes Chromosomes Cancer. 1997 Dec;20(4):383-91 [9408755.001]
  • [Cites] Ann Intern Med. 2008 Mar 4;148(5):358-69 [18252678.001]
  • [Cites] Clin Cancer Res. 2003 Oct 15;9(13):5044-52 [14581380.001]
  • [Cites] Surgery. 1973 Feb;73(2):307-20 [4265314.001]
  • [Cites] Mol Cancer. 2003 Jan 07;2:7 [12537585.001]
  • [Cites] Cancer Res. 2008 Jan 15;68(2):545-52 [18199551.001]
  • [Cites] Ann Surg. 2007 Aug;246(2):173-80 [17667493.001]
  • [Cites] Ann Surg. 2004 Aug;240(2):293-8 [15273554.001]
  • [Cites] N Engl J Med. 2004 Dec 30;351(27):2817-26 [15591335.001]
  • [Cites] Ann Surg. 1996 Feb;223(2):147-53 [8597508.001]
  • [Cites] Am J Pathol. 2000 Jun;156(6):2123-33 [10854233.001]
  • [Cites] Cancer Res. 2002 May 15;62(10):2890-6 [12019169.001]
  • [Cites] J Am Coll Surg. 1999 Jul;189(1):1-7 [10401733.001]
  • [Cites] Arch Surg. 2008 Jan;143(1):75-83; discussion 83 [18209156.001]
  • [Cites] J Gastrointest Surg. 2008 Apr;12(4):701-6 [18027062.001]
  • [Cites] J Gastrointest Surg. 2006 Mar;10(3):347-56 [16504879.001]
  • [Cites] Curr Opin Cell Biol. 1998 Apr;10(2):262-7 [9561851.001]
  • [Cites] Cancer Biol Ther. 2002 Nov-Dec;1(6):607-13 [12642681.001]
  • [Cites] Ann Surg Oncol. 2006 Sep;13(9):1189-200 [16955385.001]
  • [Cites] Blood. 1995 Aug 1;86(3):841-54 [7620180.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Aug 15;97(17):9624-9 [10944227.001]
  • [Cites] World J Surg. 1997 Feb;21(2):195-200 [8995078.001]
  • [Cites] World J Gastroenterol. 2007 Jul 21;13(27):3714-20 [17659731.001]
  • [Cites] Cell. 1988 May 20;53(4):549-54 [2453289.001]
  • [Cites] N Engl J Med. 2001 Apr 19;344(16):1196-206 [11309634.001]
  • [Cites] Surgery. 2007 May;141(5):610-8 [17462460.001]
  • (PMID = 18677542.001).
  • [ISSN] 1873-4626
  • [Journal-full-title] Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
  • [ISO-abbreviation] J. Gastrointest. Surg.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / KRAS protein, human; 0 / Proto-Oncogene Proteins; EC 3.6.5.2 / Proto-Oncogene Proteins p21(ras); EC 3.6.5.2 / ras Proteins
  •  go-up   go-down


56. Chen L, Tao SF, Zheng YX: Prognostic significance of vascular endothelial growth factor expression and microvessel density in carcinoma of ampulla of Vater. Hepatogastroenterology; 2006 Jan-Feb;53(67):45-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic significance of vascular endothelial growth factor expression and microvessel density in carcinoma of ampulla of Vater.
  • BACKGROUND/AIMS: To investigate whether the expression of vascular endothelial growth factor (VEGF) and microvessel density (MVD) are of prognostic significance in ampullary carcinoma.
  • METHODOLOGY: Twenty-two resected tumor specimens from patients with ampullary carcinoma were immunohistochemically stained for VEGF and CD34 (surrogate for vessels) by streptavidin-peroxidase method.
  • CONCLUSIONS: VEGF is positively correlated with MVD in ampullary carcinoma.
  • VEGF and angiogenesis may play an important role in lymph node metastasis and progression of ampullary carcinoma.
  • VEGF and MVD appear to be important prognostic predictor in patients with ampullary carcinoma.
  • [MeSH-major] Ampulla of Vater. Carcinoma / blood supply. Carcinoma / metabolism. Common Bile Duct Neoplasms / blood supply. Common Bile Duct Neoplasms / metabolism. Vascular Endothelial Growth Factor A / biosynthesis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16506374.001).
  • [ISSN] 0172-6390
  • [Journal-full-title] Hepato-gastroenterology
  • [ISO-abbreviation] Hepatogastroenterology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Vascular Endothelial Growth Factor A
  •  go-up   go-down


57. Ishii Y, Takahashi M, Yoshida S, Suzuki K: [A case of hepatic metastases of ampullary carcinoma which completely responded to intrahepatic infusion of 5-FU with low-dose l-leucovorin]. Gan To Kagaku Ryoho; 2005 Aug;32(8):1175-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of hepatic metastases of ampullary carcinoma which completely responded to intrahepatic infusion of 5-FU with low-dose l-leucovorin].
  • A 70-year-old man was admitted with an ampullary carcinoma with multiple hepatic metastases.
  • [MeSH-major] Ampulla of Vater. Duodenal Neoplasms / pathology. Fluorouracil / administration & dosage. Leucovorin / administration & dosage. Liver Neoplasms / drug therapy. Liver Neoplasms / secondary

  • MedlinePlus Health Information. consumer health - Intestinal Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • Hazardous Substances Data Bank. LEUCOVORIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16121924.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil
  •  go-up   go-down


58. Ho ML, Girardi PA, Williams D, Lord RV: Education and imaging. Gastrointestinal: The sign of Leser-Trélat. J Gastroenterol Hepatol; 2008 Apr;23(4):672
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Ampulla of Vater. Carcinoma in Situ / pathology. Common Bile Duct Neoplasms / pathology. Keratosis, Seborrheic / pathology. Paraneoplastic Syndromes / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18397494.001).
  • [ISSN] 1440-1746
  • [Journal-full-title] Journal of gastroenterology and hepatology
  • [ISO-abbreviation] J. Gastroenterol. Hepatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  •  go-up   go-down


59. Casaretto E, Andrada DG, Granero LE: [Results of cephalic pancreaticoduodenectomy for ampullary carcinoma. Analysis of 18 consecutive cases]. Acta Gastroenterol Latinoam; 2010 Mar;40(1):22-31
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Results of cephalic pancreaticoduodenectomy for ampullary carcinoma. Analysis of 18 consecutive cases].
  • [Transliterated title] Resultados de la duodenopancreatectomía cefálica en el tratamiento del carcinoma de la ampolla de vater. Análisis de 18 casos consecutivos.
  • BACKGROUND: Complete resection offers the only potential cure for ampullary carcinoma.
  • AIM: The aim of this study was to assess the results of cephalic pancreaticoduodenectomy for patients with ampullary carcinoma based on mortality, hospital morbidity, late morbidity, and survival.
  • PATIENTS AND METHODS: We retrospectively and prospectively reviewed all patients who underwent cephalic pancreaticoduodenectomy, between October 1994 and October 2006 for ampullary carcinoma.
  • CONCLUSIONS: Cephalic pancreaticoduodenectomy is the surgical procedure of choice for ampullary carcinoma, with low hospital mortality, and the best chance for cure in patients with node-negative disease.
  • [MeSH-major] Ampulla of Vater. Carcinoma / surgery. Common Bile Duct Neoplasms / surgery. Pancreaticoduodenectomy
  • [MeSH-minor] Adult. Aged. Female. Humans. Kaplan-Meier Estimate. Male. Middle Aged. Neoplasm Recurrence, Local. Neoplasm Staging. Prospective Studies. Retrospective Studies. Treatment Failure

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20446393.001).
  • [ISSN] 0300-9033
  • [Journal-full-title] Acta gastroenterologica Latinoamericana
  • [ISO-abbreviation] Acta Gastroenterol. Latinoam.
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Argentina
  •  go-up   go-down


60. Song HG, Yoo KS, Ju NR, Park JC, Jung JO, Shin WG, Moon JH, Kim JP, Kim KO, Park CH, Hahn T, Park SH, Kim JH, Lee IJ, Min SK, Park CK: [A case of adenosquamous carcinoma of the papilla of Vater]. Korean J Gastroenterol; 2006 Aug;48(2):132-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of adenosquamous carcinoma of the papilla of Vater].
  • Adenosquamous carcinoma of the papilla of Vater is a rare tumor and only a few cases have been reported so far.
  • Here, we report a case of adenosquamous carcinoma in a 76-year-old male who presented with jaundice and right upper quadrant abdominal pain.
  • On endoscopy, obstructing and ulcerated mass was noted on the papilla of Vater.
  • Histopathological inspection of the biopsied specimens from mass showed adenosquamous cell carcinoma of the papilla of Vater.
  • This is the first case report on adenosquamous carcinoma of the papilla of Vater in Korea.
  • [MeSH-major] Ampulla of Vater / pathology. Carcinoma, Adenosquamous / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16929159.001).
  • [ISSN] 1598-9992
  • [Journal-full-title] The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi
  • [ISO-abbreviation] Korean J Gastroenterol
  • [Language] kor
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Korea (South)
  •  go-up   go-down


61. Chiche L, Alkofer B, Parienti JJ, Rouleau V, Salamé E, Samama G, Segol P: Usefulness of follow-up after pancreatoduodenectomy for carcinoma of the ampulla of Vater. HPB (Oxford); 2007;9(2):140-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Usefulness of follow-up after pancreatoduodenectomy for carcinoma of the ampulla of Vater.
  • BACKGROUND: The prognosis for carcinoma of the ampulla of Vater (CAV) is better than for pancreatic cancer.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Arch Surg. 1999 May;134(5):526-32 [10323425.001]
  • [Cites] HPB Surg. 1998;11(1):1-11 [9830575.001]
  • [Cites] Hepatogastroenterology. 1999 May-Jun;46(27):1973-9 [10430380.001]
  • [Cites] Hepatogastroenterology. 1999 Jul-Aug;46(28):2429-33 [10522012.001]
  • [Cites] Hepatogastroenterology. 1999 Nov-Dec;46(30):3274-5 [10626200.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2000 Jul 1;47(4):945-53 [10863064.001]
  • [Cites] Arch Surg. 2001 Jan;136(1):65-9 [11146780.001]
  • [Cites] Hepatogastroenterology. 2002 Jan-Feb;49(43):247-8 [11941966.001]
  • [Cites] Hepatogastroenterology. 2002 Jul-Aug;49(46):1116-9 [12143216.001]
  • [Cites] Ann Surg Oncol. 2003 Dec;10(10):1176-83 [14654474.001]
  • [Cites] Hepatogastroenterology. 2004 Sep-Oct;51(59):1275-7 [15362731.001]
  • [Cites] Surgery. 2004 Nov;136(5):994-1002 [15523392.001]
  • [Cites] J Gastrointest Surg. 2004 Nov;8(7):775-84; discussion 784 [15531230.001]
  • [Cites] J Clin Oncol. 2005 Mar 20;23(9):1811-8 [15774774.001]
  • [Cites] Arch Surg. 1991 Mar;126(3):353-7 [1998478.001]
  • [Cites] Cancer. 1990 Oct 15;66(8):1717-20 [2208026.001]
  • [Cites] Ann Surg. 1995 Nov;222(5):632-7 [7487210.001]
  • [Cites] World J Surg. 1995 Jan-Feb;19(1):102-6; discussion 106-7 [7740792.001]
  • [Cites] Surgery. 1995 Mar;117(3):247-53 [7878528.001]
  • [Cites] Br J Surg. 1994 May;81(5):668-71 [7913860.001]
  • [Cites] J Am Coll Surg. 1994 Nov;179(5):545-52 [7952456.001]
  • [Cites] Surg Gynecol Obstet. 1993 Jan;176(1):33-8 [8093983.001]
  • [Cites] Eur J Surg. 1993 Feb;159(2):95-100 [8098633.001]
  • [Cites] Surg Gynecol Obstet. 1993 Oct;177(4):366-70 [8211580.001]
  • [Cites] World J Surg. 1996 Jul-Aug;20(6):707-12 [8662157.001]
  • [Cites] Eur J Surg. 1996 Jun;162(6):477-81 [8817225.001]
  • [Cites] Gut. 1997 Mar;40(3):350-5 [9135524.001]
  • [Cites] World J Surg. 1997 May;21(4):379-83 [9143568.001]
  • [Cites] Surgery. 1997 Jun;121(6):611-7 [9186460.001]
  • [Cites] Ann R Coll Surg Engl. 1997 Jul;79(4):259-63 [9244068.001]
  • [Cites] Br J Surg. 1997 Oct;84(10):1399-401 [9361598.001]
  • [Cites] Am J Surg. 1997 Dec;174(6):600-3; discussion 603-4 [9409581.001]
  • [Cites] Ann Surg. 1998 Jun;227(6):821-31 [9637545.001]
  • [Cites] Ann Surg. 1998 Jul;228(1):87-94 [9671071.001]
  • [Cites] J Korean Med Sci. 1999 Apr;14(2):220-2 [10331573.001]
  • (PMID = 18333130.001).
  • [ISSN] 1365-182X
  • [Journal-full-title] HPB : the official journal of the International Hepato Pancreato Biliary Association
  • [ISO-abbreviation] HPB (Oxford)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2020781
  •  go-up   go-down


62. Santini D, Tonini G, Vecchio FM, Borzomati D, Vincenzi B, Valeri S, Antinori A, Castri F, Coppola R, Magistrelli P, Nuzzo G, Picciocchi A: Prognostic value of Bax, Bcl-2, p53, and TUNEL staining in patients with radically resected ampullary carcinoma. J Clin Pathol; 2005 Feb;58(2):159-65
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic value of Bax, Bcl-2, p53, and TUNEL staining in patients with radically resected ampullary carcinoma.
  • BACKGROUND: There is a lack of data in the literature concerning the identification of potential prognostic factors in ampullary adenocarcinoma.
  • AIMS: To examine the prognostic significance of Bax, Bcl-2, and p53 protein expression and the apoptotic index in a large cohort of uniformly treated patients with radically resected ampullary cancer.
  • METHODS: All patients with a pathological diagnosis of ampullary cancer and radical resection were evaluated.
  • RESULTS: Thirty nine tumour specimens from patients with radically resected ampullary adenocarcinoma were studied.
  • CONCLUSIONS: These results provide evidence that apoptosis may be an important prognostic factor in patients with radically resected ampullary cancer.
  • This study is the first to assess the clinical usefulness of Bax expression in radically resected ampullary cancer.
  • [MeSH-major] Adenocarcinoma / chemistry. Ampulla of Vater. Common Bile Duct Neoplasms / chemistry. In Situ Nick-End Labeling / methods. Proto-Oncogene Proteins c-bcl-2 / analysis. Tumor Suppressor Protein p53 / analysis

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Cancer. 1992 Feb 20;50(4):528-32 [1537617.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Apr 28;95(9):4997-5002 [9560217.001]
  • [Cites] Br J Cancer. 2000 Jan;82(2):374-80 [10646891.001]
  • [Cites] Eur J Gastroenterol Hepatol. 2000 Jan;12(1):75-9 [10656214.001]
  • [Cites] Gut. 2000 Jun;46(6):842-8 [10807898.001]
  • [Cites] Mod Pathol. 2000 Dec;13(12):1300-7 [11144926.001]
  • [Cites] J Clin Oncol. 2001 Apr 15;19(8):2272-81 [11304781.001]
  • [Cites] Eur J Surg Oncol. 2001 Sep;27(6):549-57 [11520088.001]
  • [Cites] Ann Surg. 2001 Sep;234(3):344-50; discussion 350-1 [11524587.001]
  • [Cites] Hepatogastroenterology. 2001 Sep-Oct;48(41):1266-70 [11677943.001]
  • [Cites] Br J Cancer. 2002 Mar 18;86(6):886-92 [11953819.001]
  • [Cites] Eur J Surg Oncol. 2002 Sep;28(6):637-44 [12359201.001]
  • [Cites] J Korean Med Sci. 2003 Apr;18(2):218-24 [12692419.001]
  • [Cites] Mol Pathol. 2003 Dec;56(6):336-41 [14645696.001]
  • [Cites] Ann Surg. 1990 Apr;211(4):447-58 [2322039.001]
  • [Cites] Arch Surg. 1990 Jun;125(6):723-6 [2189376.001]
  • [Cites] Int J Cancer. 1992 Apr 1;50(6):859-62 [1555884.001]
  • [Cites] Nature. 1992 Jul 2;358(6381):15-6 [1614522.001]
  • [Cites] Cancer Res. 1992 Sep 1;52(17):4828-31 [1324796.001]
  • [Cites] Gastroenterology. 1994 Jan;106(1):42-8 [8276207.001]
  • [Cites] Cell. 1995 Jan 27;80(2):293-9 [7834749.001]
  • [Cites] Surgery. 1995 Mar;117(3):247-53 [7878528.001]
  • [Cites] Cancer. 1995 Apr 15;75(8):2069-76 [7697596.001]
  • [Cites] Cancer Res. 1995 Oct 1;55(19):4471-8 [7671262.001]
  • [Cites] Br J Surg. 1995 Dec;82(12):1686-91 [8548242.001]
  • [Cites] Ann Surg. 1998 Jul;228(1):87-94 [9671071.001]
  • [Cites] J Clin Oncol. 1998 Aug;16(8):2583-90 [9704707.001]
  • [Cites] Clin Cancer Res. 1997 Jan;3(1):129-33 [9815548.001]
  • [Cites] Gut. 1998 Sep;43(3):414-21 [9863489.001]
  • [Cites] Mol Hum Reprod. 1998 Dec;4(12):1099-109 [9872359.001]
  • [Cites] Clin Cancer Res. 1997 Oct;3(10):1841-7 [9815572.001]
  • [Cites] Hepatogastroenterology. 1999 Mar-Apr;46(26):1187-91 [10370689.001]
  • [Cites] J Surg Oncol. 1996 Feb;61(2):100-5 [8606540.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Dec 10;93(25):14559-63 [8962091.001]
  • [Cites] Cell. 1997 Apr 18;89(2):175-84 [9108473.001]
  • [Cites] Gut. 1997 Mar;40(3):350-5 [9135524.001]
  • [Cites] Ann Surg. 1997 May;225(5):590-9; discussion 599-600 [9193186.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Oct 14;94(21):11357-62 [9326614.001]
  • [Cites] Blood. 1997 Oct 15;90(8):3173-8 [9376600.001]
  • [Cites] J Biol Chem. 1997 Dec 12;272(50):31482-8 [9395483.001]
  • [Cites] J Biol Chem. 1998 Mar 27;273(13):7770-5 [9516487.001]
  • [Cites] World J Surg. 2000 Jan;24(1):54-9 [10594204.001]
  • (PMID = 15677536.001).
  • [ISSN] 0021-9746
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / BAX protein, human; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / Tumor Suppressor Protein p53; 0 / bcl-2-Associated X Protein
  • [Other-IDs] NLM/ PMC1770581
  •  go-up   go-down


63. Lesurtel M, Dehni N, Tiret E, Parc R, Paye F: Palliative surgery for unresectable pancreatic and periampullary cancer: a reappraisal. J Gastrointest Surg; 2006 Feb;10(2):286-91
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Palliative surgery for unresectable pancreatic and periampullary cancer: a reappraisal.
  • This study aimed to reappraise short-term and long-term results of palliative biliary and gastric bypass surgery in patients with unresectable pancreatic head carcinoma found at explorative laparotomy.
  • We retrospectively analyzed 83 consecutive patients whose pancreatic head carcinoma appeared unresectable at laparotomy (vascular involvement [57%], liver metastases [24%], distant metastatic lymph nodes [11%], peritoneal implants [8%]) and who underwent palliative surgical concomitant biliary and gastric bypass.
  • These data demonstrate that, in patients with unresectable pancreatic head carcinoma at laparotomy, palliative concomitant biliary and gastric bypass in a single procedure is safe and long-term efficient.
  • [MeSH-major] Ampulla of Vater / surgery. Common Bile Duct Neoplasms / surgery. Palliative Care. Pancreatic Neoplasms / surgery
  • [MeSH-minor] Biliopancreatic Diversion / methods. Carcinoma / secondary. Carcinoma / surgery. Cholangitis / etiology. Enteral Nutrition. Female. Follow-Up Studies. Gastric Bypass / methods. Gastric Emptying / physiology. Gastric Outlet Obstruction / etiology. Humans. Intubation, Gastrointestinal. Length of Stay. Liver Neoplasms / secondary. Lymphatic Metastasis / pathology. Male. Middle Aged. Peritoneal Neoplasms / secondary. Postoperative Complications. Retrospective Studies. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • MedlinePlus Health Information. consumer health - Palliative Care.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Surg. 1993 Feb;80(2):237-9 [7680270.001]
  • [Cites] Gut. 1989 Aug;30(8):1132-5 [2475392.001]
  • [Cites] Surg Clin North Am. 1989 Jun;69(3):599-611 [2471281.001]
  • [Cites] J Hepatobiliary Pancreat Surg. 2001;8(4):367-73 [11521183.001]
  • [Cites] Gastroenterol Clin Biol. 2001 Sep;25(2 Pt 2):C7-14 [11787383.001]
  • [Cites] AJR Am J Roentgenol. 1997 Oct;169(4):1079-83 [9308468.001]
  • [Cites] Gastrointest Endosc. 1992 Nov-Dec;38(6):750-2 [1473699.001]
  • [Cites] Ann Surg. 1999 Sep;230(3):322-8; discussion 328-30 [10493479.001]
  • [Cites] Br J Surg. 1997 Oct;84(10):1402-6 [9361599.001]
  • [Cites] Gastroenterol Clin Biol. 2000 Aug-Sep;24(8-9):714-8 [11011246.001]
  • [Cites] Ann Surg. 2003 Dec;238(6):894-902; discussion 902-5 [14631226.001]
  • [Cites] Surg Gynecol Obstet. 1993 Jan;176(1):1-10 [7678945.001]
  • [Cites] Am J Surg. 1993 Dec;166(6):632-6; discussion 636-7 [7506010.001]
  • [Cites] Gastrointest Endosc. 1998 Mar;47(3):267-70 [9540881.001]
  • [Cites] Endoscopy. 2003 Jun;35(6):483-9 [12783345.001]
  • [Cites] Eur J Surg Oncol. 1993 Aug;19(4):342-7 [7689488.001]
  • [Cites] Int J Pancreatol. 2000 Feb;27(1):51-8 [10811023.001]
  • [Cites] Surg Endosc. 2002 Feb;16(2):310-2 [11967685.001]
  • [Cites] Br J Surg. 1992 Aug;79(8):795-8 [1382797.001]
  • [Cites] Gastrointest Endosc. 1997 Aug;46(2):161-5 [9283868.001]
  • [Cites] Ann Surg. 1993 Apr;217(4):356-68 [7682052.001]
  • [Cites] Arch Surg. 1971 Aug;103(2):330-4 [4104934.001]
  • [Cites] Lancet. 1994 Dec 17;344(8938):1655-60 [7996958.001]
  • [Cites] Br J Surg. 1992 Jan;79(1):8-20 [1371087.001]
  • [Cites] J Am Coll Surg. 1999 Jun;188(6):658-66; discussion 666-9 [10359359.001]
  • [Cites] Endoscopy. 1992 Jun;24(5):433-5 [1380448.001]
  • [Cites] World J Surg. 2000 Jan;24(1):60-4; discussion 64-5 [10594205.001]
  • [Cites] Liver Transpl. 2000 May;6(3):302-8 [10827230.001]
  • [Cites] Br J Surg. 1988 Dec;75(12):1166-8 [2466520.001]
  • [Cites] Gastrointest Endosc. 2001 Mar;53(3):329-32 [11231392.001]
  • (PMID = 16455463.001).
  • [ISSN] 1091-255X
  • [Journal-full-title] Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
  • [ISO-abbreviation] J. Gastrointest. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


64. Perrone G, Morini S, Santini D, Rabitti C, Vincenzi B, Alloni R, Antinori A, Magistrelli P, Lai R, Cass C, Mackey JR, Coppola R, Tonini G, Onetti Muda A: Human equilibrative nucleoside transporter 1 and carcinoma of the ampulla of Vater: expression differences in tumour histotypes. Eur J Histochem; 2010;54(3):e38
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Human equilibrative nucleoside transporter 1 and carcinoma of the ampulla of Vater: expression differences in tumour histotypes.
  • The human equilibrative nucleoside transporter 1 (hENT1) is the major means by which gemcitabine enters human cells; recent evidence exists that hENT1 is expressed in carcinoma of the ampulla of Vater and that it should be considered as a molecular prognostic marker for patients with resected ampullary cancer.
  • Aim of the present study is to evaluate the variations of hENT1 expression in ampullary carcinomas and to correlate such variations with histological subtypes and clinicopathological parameters.
  • Forty-one ampullary carcinomas were histologically classified into intestinal, pancreaticobiliary and unusual types. hENT1 and Ki67 expression were evaluated by immunohistochemistry, and apoptotic cells were identified by the terminal deoxynucleotidyl transferase mediated deoxyuridine triphosphate biotin nick end labelling (TUNEL) method. hENT1 overexpression was detected in 63.4% ampullary carcinomas.
  • Our results on hENT1 expression suggest that classification of ampullary carcinoma by morphological subtypes may represent an additional tool in prospective clinical trials aimed at examining treatment efficacy; in addition, data obtained from Ki67 and TUNEL suggest a key role of hENT1 in tumour growth of ampullary carcinoma.
  • [MeSH-major] Adenocarcinoma / pathology. Ampulla of Vater / pathology. Carcinoma / metabolism. Equilibrative Nucleoside Transporter 1 / metabolism. Intestinal Neoplasms / metabolism. Pancreatic Neoplasms / metabolism

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Hepatobiliary Pancreat Surg. 2004;11(5):301-9 [15549428.001]
  • [Cites] Am J Gastroenterol. 1999 Aug;94(8):2128-34 [10445539.001]
  • [Cites] Mol Med Today. 1999 May;5(5):216-24 [10322314.001]
  • [Cites] Cancer Res. 1998 Oct 1;58(19):4349-57 [9766663.001]
  • [Cites] Virchows Arch. 1996 Jul;428(4-5):229-35 [8764931.001]
  • [Cites] Cancer. 1996 Jan 15;77(2):255-64 [8625232.001]
  • [Cites] Int J Cancer. 1996 Jan 17;65(2):173-7 [8567113.001]
  • [Cites] Jpn J Cancer Res. 1994 Feb;85(2):161-6 [7511574.001]
  • [Cites] Cancer. 1988 Apr 1;61(7):1394-402 [3422832.001]
  • [Cites] Clin Cancer Res. 2004 Oct 15;10(20):6956-61 [15501974.001]
  • [Cites] Mod Pathol. 2005 Apr;18(4):558-64 [15529184.001]
  • [Cites] Am J Surg Pathol. 2004 Jul;28(7):875-82 [15223956.001]
  • [Cites] Cancer. 2002 Aug 15;95(4 Suppl):941-5 [12209675.001]
  • [Cites] J Surg Oncol. 2002 Apr;79(4):236-42 [11920781.001]
  • [Cites] Clin Cancer Res. 2002 Jan;8(1):110-6 [11801546.001]
  • [Cites] Gastroenterology. 2009 Jan;136(1):187-95 [18992248.001]
  • [Cites] Ann Oncol. 2008 Apr;19(4):724-8 [18187485.001]
  • [Cites] Am J Physiol Renal Physiol. 2007 Jul;293(1):F200-11 [17409283.001]
  • [Cites] Crit Rev Oncol Hematol. 2007 Mar;61(3):230-42 [17157524.001]
  • [Cites] Virchows Arch. 2006 Sep;449(3):334-40 [16906389.001]
  • [Cites] Can J Gastroenterol. 2005 Dec;19(12):711-6 [16341310.001]
  • [Cites] Lung Cancer. 2005 Sep;49(3):363-70 [15923058.001]
  • [Cites] Clin Cancer Res. 2005 May 15;11(10):3784-9 [15897577.001]
  • (PMID = 20839414.001).
  • [ISSN] 2038-8306
  • [Journal-full-title] European journal of histochemistry : EJH
  • [ISO-abbreviation] Eur J Histochem
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Equilibrative Nucleoside Transporter 1
  • [Other-IDs] NLM/ PMC3167316
  •  go-up   go-down


65. Valle J, Wasan H, Palmer DH, Cunningham D, Anthoney A, Maraveyas A, Madhusudan S, Iveson T, Hughes S, Pereira SP, Roughton M, Bridgewater J, ABC-02 Trial Investigators: Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med; 2010 Apr 8;362(14):1273-81
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer.
  • BACKGROUND: There is no established standard chemotherapy for patients with locally advanced or metastatic biliary tract cancer.
  • METHODS: We randomly assigned 410 patients with locally advanced or metastatic cholangiocarcinoma, gallbladder cancer, or ampullary cancer to receive either cisplatin (25 mg per square meter of body-surface area) followed by gemcitabine (1000 mg per square meter on days 1 and 8, every 3 weeks for eight cycles) or gemcitabine alone (1000 mg per square meter on days 1, 8, and 15, every 4 weeks for six cycles) for up to 24 weeks.
  • Cisplatin plus gemcitabine is an appropriate option for the treatment of patients with advanced biliary cancer. (ClinicalTrials.gov number, NCT00262769. )

  • Genetic Alliance. consumer health - Biliary Tract Cancer.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2010 Massachusetts Medical Society
  • [CommentIn] Z Gastroenterol. 2010 Aug;48(8):850-1 [20687022.001]
  • [CommentIn] N Engl J Med. 2010 Apr 8;362(14):1335-7 [20375411.001]
  • [CommentIn] J Hepatol. 2011 Mar;54(3):577-8 [21112109.001]
  • [CommentIn] N Engl J Med. 2010 Jul 8;363(2):192; author reply 192-3 [20653076.001]
  • [CommentIn] N Engl J Med. 2010 Jul 8;363(2):192; author reply 192-3 [20647216.001]
  • [CommentIn] Expert Rev Gastroenterol Hepatol. 2010 Aug;4(4):395-7 [20678012.001]
  • (PMID = 20375404.001).
  • [ISSN] 1533-4406
  • [Journal-full-title] The New England journal of medicine
  • [ISO-abbreviation] N. Engl. J. Med.
  • [Language] eng
  • [Databank-accession-numbers] ClinicalTrials.gov/ NCT00262769
  • [Grant] United Kingdom / Cancer Research UK / /
  • [Publication-type] Clinical Trial, Phase III; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine; Q20Q21Q62J / Cisplatin
  • [Investigator] Nicholson M; Corrie P; Eatock M; Falk S; Elyan S; Valle J; Anthony A; Nicoll J; Kulkarni R; Osbourne R; Garcia Alonso A; Wasan H; Waters J; Harrison M; Adamson D; Rees C; Bridgewater J; Madhusudan S; McAdam K; Bridgewater J; Maraveyas A; Palmer D; Hickish T; Meyer T; Cunningham D; Iveson T; Middleton G; Slater S; Lofts F; Archer C; Iveson T; Iveson T; Bridgewater J; Mukherjee S; Wadsley J; Gollins S
  •  go-up   go-down


66. Barauskas G, Gulbinas A, Pranys D, Dambrauskas Z, Pundzius J: Tumor-related factors and patient's age influence survival after resection for ampullary adenocarcinoma. J Hepatobiliary Pancreat Surg; 2008;15(4):423-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tumor-related factors and patient's age influence survival after resection for ampullary adenocarcinoma.
  • BACKGROUND/PURPOSE: The majority of surgeons agree that ampullary adenocarcinoma should be removed by partial pancreatoduodenectomy.
  • Favoring extended resection, based on the uncertainty of the preoperative diagnosis and the higher probability of clear resection margins, we aimed to disclose the results of this surgical procedure in terms of postoperative morbidity and mortality, and to identify prognosticators of long-term survival.
  • METHODS: We documented, prospectively, 25 consecutive patients with adenocarcinoma of the papilla of Vater in whom pylorus-preserving pancreatoduodenectomy was performed.
  • Clinical data, pathology reports, International Union Against Cancer (UICC) tumor stage, postoperative morbidity, mortality, and long-term follow-up results were evaluated.
  • CONCLUSIONS: Pancreatoduodenectomy for ampullary carcinoma is reasonable in terms of postoperative morbidity and mortality.
  • [MeSH-major] Adenocarcinoma / mortality. Ampulla of Vater. Common Bile Duct Neoplasms / mortality. Pancreaticoduodenectomy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18670845.001).
  • [ISSN] 0944-1166
  • [Journal-full-title] Journal of hepato-biliary-pancreatic surgery
  • [ISO-abbreviation] J Hepatobiliary Pancreat Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


67. Kamisawa T, Tu Y, Nakajima H, Egawa N, Tsuruta K, Okamoto A: Usefulness of biopsying the major duodenal papilla to diagnose autoimmune pancreatitis: a prospective study using IgG4-immunostaining. World J Gastroenterol; 2006 Apr 7;12(13):2031-3
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Usefulness of biopsying the major duodenal papilla to diagnose autoimmune pancreatitis: a prospective study using IgG4-immunostaining.
  • AIM: To examine the histological and immunohistochemical findings of biopsy specimens taken from the major duodenal papilla of autoimmune pancreatitis (AIP) patients.
  • METHODS: The major duodenal papilla in the resected pancreas of 3 patients with AIP and of 5 control patients [pancreatic carcinoma (n = 3) and chronic alcoholic pancreatitis (n = 2)] was immunostained using anti-CD4-T cell, CD8-T cell and IgG4 antibodies.
  • Forceps biopsy specimens taken from the major duodenal papilla of 2 patients with AIP and 5 control patients with suspected papillitis were prospectively taken during duodenoscopy and immunohistochemically examined.
  • RESULTS: Moderate or severe lymphoplasmacytic infiltration including many CD4-positive or CD8-positive T lymphocytes and IgG4-positive plasma cells (>or=10/HPF), was observed in the major duodenal papilla of all 3 patients with AIP.
  • The same findings were also detected in the biopsy specimens taken from the major duodenal papilla of 2 patients with AIP, but in controls, there were only a few (<or=3/HPF) IgG4-positive plasma cells infiltrating the major duodenal papilla.
  • CONCLUSIONS: An abundant infiltration of IgG4-positive plasma cells is specifically detected in the major duodenal papilla of patients with AIP.
  • Although this is a preliminary study, IgG4-immunostaining of biopsy specimens taken from the major duodenal papilla may support the diagnosis of AIP.
  • [MeSH-major] Ampulla of Vater / pathology. Autoimmune Diseases / diagnosis. Pancreatitis / diagnosis

  • Genetic Alliance. consumer health - Pancreatitis.
  • MedlinePlus Health Information. consumer health - Autoimmune Diseases.
  • MedlinePlus Health Information. consumer health - Pancreatitis.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 2001 Mar 8;344(10):732-8 [11236777.001]
  • [Cites] Gastrointest Endosc. 2002 Jun;55(7):877-82 [12024144.001]
  • [Cites] Gut. 2002 Jul;51(1):1-4 [12077078.001]
  • [Cites] Gastrointest Endosc. 2002 Dec;56(6):880-4 [12447302.001]
  • [Cites] Gut. 2003 May;52(5):683-7 [12692053.001]
  • [Cites] Pancreas. 2005 Jul;31(1):28-31 [15968244.001]
  • [Cites] Gastroenterology. 2003 Nov;125(5):1557-8 [14628815.001]
  • [Cites] Am J Gastroenterol. 2003 Dec;98(12):2694-9 [14687819.001]
  • [Cites] Pancreas. 2004 Aug;29(2):162-6 [15257109.001]
  • [Cites] Scand J Gastroenterol. 2004 Nov;39(11):1154-8 [15545176.001]
  • [Cites] J Gastroenterol. 2003;38(10):982-4 [14614606.001]
  • (PMID = 16610052.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Immunoglobulin G
  • [Other-IDs] NLM/ PMC4087680
  •  go-up   go-down


68. Keene KS, Rich TA, Penberthy DR, Shepard RC, Adams R, Jones RS: Clinical experience with chronomodulated infusional 5-fluorouracil chemoradiotherapy for pancreatic adenocarcinoma. Int J Radiat Oncol Biol Phys; 2005 May 1;62(1):97-103
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical experience with chronomodulated infusional 5-fluorouracil chemoradiotherapy for pancreatic adenocarcinoma.
  • PURPOSE: To evaluate retrospectively the efficacy and chronic toxicities of concurrent radiotherapy and chronomodulated infusion 5-fluorouracil (5-FU) in patients with pancreatic adenocarcinoma.
  • METHODS AND MATERIALS: Twenty-eight patients with pancreatic adenocarcinoma were treated between January 1997 and May 2000 with 5-FU chronomodulated chemoradiotherapy.
  • Eight patients had unresectable disease and 20 were treated after pancreatic resection.
  • If the 3 patients with carcinoma of the ampulla were removed from the data set, the mean overall survival in the resected patients was 34 months, with a 3-year and 5-year actuarial survival rate of 40% and 17%, respectively.
  • [MeSH-major] Adenocarcinoma / drug therapy. Adenocarcinoma / radiotherapy. Antimetabolites, Antineoplastic / administration & dosage. Chronotherapy. Fluorouracil / administration & dosage. Pancreatic Neoplasms / drug therapy. Pancreatic Neoplasms / radiotherapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Ampulla of Vater. Combined Modality Therapy. Female. Humans. Male. Middle Aged. Neoplasm Recurrence, Local / drug therapy. Neoplasm Recurrence, Local / radiotherapy. Retrospective Studies. Survival Rate

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15850908.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; U3P01618RT / Fluorouracil
  •  go-up   go-down


69. Hosaka A, Nagayoshi M, Sugizaki K, Masaki Y: Gallbladder perforation associated with carcinoma of the duodenal papilla: a case report. World J Surg Oncol; 2010;8:41
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gallbladder perforation associated with carcinoma of the duodenal papilla: a case report.
  • A tumor of the ampulla of Vater causes gradually progressive symptoms, and is rarely associated with perforation of the gallbladder.
  • CASE PRESENTATION: A 56-year-old man with carcinoma of the ampulla of Vater presented with spontaneous gallbladder perforation and localized bile peritonitis.
  • Postoperative upper gastrointestinal endoscopy demonstrated a slightly enlarged duodenal papilla, and biopsy revealed adenocarcinoma of the ampulla.
  • CONCLUSION: Ampullary carcinoma can be associated with gallbladder perforation and present with acute manifestations.
  • [MeSH-major] Adenocarcinoma / pathology. Ampulla of Vater / pathology. Common Bile Duct Neoplasms / pathology. Gallbladder / pathology. Gallbladder Diseases / diagnosis
  • [MeSH-minor] Abdominal Pain. Humans. Male. Middle Aged. Pancreaticoduodenectomy. Peritonitis / diagnosis. Rupture, Spontaneous. Tomography, X-Ray Computed. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Gallbladder Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Ultrasound. 2002 Jun;30(5):270-4 [12116106.001]
  • [Cites] Hepatogastroenterology. 2003 May-Jun;50(51):621-4 [12828046.001]
  • [Cites] World J Gastroenterol. 2003 Dec;9(12):2821-3 [14669342.001]
  • [Cites] J Hepatobiliary Pancreat Surg. 2004;11(4):232-8 [15368106.001]
  • [Cites] ANZ J Surg. 2004 Oct;74(10):843-6 [15456428.001]
  • [Cites] Abdom Imaging. 1994 May-Jun;19(3):239-42 [8019352.001]
  • [Cites] Surg Today. 2007;37(8):633-7 [17643203.001]
  • [Cites] J Clin Gastroenterol. 2006 Feb;40(2):162-6 [16394879.001]
  • [Cites] Am J Surg. 2006 Aug;192(2):161-4 [16860623.001]
  • [Cites] J Hepatobiliary Pancreat Surg. 2006;13(6):549-55 [17139430.001]
  • [Cites] World J Gastroenterol. 2006 Dec 28;12(48):7832-6 [17203529.001]
  • [Cites] Dig Surg. 2007;24(2):131-6 [17446708.001]
  • [Cites] Arch Surg. 1999 May;134(5):526-32 [10323425.001]
  • (PMID = 20487525.001).
  • [ISSN] 1477-7819
  • [Journal-full-title] World journal of surgical oncology
  • [ISO-abbreviation] World J Surg Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2887867
  •  go-up   go-down


70. Agaram NP, Shia J, Tang LH, Klimstra DS: DNA mismatch repair deficiency in ampullary carcinoma: a morphologic and immunohistochemical study of 54 cases. Am J Clin Pathol; 2010 May;133(5):772-80
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] DNA mismatch repair deficiency in ampullary carcinoma: a morphologic and immunohistochemical study of 54 cases.
  • The significance of DNA mismatch repair (MMR) deficiency or microsatellite instability (MSI) in ampullary carcinomas remains to be defined.
  • This study evaluated the MMR status in 54 consecutive ampullary adenocarcinomas by immunohistochemical and morphologic studies.
  • Thus, MMR deficiency occurs in ampullary carcinoma but appears less frequent than in colorectal carcinoma (CRC).
  • Typical MSI-high histologic features of CRC, such as increased TIL counts, seem to have similar yet subtly different implications in ampullary carcinoma.
  • [MeSH-major] Adenocarcinoma / pathology. Adenoma / pathology. Ampulla of Vater / pathology. Common Bile Duct Neoplasms / pathology. DNA Mismatch Repair / genetics. Nuclear Proteins

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20395525.001).
  • [ISSN] 1943-7722
  • [Journal-full-title] American journal of clinical pathology
  • [ISO-abbreviation] Am. J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adaptor Proteins, Signal Transducing; 0 / Biomarkers, Tumor; 0 / DNA-Binding Proteins; 0 / G-T mismatch-binding protein; 0 / MLH1 protein, human; 0 / Nuclear Proteins; EC 3.6.1.3 / MSH2 protein, human; EC 3.6.1.3 / MutS Homolog 2 Protein
  •  go-up   go-down


71. Imazu H, Uchiyama Y, Matsunaga K, Ikeda K, Kakutani H, Sasaki Y, Sumiyama K, Ang TL, Omar S, Tajiri H: Contrast-enhanced harmonic EUS with novel ultrasonographic contrast (Sonazoid) in the preoperative T-staging for pancreaticobiliary malignancies. Scand J Gastroenterol; 2010 Jun;45(6):732-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The final diagnosis were pancreatic cancer in 11, bile duct cancer in 7, gallbladder cancer in 4 and ampullary cancer in 4.
  • CH-EUS staged correctly in all of these six cases, whereas H-EUS misdiagnosed the depth of invasion in one case of gallbladder cancer and one case of ampullary cancer, and invasion of portal vein in two cases of pancreatic cancer and two cases of bile duct cancer.
  • CONCLUSION: The depth of invasion of biliary cancer and vascular invasion of pancreatic and biliary cancer could be demonstrated more clearly with CH-EUS compared to H-EUS.
  • [MeSH-major] Biliary Tract Neoplasms / ultrasonography. Contrast Media / administration & dosage. Endosonography / methods. Ferric Compounds. Iron. Neoplasm Staging / methods. Oxides. Pancreatic Neoplasms / ultrasonography
  • [MeSH-minor] Diagnosis, Differential. Follow-Up Studies. Humans. Injections, Intravenous. Pilot Projects. Preoperative Period. Prospective Studies. Reproducibility of Results

  • MedlinePlus Health Information. consumer health - Iron.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • Hazardous Substances Data Bank. IRON, ELEMENTAL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20205504.001).
  • [ISSN] 1502-7708
  • [Journal-full-title] Scandinavian journal of gastroenterology
  • [ISO-abbreviation] Scand. J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Contrast Media; 0 / Ferric Compounds; 0 / Oxides; 0 / Sonazoid; E1UOL152H7 / Iron
  •  go-up   go-down


72. Wasan SM, Ross WA, Staerkel GA, Lee JH: Use of expandable metallic biliary stents in resectable pancreatic cancer. Am J Gastroenterol; 2005 Sep;100(9):2056-61
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Use of expandable metallic biliary stents in resectable pancreatic cancer.
  • AIM: To compare the efficacy of metal versus plastic stents for biliary strictures in patients with surgically resectable pancreatic cancer.
  • Of the 12 patients with pancreaticoduodenectomy, 10 had pancreatic adenocarcinoma, 1 intraductal papillary mucinous tumor, and 1 ampullary cancer.
  • Of the 35 patients, 27 had pancreatic adenocarcinoma, 5 ampullary cancer, 1 neuroendocrine tumor, 1 microcystic adenoma, and 1 autoimmune pancreatitis.
  • CONCLUSIONS: Contrary to the belief that metal stents are contraindicated for patients with surgically resectable pancreatic cancer, our study demonstrated that metal stents provided a longer patency rate, fewer ERCP sessions, and fewer episodes of cholangitis without adding any intra- or postoperative complications.
  • Therefore, metal stents should be considered for patients with resectable pancreatic cancer, especially if surgery is not immediately planned as more patients are now receiving preoperative chemoradiation.
  • [MeSH-major] Pancreatic Neoplasms / surgery. Pancreatic Neoplasms / therapy. Stents

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16128952.001).
  • [ISSN] 0002-9270
  • [Journal-full-title] The American journal of gastroenterology
  • [ISO-abbreviation] Am. J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Metals; 0 / Plastics
  •  go-up   go-down


73. Sakata J, Shirai Y, Wakai T, Yokoyama N, Sakata E, Akazawa K, Hatakeyama K: Number of positive lymph nodes independently affects long-term survival after resection in patients with ampullary carcinoma. Eur J Surg Oncol; 2007 Apr;33(3):346-51
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Number of positive lymph nodes independently affects long-term survival after resection in patients with ampullary carcinoma.
  • AIM: The nodal status is an established prognostic factor in ampullary carcinoma.
  • METHODS: Of 73 consecutive patients treated for ampullary carcinoma, 62 underwent pancreaticoduodenectomy with regional lymphadenectomy.
  • CONCLUSION: The number, not the location, of positive regional lymph nodes independently affects long-term survival after resection in patients with ampullary carcinoma.
  • [MeSH-major] Ampulla of Vater / surgery. Common Bile Duct Neoplasms / surgery. Lymph Nodes / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17097846.001).
  • [ISSN] 0748-7983
  • [Journal-full-title] European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  • [ISO-abbreviation] Eur J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


74. Gandini R, Fabiano S, Pipitone V, Spinelli A, Reale CA, Colangelo V, Pampana E, Romagnoli A, Simonetti G: Management of biliary neoplastic obstruction with two different metallic stents implanted in one session. Cardiovasc Intervent Radiol; 2005 Jan-Feb;28(1):48-52
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The efficacy of the "one-step" technique using two different metallic stents (Wallstent and Ultraflex) and associated rate of complications was studied in 87 patients with jaundice secondary to malignant biliary obstruction, with bilirubin level less than 15 mg/dl and Bismuth type 1 or 2 strictures.
  • The cause of the obstruction was pancreatic carcinoma in 38 patients (44%), lymph node metastasis in 20 patients (23%), gallbladder carcinoma in 13 patients (15%), cholangiocarcinoma in 12 patients (14%) and ampullary carcinoma in four patients (5%).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15772722.001).
  • [ISSN] 0174-1551
  • [Journal-full-title] Cardiovascular and interventional radiology
  • [ISO-abbreviation] Cardiovasc Intervent Radiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


75. Kala Z, Weber P, Hemmelová B, Marek F, Hlavsa J, Sobotka M: Ampullary tumours (ampullomas) in the elderly--an interdisciplinary problem. Indian J Med Res; 2010 Mar;131:418-21
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ampullary tumours (ampullomas) in the elderly--an interdisciplinary problem.
  • BACKGROUND & OBJECTIVES: Ampullary cancer is one of the periampullary tumours with better prognosis, but relapses occur early in some patients.
  • METHODS: Between 2005 and 2007, 19 patients (12 male, 7 female) aged over 65 yr (range 66 and 83 yr) with diagnosis of ampulloma were operated.
  • RESULTS: Of the 19 patients, 6 underwent local surgical ampullectomy with reinsertion of ductus choledochus and Wirsungi's duct for benign or early cancer lesion and 13 underwent PDE (Whipple operation).
  • INTERPRETATION & CONCLUSIONS: Diagnosis and therapy of ampullary tumours is multimodal.
  • [MeSH-major] Ampulla of Vater / pathology. Ampulla of Vater / surgery. Common Bile Duct Diseases / diagnosis. Common Bile Duct Diseases / therapy. Common Bile Duct Neoplasms / surgery

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20418556.001).
  • [ISSN] 0971-5916
  • [Journal-full-title] The Indian journal of medical research
  • [ISO-abbreviation] Indian J. Med. Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  •  go-up   go-down


76. Santini D, Baldi A, Vincenzi B, Mellone P, Campioni M, Antinori A, Borzomati D, Coppola R, Magistrelli P, Tonini G: Mucin 2 (MUC2) and mucin 5 (MUC5) expression is not associated with prognosis in patients with radically resected ampullary carcinoma. J Clin Pathol; 2007 Sep;60(9):1069-70
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mucin 2 (MUC2) and mucin 5 (MUC5) expression is not associated with prognosis in patients with radically resected ampullary carcinoma.
  • [MeSH-major] Ampulla of Vater. Biomarkers, Tumor / metabolism. Common Bile Duct Neoplasms / metabolism. Mucins / metabolism
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Mucin-2. Mucin-5B. Neoplasm Proteins / metabolism. Prognosis. Survival Analysis

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Metastasis Rev. 2004 Jan-Jun;23(1-2):77-99 [15000151.001]
  • [Cites] Am J Surg Pathol. 2004 Jul;28(7):875-82 [15223956.001]
  • [Cites] Br J Cancer. 1977 Jan;35(1):1-39 [831755.001]
  • [Cites] Gastroenterology. 1994 Apr;106(4):1054-61 [8143972.001]
  • [Cites] Annu Rev Physiol. 1995;57:607-34 [7778880.001]
  • [Cites] Pathol Int. 1997 Dec;47(12):813-30 [9503463.001]
  • [Cites] J Hepatobiliary Pancreat Surg. 2004;11(5):301-9 [15549428.001]
  • [Cites] Am J Clin Pathol. 2005 Sep;124(3):361-70 [16191504.001]
  • (PMID = 17761747.001).
  • [ISSN] 0021-9746
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / MUC2 protein, human; 0 / MUC5B protein, human; 0 / Mucin-2; 0 / Mucin-5B; 0 / Mucins; 0 / Neoplasm Proteins
  • [Other-IDs] NLM/ PMC1972431
  •  go-up   go-down


77. Vermeil V, D'Amore L, Ceci F, Dassatti MR, Negro A, Gossetti F, Negro P: [Familial polyposis coli associated with carcinoma of the uterine cervix]. Chir Ital; 2008 May-Jun;60(3):355-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Familial polyposis coli associated with carcinoma of the uterine cervix].
  • [Transliterated title] Poliposi familiare del colon in associazione a carcinoma della cervice uterina.
  • Familial polyposis coli is a heterogeneous disease with a broad spectrum of clinical manifestations including not only multiple polyposis of the small bowel, but also multiple primary tumours, such as carcinoma of the ampulla of Vater, subcutaneous tumours, bone tumours, central nervous system tumous and gynaecological malignancies.
  • [MeSH-major] Adenomatous Polyposis Coli. Carcinoma in Situ. Neoplasms, Multiple Primary. Uterine Cervical Neoplasms


78. Hustinx SR, Fukushima N, Zahurak ML, Riall TS, Maitra A, Brosens L, Cameron JL, Yeo CJ, Offerhaus GJ, Hruban RH, Goggins M: Expression and prognostic significance of 14-3-3sigma and ERM family protein expression in periampullary neoplasms. Cancer Biol Ther; 2005 May;4(5):596-601
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Aberrant gene expression in pancreatic ductal adenocarcinomas contributes to the dismal outcome of patients who develop this disease.
  • The 5' region of 14-3-3sigma (stratifin) is hypomethylated in pancreatic adenocarcinomas and is associated with gene overexpression.
  • In multiple experimental systems, ezrin (ERM, Radixin, Moesin) has been identified as being important in the metastatic behavior of pancreatic and other cancers.
  • We investigated the prognostic significance of aberrant expression of 14-3-3sigma and the ERM proteins (Ezrin, radixin, Moesin) in a series of invasive periampullary adenocarcinomas including 300 infiltrating pancreatic adenocarcinomas, 54 ampullary adenocarcinomas, and 33 noninvasive intraductal papillary mucinous neoplasms from patients who underwent pancreaticoduodenal resection at The Johns Hopkins Hospital, Baltimore, MD, between 1991 and 2003.
  • A similar proportion of ampullary cancers showed 14-3-3sigma and ERM protein expression.
  • Aberrant expression of 14-3-3sigma may contribute to the outcome of patients with pancreatic ductal adenocarcinoma.
  • [MeSH-major] Ampulla of Vater / metabolism. Biomarkers, Tumor / metabolism. Common Bile Duct Diseases / metabolism. DNA-Binding Proteins / metabolism. Exonucleases / metabolism. Neoplasm Proteins / metabolism. Pancreatic Neoplasms / diagnosis. Pancreatic Neoplasms / metabolism. Transcription Factors / metabolism
  • [MeSH-minor] 14-3-3 Proteins. Adenocarcinoma / metabolism. Adenocarcinoma, Mucinous / metabolism. Adult. Aged. Aged, 80 and over. Carcinoma, Pancreatic Ductal / metabolism. Exoribonucleases. Female. Gene Expression Regulation, Neoplastic. Humans. Immunohistochemistry. Male. Middle Aged. Multivariate Analysis. Prognosis. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15908786.001).
  • [ISSN] 1538-4047
  • [Journal-full-title] Cancer biology & therapy
  • [ISO-abbreviation] Cancer Biol. Ther.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / 14-3-3 Proteins; 0 / Biomarkers, Tumor; 0 / DNA-Binding Proteins; 0 / ETV5 protein, human; 0 / Neoplasm Proteins; 0 / Transcription Factors; EC 3.1.- / Exonucleases; EC 3.1.- / Exoribonucleases; EC 3.1.- / SFN protein, human
  •  go-up   go-down


79. Suda K: Histopathology of the minor duodenal papilla. Dig Surg; 2010;27(2):137-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Histopathology of the minor duodenal papilla.
  • The minor duodenal papilla, which is the orifice of the accessory, or dorsal, pancreatic duct/Santorini duct, mostly accompanied by pancreatic tissue, is situated about 2 cm ventroproximal to the major duodenal papilla.
  • The patency of the terminal accessory pancreatic duct (APD) is recognized in about half or more of cases, and is related to the degree of fibrosis.
  • Pancreatic tissue was found in about 80% of cases in the minor papilla.
  • Among these cases, pancreatic tissue was continuous and/or closely related to the proper pancreas in about 40% of cases, and might have the same exocrine and endocrine morphologies/functions, suggesting that it is a portion of the dorsal pancreas and not an ectopic one.
  • Endocrine cell micronests are frequently found in the ductal wall/surrounding area of the terminal APD, and predominantly consist of somatostatin- and/or pancreatic-polypeptide-containing cells.
  • In cases of pancreas divisum, inadequate pancreatic juice drainage from the minor papilla might occur, resulting in dorsal pancreatitis.
  • In the minor papilla, all ductal tumors may occur, such as an intraductal papillary mucinous neoplasms and invasive ductal carcinoma, but carcinoid tumors are rare.
  • [MeSH-major] Pancreatic Ducts / pathology
  • [MeSH-minor] Ampulla of Vater / pathology. Enteroendocrine Cells / pathology. Humans. Pancreas / pathology. Pancreatic Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2010 S. Karger AG, Basel.
  • (PMID = 20551659.001).
  • [ISSN] 1421-9883
  • [Journal-full-title] Digestive surgery
  • [ISO-abbreviation] Dig Surg
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Switzerland
  • [Number-of-references] 12
  •  go-up   go-down


80. Iwasa S, Morizane C, Okusaka T, Ueno H, Ikeda M, Kondo S, Tanaka T, Nakachi K, Mitsunaga S, Kojima Y, Hagihara A, Hiraoka N: Cisplatin and etoposide as first-line chemotherapy for poorly differentiated neuroendocrine carcinoma of the hepatobiliary tract and pancreas. Jpn J Clin Oncol; 2010 Apr;40(4):313-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cisplatin and etoposide as first-line chemotherapy for poorly differentiated neuroendocrine carcinoma of the hepatobiliary tract and pancreas.
  • OBJECTIVE: The combination chemotherapy consisting of cisplatin and etoposide, one of the standard regimens for small cell lung cancer, has been widely used to treat extrapulmonary poorly differentiated neuroendocrine carcinomas.
  • METHODS: We reviewed the cases in our database from October 1995 to January 2009 and retrospectively examined the clinical data of patients, with unresectable or recurrent poorly differentiated neuroendocrine carcinoma arising from the hepatobiliary tract and pancreas, who received combination chemotherapy with cisplatin and etoposide as the first-line treatment.
  • The primary tumor site was the liver in 2 patients, gallbladder in 8 patients, pancreas in 10 patients and ampulla of Vater in 1 patient.
  • CONCLUSIONS: Cisplatin and etoposide combination as the first-line chemotherapy for hepatobiliary or pancreatic poorly differentiated neuroendocrine carcinoma had only marginal antitumor activity and relatively severe toxicity compared with previous studies on extrapulmonary poorly differentiated neuroendocrine carcinoma treated with the same regimen.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biliary Tract Neoplasms / drug therapy. Carcinoma, Neuroendocrine / drug therapy. Liver Neoplasms / drug therapy. Pancreatic Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20047862.001).
  • [ISSN] 1465-3621
  • [Journal-full-title] Japanese journal of clinical oncology
  • [ISO-abbreviation] Jpn. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 6PLQ3CP4P3 / Etoposide; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


81. Miyakawa S, Ishihara S, Takada T, Miyazaki M, Tsukada K, Nagino M, Kondo S, Furuse J, Saito H, Tsuyuguchi T, Kimura F, Yoshitomi H, Nozawa S, Yoshida M, Wada K, Amano H, Miura F, Japanese Association of Biliary Surgery, Japanese Society of Hepato-Biliary-Pancreatic Surgery, Japan Society of Clinical Oncology: Flowcharts for the management of biliary tract and ampullary carcinomas. J Hepatobiliary Pancreat Surg; 2008;15(1):7-14
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Flowcharts for the management of biliary tract and ampullary carcinomas.
  • No strategies for the diagnosis and treatment of biliary tract carcinoma have been clearly described.
  • We developed flowcharts for the diagnosis and treatment of biliary tract carcinoma on the basis of the best clinical evidence.
  • Risk factors for bile duct carcinoma are a dilated type of pancreaticobiliary maljunction (PBM) and primary sclerosing cholangitis.
  • A nondilated type of PBM is a risk factor for gallbladder carcinoma.
  • Symptoms that may indicate biliary tract carcinoma are jaundice and pain in the upper right area of the abdomen.
  • The first step of diagnosis is to carry out blood biochemistry tests and ultrasonography (US) of the abdomen.
  • The second step of diagnosis is to find the local extension of the carcinoma by means of computed tomography (CT), magnetic resonance imaging (MRI), magnetic resonance cholangiopancreatography (MRCP), percutaneous transhepatic cholangiography (PTC), and endoscopic retrograde cholangiopancreatography (ERCP).
  • Because resection is the only way to completely cure biliary tract carcinoma, the indications for resection are determined first.
  • [MeSH-major] Algorithms. Ampulla of Vater. Biliary Tract Neoplasms. Carcinoma

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Surgery. 1985 Oct;98(4):752-9 [4049246.001]
  • [Cites] Lancet. 1987 Jul 11;2(8550):57-62 [2439854.001]
  • [Cites] J Gastroenterol Hepatol. 2003 Aug;18(8):950-3 [12859725.001]
  • [Cites] Ann Intern Med. 2003 Oct 7;139(7):547-57 [14530225.001]
  • [Cites] Ann Surg. 2003 Nov;238(5):720-7 [14578735.001]
  • [Cites] Gastroenterology. 2003 Nov;125(5):1355-63 [14598251.001]
  • [Cites] J Hepatobiliary Pancreat Surg. 2003;10(5):345-51 [14598134.001]
  • [Cites] Clin Gastroenterol Hepatol. 2004 Apr;2(4):273-85 [15067620.001]
  • [Cites] Gut. 2004 May;53(5):729-34 [15082593.001]
  • [Cites] Ann Surg. 1991 Jan;213(1):21-5 [1845927.001]
  • [Cites] J Nucl Med Allied Sci. 1990 Oct-Dec;34(4 Suppl):97-102 [2092159.001]
  • [Cites] Am J Surg. 1991 Apr;161(4):454-8 [1709795.001]
  • [Cites] Semin Liver Dis. 1991 Feb;11(1):26-30 [1646485.001]
  • [Cites] Br J Surg. 1991 Jun;78(6):727-31 [2070244.001]
  • [Cites] World J Surg. 1991 May-Jun;15(3):357-66 [1853615.001]
  • [Cites] Eur J Surg. 1991 Oct;157(10):587-9 [1687249.001]
  • [Cites] Anticancer Res. 1992 Sep-Oct;12(5):1687-93 [1332581.001]
  • [Cites] Lancet. 1992 Dec 19-26;340(8834-8835):1488-92 [1281903.001]
  • [Cites] Endoscopy. 1993 Jan;25(1):76-80 [8384103.001]
  • [Cites] J Surg Oncol Suppl. 1993;3:131-3 [8389160.001]
  • [Cites] Endoscopy. 1993 Mar;25(3):213-8 [7686100.001]
  • [Cites] Mayo Clin Proc. 1993 Sep;68(9):874-9 [8396700.001]
  • [Cites] Cancer. 1994 Jun 15;73(12):2922-9 [8199989.001]
  • [Cites] Lancet. 1994 Dec 17;344(8938):1655-60 [7996958.001]
  • [Cites] Ann Surg. 1996 Apr;223(4):384-94 [8633917.001]
  • [Cites] Br J Surg. 1996 Apr;83(4):478-81 [8665234.001]
  • [Cites] Eur J Surg Oncol. 1996 Aug;22(4):366-71 [8783654.001]
  • [Cites] Ann Oncol. 1996 Aug;7(6):593-600 [8879373.001]
  • [Cites] Cancer. 1997 Mar 1;79(5):892-9 [9041150.001]
  • [Cites] Gastrointest Endosc. 1997 Mar;45(3):251-60 [9087831.001]
  • [Cites] Hepatogastroenterology. 1997 Sep-Oct;44(17):1477-83 [9356876.001]
  • [Cites] Gastroenterologist. 1997 Dec;5(4):306-15 [9436006.001]
  • [Cites] AJR Am J Roentgenol. 1998 Feb;170(2):403-8 [9456954.001]
  • [Cites] Ann Surg. 1998 Mar;227(3):405-11 [9527064.001]
  • [Cites] Endoscopy. 1989 Dec;21 Suppl 1:351-6 [2606085.001]
  • [Cites] Semin Liver Dis. 1990 May;10(2):131-41 [2162565.001]
  • [Cites] World J Surg. 1990 Jul-Aug;14(4):535-43; discussion 544 [2166381.001]
  • [Cites] Surg Clin North Am. 1990 Dec;70(6):1429-47 [2174191.001]
  • [Cites] Br J Surg. 2000 Jan;87(1):110-5 [10606921.001]
  • [Cites] Am J Gastroenterol. 2000 Jan;95(1):204-7 [10638584.001]
  • [Cites] Gut. 2000 Feb;46(2):250-4 [10644321.001]
  • [Cites] Br J Surg. 2000 Apr;87(4):418-22 [10759735.001]
  • [Cites] Curr Gastroenterol Rep. 1999 Apr;1(2):95-101 [10980934.001]
  • [Cites] J Hepatobiliary Pancreat Surg. 2000;7(2):122-7 [10982603.001]
  • [Cites] J Hepatobiliary Pancreat Surg. 2000;7(2):135-41 [10982605.001]
  • [Cites] Ann Surg. 2001 Mar;233(3):385-92 [11224627.001]
  • [Cites] Am J Surg. 2001 Jan;181(1):52-9; discussion 87 [11248177.001]
  • [Cites] Am J Surg. 2001 Jan;181(1):65-70 [11248179.001]
  • [Cites] J Hepatobiliary Pancreat Surg. 2001;8(1):58-64 [11294291.001]
  • [Cites] J Am Coll Surg. 2001 Jun;192(6):726-34 [11400966.001]
  • [Cites] Ann Surg. 2001 Jul;234(1):47-55 [11420482.001]
  • [Cites] Radiology. 2001 Jul;220(1):90-6 [11425978.001]
  • [Cites] World J Surg. 2001 Oct;25(10):1277-83 [11596890.001]
  • [Cites] Radiographics. 2002 Jan-Feb;22(1):173-87 [11796906.001]
  • [Cites] Br J Surg. 2002 Feb;89(2):179-84 [11856130.001]
  • [Cites] Ann Surg. 2002 Mar;235(3):392-9 [11882761.001]
  • [Cites] J Comput Assist Tomogr. 2002 May-Jun;26(3):405-10 [12016370.001]
  • [Cites] Eur Radiol. 2002 Aug;12(8):1993-9 [12136317.001]
  • [Cites] Br J Surg. 2002 Oct;89(10):1260-7 [12296893.001]
  • [Cites] Gut. 2002 Nov;51 Suppl 6:VI1-9 [12376491.001]
  • [Cites] J Magn Reson Imaging. 2002 Dec;16(6):676-84 [12451581.001]
  • [Cites] Gastrointest Endosc. 2003 Feb;57(2):178-82 [12556780.001]
  • [Cites] Ann Surg. 2003 Feb;237(2):208-17 [12560779.001]
  • [Cites] Lancet Oncol. 2003 Mar;4(3):167-76 [12623362.001]
  • [Cites] Ann Surg. 2003 Jul;238(1):73-83 [12832968.001]
  • [Cites] Ann Surg. 2003 Jul;238(1):84-92 [12832969.001]
  • [Cites] Arch Surg. 1998 Jul;133(7):735-9 [9688001.001]
  • [Cites] Gastrointest Endosc. 1998 Oct;48(4):406-10 [9786115.001]
  • [Cites] Ann Surg. 1999 Jan;229(1):76-83 [9923803.001]
  • [Cites] Hepatogastroenterology. 1998 Nov-Dec;45(24):2020-6 [9951857.001]
  • [Cites] Gastrointest Endosc. 1999 Mar;49(3 Pt 1):349-57 [10049419.001]
  • [Cites] Arch Surg. 1999 May;134(5):526-32 [10323425.001]
  • [Cites] N Engl J Med. 1999 Jul 22;341(4):258-64 [10413739.001]
  • [Cites] Hepatogastroenterology. 1999 May-Jun;46(27):1585-91 [10430299.001]
  • [Cites] Ann Surg. 1999 Aug;230(2):131-42 [10450725.001]
  • [Cites] N Engl J Med. 1999 Oct 28;341(18):1368-78 [10536130.001]
  • [Cites] Ann Surg. 2005 Jan;241(1):77-84 [15621994.001]
  • [Cites] Am J Clin Oncol. 2005 Feb;28(1):21-3 [15685030.001]
  • [Cites] Hepatogastroenterology. 2005 Jan-Feb;52(61):5-7 [15782981.001]
  • [Cites] Ann Surg. 2005 May;241(5):693-9; discussion 699-702 [15849505.001]
  • [Cites] Gastrointest Endosc. 2005 Sep;62(3):374-82 [16111955.001]
  • [Cites] Lancet. 2005 Oct 8;366(9493):1303-14 [16214602.001]
  • [Cites] Am J Gastroenterol. 2005 Nov;100(11):2426-30 [16279895.001]
  • [Cites] J Am Coll Surg. 2006 Jan;202(1):87-92 [16377501.001]
  • [Cites] J Clin Gastroenterol. 2006 Feb;40(2):162-6 [16394879.001]
  • [Cites] Cancer Chemother Pharmacol. 2006 May;57(5):647-53 [16142487.001]
  • [Cites] Ann Surg. 2006 Mar;243(3):364-72 [16495702.001]
  • [Cites] AJR Am J Roentgenol. 2006 Jun;186(6):1580-6 [16714646.001]
  • [Cites] Ann Surg. 2006 Aug;244(2):240-7 [16858186.001]
  • [Cites] Am Surg. 2006 Jul;72(7):599-604; discussion 604-5 [16875081.001]
  • [Cites] Surgery. 2007 May;141(5):581-8 [17462457.001]
  • [Cites] J Hepatobiliary Pancreat Surg. 2007;14(4):351-7 [17653632.001]
  • [Cites] Gastrointest Endosc. 2007 Oct;66(4):730-6 [17905015.001]
  • [Cites] J Hepatobiliary Pancreat Surg. 2008;15(1):2-6 [18274838.001]
  • [Cites] Oncology. 2004;66(2):138-42 [15138366.001]
  • [Cites] Ann Surg. 2004 Jul;240(1):95-101 [15213624.001]
  • [Cites] J Hepatobiliary Pancreat Surg. 2004;11(4):239-44 [15368107.001]
  • [Cites] Radiology. 2004 Oct;233(1):234-40 [15333766.001]
  • (PMID = 18274839.001).
  • [ISSN] 0944-1166
  • [Journal-full-title] Journal of hepato-biliary-pancreatic surgery
  • [ISO-abbreviation] J Hepatobiliary Pancreat Surg
  • [Language] eng
  • [Publication-type] Journal Article; Practice Guideline; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Other-IDs] NLM/ PMC2794355
  • [Investigator] Kai M; Kimura Y; Kai S; Kimura Y; Sawada S; Shimizu H; Nakagawara H; Nakachi K; Yoshitome H; Saisyo H; Shikata S; Nimura Y
  •  go-up   go-down


82. Furuse J, Okusaka T, Funakoshi A, Yamao K, Nagase M, Ishii H, Nakachi K, Ueno H, Ikeda M, Morizane C, Horikawa Y, Mizuno N: Early phase II study of uracil-tegafur plus doxorubicin in patients with unresectable advanced biliary tract cancer. Jpn J Clin Oncol; 2006 Sep;36(9):552-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Early phase II study of uracil-tegafur plus doxorubicin in patients with unresectable advanced biliary tract cancer.
  • BACKGROUND: Standard chemotherapy for advanced biliary tract cancer has not been established.
  • The purpose of this study was to evaluate the efficacy and toxicity of a combination chemotherapy of uracil-tegafur (UFT) and doxorubicin in patients with unresectable advanced biliary tract cancer.
  • METHODS: Patients with histologically or cytologically confirmed, measurable biliary tract cancer, including intrahepatic or extrahepatic cholangiocarcinoma, gallbladder cancer and ampulla of Vater cancer, which was not amenable to surgery, were eligible for the study.
  • CONCLUSIONS: Combination chemotherapy of UFT and doxorubicin was well tolerated and showed preliminary moderate activity against advanced biliary tract cancer.

  • Genetic Alliance. consumer health - Biliary Tract Cancer.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16887837.001).
  • [ISSN] 0368-2811
  • [Journal-full-title] Japanese journal of clinical oncology
  • [ISO-abbreviation] Jpn. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Chemical-registry-number] 1548R74NSZ / Tegafur; 56HH86ZVCT / Uracil; 80168379AG / Doxorubicin; 1-UFT protocol
  •  go-up   go-down


83. Bhatia S, Miller RC, Haddock MG, Donohue JH, Krishnan S: Adjuvant therapy for ampullary carcinomas: the Mayo Clinic experience. Int J Radiat Oncol Biol Phys; 2006 Oct 1;66(2):514-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adjuvant therapy for ampullary carcinomas: the Mayo Clinic experience.
  • PURPOSE: To determine the effects of adjuvant radiotherapy and chemotherapy for carcinoma of the ampulla of Vater.
  • METHODS AND MATERIALS: We retrospectively reviewed the records of 125 patients who underwent definitive surgery for carcinomas involving the ampulla of Vater between April 1977 and February 2005 and who survived more than 50 days after surgery.
  • [MeSH-major] Ampulla of Vater. Common Bile Duct Neoplasms / drug therapy. Common Bile Duct Neoplasms / radiotherapy

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16863684.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; U3P01618RT / Fluorouracil
  •  go-up   go-down


84. Park SK, Andreotti G, Sakoda LC, Gao YT, Rashid A, Chen J, Chen BE, Rosenberg PS, Shen MC, Wang BS, Han TQ, Zhang BH, Yeager M, Chanock S, Hsing AW: Variants in hormone-related genes and the risk of biliary tract cancers and stones: a population-based study in China. Carcinogenesis; 2009 Apr;30(4):606-14
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Biliary tract cancers, encompassing gallbladder, extrahepatic bile duct and ampulla of Vater cancers, are uncommon but often fatal malignancies.
  • This study included subjects who completed an interview and provided blood, which totaled 411 biliary tract cancer and 893 biliary stone patients and 786 healthy Shanghai residents.
  • The CYP1A1 IVS1 + 606 (rs2606345) T allele was associated with gallbladder [odds ratio (OR) = 2.0, 95% confidence interval (CI), 1.3-3.0] and bile duct cancers (OR = 1.8, 95% CI = 1.1-3.1), whereas the CYP1A1 Ex7 + 131 (rs1048943) G allele was associated with ampulla of Vater cancer (OR = 2.9, 95% CI = 1.5-5.4).
  • After taking into account multiple comparisons for SNPs within each gene, CYP1A1 was significantly associated with gallbladder (P = 0.004) and ampulla of Vater cancers (P = 0.01), but borderline with bile duct cancer (P = 0.06).
  • The effect of CYP1A1 IVS1 + 606 on gallbladder cancer was more pronounced among non-obese (body mass index < 23) (OR = 3.3, 95% CI = 1.8-6.1; P interaction = 0.001).
  • Among women taking oral contraceptives, the effect of SHBG Ex8 + 6 (rs6259) on gallbladder cancer (OR = 6.7, 95% CI = 2.2-20.5; P interaction = 0.001) and stones (OR = 2.3, 95% CI = 1.1-4.9; P-interaction = 0.05) was statistically significant.

  • MedlinePlus Health Information. consumer health - Hormones.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2000 Jan;9(1):3-28 [10667460.001]
  • [Cites] Menopause. 2000 May-Jun;7(3):162-7 [10810961.001]
  • [Cites] Pharmacogenetics. 2000 Aug;10(6):519-30 [10975606.001]
  • [Cites] Ann Intern Med. 2001 Oct 2;135(7):493-501 [11578152.001]
  • [Cites] Am J Hum Genet. 2002 Feb;70(2):425-34 [11791212.001]
  • [Cites] Trends Endocrinol Metab. 2002 Apr;13(3):122-8 [11893526.001]
  • [Cites] J Exp Clin Cancer Res. 2002 Mar;21(1):119-24 [12071517.001]
  • [Cites] Int J Cancer. 2002 Jun 10;99(5):762-3 [12115514.001]
  • [Cites] J Endocrinol Invest. 2002 Nov;25(10):893-8 [12508952.001]
  • [Cites] Int J Cancer. 2003 Jun 20;105(3):408-12 [12704678.001]
  • [Cites] Nucleic Acids Res. 2004 Jan 1;32(Database issue):D528-32 [14681474.001]
  • [Cites] Acta Endocrinol Suppl (Copenh). 1980;232:1-127 [6770572.001]
  • [Cites] Recent Prog Horm Res. 1982;38:457-510 [6750727.001]
  • [Cites] J Natl Cancer Inst. 1985 Apr;74(4):741-5 [3857369.001]
  • [Cites] Cancer. 1987 Jun 15;59(12):2112-6 [3567872.001]
  • [Cites] Jpn J Cancer Res. 1989 Oct;80(10):932-8 [2515177.001]
  • [Cites] J Clin Epidemiol. 1990;43(7):687-92 [2370576.001]
  • [Cites] J Clin Invest. 1991 Jan;87(1):237-46 [1845870.001]
  • [Cites] Contraception. 1991 Jun;43(6):667-93 [1868737.001]
  • [Cites] J Toxicol Environ Health. 1993 Oct-Nov;40(2-3):309-16 [7901425.001]
  • [Cites] Int J Cancer. 1994 Apr 15;57(2):146-53 [8157350.001]
  • [Cites] Cancer Causes Control. 1994 May;5(3):267-72 [8061176.001]
  • [Cites] Toxicol Lett. 1995 May;77(1-3):357-62 [7618162.001]
  • [Cites] Mol Biol Evol. 1995 Sep;12(5):921-7 [7476138.001]
  • [Cites] Eur J Cancer Prev. 1996 Aug;5(4):241-7 [8894561.001]
  • [Cites] J Cell Biochem Suppl. 1996;25:15-22 [9027593.001]
  • [Cites] J Natl Cancer Inst. 1997 Aug 6;89(15):1132-8 [9262251.001]
  • [Cites] Int J Cancer. 1998 Jan 30;75(3):368-70 [9455795.001]
  • [Cites] Am J Gastroenterol. 1999 Jan;94(1):149-52 [9934746.001]
  • [Cites] Hepatogastroenterology. 1999 May-Jun;46(27):1529-32 [10430289.001]
  • [Cites] Bioinformatics. 2005 Jan 15;21(2):263-5 [15297300.001]
  • [Cites] Expert Opin Drug Saf. 2006 Jan;5(1):117-29 [16370961.001]
  • [Cites] J Sex Med. 2006 Jan;3(1):104-13 [16409223.001]
  • [Cites] Int J Cancer. 2006 Apr 1;118(7):1591-602 [16397865.001]
  • [Cites] Int J Cancer. 2006 Jun 1;118(11):2847-53 [16381022.001]
  • [Cites] Fertil Steril. 2006 May;85(5):1319-40 [16647374.001]
  • [Cites] Carcinogenesis. 2006 Jun;27(6):1251-6 [16361272.001]
  • [Cites] Stat Med. 2006 Sep 30;25(18):3134-49 [16252274.001]
  • [Cites] J Gastroenterol Hepatol. 2006 Nov;21(11):1737-43 [16984599.001]
  • [Cites] Br J Cancer. 2007 Dec 3;97(11):1577-82 [18000509.001]
  • [Cites] Int J Cancer. 2008 Apr 15;122(8):1849-53 [18076042.001]
  • [Cites] Cancer Res. 2008 Aug 1;68(15):6442-52 [18676870.001]
  • [Cites] Br J Cancer. 2008 Sep 2;99(5):811-5 [18728671.001]
  • (PMID = 19168589.001).
  • [ISSN] 1460-2180
  • [Journal-full-title] Carcinogenesis
  • [ISO-abbreviation] Carcinogenesis
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CO / N01-CO-12400
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Contraceptives, Oral, Hormonal; 0 / Hormones; 9007-49-2 / DNA; EC 1.14.14.1 / Cytochrome P-450 CYP1A1
  • [Other-IDs] NLM/ PMC2664453
  •  go-up   go-down


85. Peng SY, Hong DF, Liu YB, Li JT, Tao F, Tan ZJ: [A pancreas suture-less type II binding pancreaticogastrostomy]. Zhonghua Wai Ke Za Zhi; 2009 Dec 1;47(23):1764-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: From November 2008 to May 2009, 26 patients underwent pancreaticoduodenectomy and mid-segmentectomy of pancreas with type II BPG reconstruction, including 13 cases of pancreatic head cancer, 3 cases of duodenal adenocarcinoma, 2 cases of ampullary carcinoma, 4 cases of cholangiocarcinoma, 1 case of bile duct cell severe atypical hyperplasia, and 1 case of stomach cancer.
  • No mortality or pancreatic leakage occurred.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20193541.001).
  • [ISSN] 0529-5815
  • [Journal-full-title] Zhonghua wai ke za zhi [Chinese journal of surgery]
  • [ISO-abbreviation] Zhonghua Wai Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Evaluation Studies; Journal Article
  • [Publication-country] China
  •  go-up   go-down


86. Yokoyama N, Shirai Y, Wakai T, Nagakura S, Akazawa K, Hatakeyama K: Jaundice at presentation heralds advanced disease and poor prognosis in patients with ampullary carcinoma. World J Surg; 2005 Apr;29(4):519-23
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Jaundice at presentation heralds advanced disease and poor prognosis in patients with ampullary carcinoma.
  • Jaundice is a common manifestation of ampullary carcinoma.
  • The aim of this study was to evaluate the correlation between jaundice at initial presentation and the degree of tumor spread and to determine the prognostic significance of jaundice in patients with ampullary carcinoma.
  • Fifty-nine patients who had undergone curative resection for ampullary carcinoma were analyzed retrospectively.
  • Pancreatic invasion was absent in patients without jaundice.
  • In conclusion, jaundice at presentation predicts advanced-stage ampullary carcinoma and a poor prognosis.
  • Pancreatic invasion and superior mesenteric nodal involvement were not observed in nonjaundiced patients.
  • [MeSH-major] Ampulla of Vater. Common Bile Duct Neoplasms / mortality. Common Bile Duct Neoplasms / pathology. Jaundice / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Lymph Node Excision. Male. Mesentery / pathology. Middle Aged. Neoplasm Invasiveness. Pancreas / pathology. Prognosis. Retrospective Studies. Survival Analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Surg. 1996 Sep;83(9):1302-3 [8983635.001]
  • [Cites] World J Surg. 1995 Jan-Feb;19(1):102-6; discussion 106-7 [7740792.001]
  • [Cites] Ann Surg. 1998 Jul;228(1):87-94 [9671071.001]
  • [Cites] World J Surg. 1996 Jul-Aug;20(6):707-12 [8662157.001]
  • [Cites] Arch Surg. 1993 May;128(5):515-20 [8098205.001]
  • [Cites] Am Surg. 1999 Nov;65(11):1043-8 [10551754.001]
  • [Cites] J Surg Oncol. 1996 Mar;61(3):190-4 [8637205.001]
  • [Cites] Eur J Surg Oncol. 1993 Apr;19(2):147-61 [7684003.001]
  • [Cites] Surgery. 1995 Jun;117(6):616-23 [7778025.001]
  • [Cites] Hepatogastroenterology. 1993 Oct;40(5):457-62 [8270234.001]
  • [Cites] Cancer. 1987 Feb 1;59(3):506-15 [3791159.001]
  • [Cites] Gut. 1997 Mar;40(3):350-5 [9135524.001]
  • [Cites] Br J Surg. 1987 Oct;74(10):957-61 [3664230.001]
  • [Cites] Br J Surg. 1997 Jul;84(7):1012-6 [9240155.001]
  • [Cites] Arch Surg. 1991 Mar;126(3):353-7 [1998478.001]
  • [Cites] Am J Gastroenterol. 1990 Aug;85(8):994-9 [2375329.001]
  • [Cites] Arch Surg. 1999 May;134(5):526-32 [10323425.001]
  • [Cites] Cancer. 1988 Apr 1;61(7):1403-7 [2449947.001]
  • [Cites] Br J Surg. 1995 Dec;82(12):1693-6 [8548244.001]
  • (PMID = 15770375.001).
  • [ISSN] 0364-2313
  • [Journal-full-title] World journal of surgery
  • [ISO-abbreviation] World J Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


87. Ishihara S, Miyakawa S, Takada T, Takasaki K, Nimura Y, Tanaka M, Miyazaki M, Nagakawa T, Kayahara M, Horiguchi A: Status of surgical treatment of biliary tract cancer. Dig Surg; 2007;24(2):131-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Status of surgical treatment of biliary tract cancer.
  • Complete surgical resection of biliary tract carcinoma remains the best treatment.
  • The Japanese Society of Biliary Surgery has organized a registry project and established a classification of biliary tract carcinoma.
  • For hilar bile duct carcinoma, major hepatectomy is needed to increase the resection rate, and total caudate lobectomy is required for curative resection.
  • The treatment of gallbladder carcinoma with pT1 lesions is cholecystectomy.
  • PD or PPPD is the standard operation for carcinoma of the papilla of Vater.
  • [MeSH-minor] Ampulla of Vater. Bile Duct Neoplasms / surgery. Gallbladder Neoplasms / surgery. Humans. Japan

  • Genetic Alliance. consumer health - Biliary Tract Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2007 S. Karger AG, Basel.
  • (PMID = 17446708.001).
  • [ISSN] 0253-4886
  • [Journal-full-title] Digestive surgery
  • [ISO-abbreviation] Dig Surg
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Switzerland
  • [Number-of-references] 24
  •  go-up   go-down


88. Akatsu T, Aiura K, Takahashi S, Kameyama K, Kitajima M, Kitagawa Y: Signet-ring cell carcinoma of the ampulla of Vater: report of a case. Surg Today; 2007;37(12):1110-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Signet-ring cell carcinoma of the ampulla of Vater: report of a case.
  • Signet-ring cell carcinoma (SRCC) of the ampulla of Vater is uncommon, and only 13 cases have been previously described.
  • We herein report a rare case of a 43-year-old woman with SRCC in the ampulla of Vater.
  • Although this histologic type of cancer generally predicts a poor prognosis elsewhere in the gastrointestinal tract, the present patient has survived with no evidence of recurrence for 7.5 years.
  • She underwent a pancreaticoduodenectomy with an extended lymphadenectomy for ampullary carcinoma.
  • This neoplasm was classified as AcdbBi, 2.0 x 1.8 cm, ulcerative type, Panc(0), Du(2), T(2)N(0)M(-), Stage II according to the Japanese Classification on Cancer of the Biliary Tract.
  • Unfortunately, previous reports of ampullary SRCC have been limited to short-term follow-ups with a median period of only 12 months (range, 6-134 months), and long-term survival (more than 5 years) was only documented in two cases without lymph node metastasis (including the present case).
  • In conclusion, the experience gained in the present and previous cases suggests that long-term survival is possible following a curative resection in selected patients with ampullary SRCC without nodal involvement.
  • Due to the lack of sufficient evidence, additional reports are warranted to determine whether SRCC also portends a poor prognosis in patients with ampullary cancer.
  • [MeSH-major] Ampulla of Vater. Carcinoma, Signet Ring Cell / pathology. Common Bile Duct Neoplasms / pathology. Pancreaticoduodenectomy / methods
  • [MeSH-minor] Adult. Biopsy. Diagnosis, Differential. Female. Follow-Up Studies. Humans

  • Genetic Alliance. consumer health - Signet ring cell carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Surg Oncol. 1996 Jul;3(4):344-8 [8790846.001]
  • [Cites] Dis Colon Rectum. 2005 Jun;48(6):1161-8 [15868237.001]
  • [Cites] Ann Surg. 1998 Jul;228(1):87-94 [9671071.001]
  • [Cites] Br J Surg. 2004 Oct;91(10):1319-24 [15376179.001]
  • [Cites] Digestion. 1970;3(3):165-73 [4915587.001]
  • [Cites] Ann Clin Lab Sci. 2004 Autumn;34(4):471-5 [15648791.001]
  • [Cites] Am Surg. 2006 Feb;72(2):193-5 [16536256.001]
  • [Cites] Dis Colon Rectum. 1999 Sep;42(9):1176-80 [10496558.001]
  • [Cites] J Formos Med Assoc. 2004 Oct;103(10):793-6 [15490032.001]
  • [Cites] JOP. 2004 Nov 10;5(6):495-7 [15536289.001]
  • [Cites] Arch Pathol Lab Med. 1990 Oct;114(10):1071-2 [2171451.001]
  • [Cites] Helv Chir Acta. 1994 Dec;60(6):987-90 [7876027.001]
  • [Cites] Indian J Gastroenterol. 2005 Sep-Oct;24(5):222-3 [16361773.001]
  • [Cites] J Surg Oncol. 2007 Mar 15;95(4):286-90 [17326125.001]
  • [Cites] Fukuoka Igaku Zasshi. 2003 Jul;94(7):235-40 [14509231.001]
  • [Cites] Cancer. 2000 Oct 1;89(7):1418-24 [11013353.001]
  • [Cites] Hepatogastroenterology. 2002 Mar-Apr;49(44):561-3 [11995497.001]
  • [Cites] Rev Esp Enferm Dig. 1994 May;85(5):391-3 [8049111.001]
  • [Cites] Surg Today. 2003;33(6):467-9 [12768376.001]
  • [Cites] Am J Gastroenterol. 1982 Feb;77(2):111-4 [7072678.001]
  • [Cites] Arch Surg. 1999 May;134(5):526-32 [10323425.001]
  • [Cites] Br J Surg. 1995 Dec;82(12):1693-6 [8548244.001]
  • [Cites] Surg Oncol. 1994 Aug;3(4):221-7 [7834113.001]
  • [Cites] Gastrointest Endosc. 2002 Nov;56(5):733 [12397285.001]
  • (PMID = 18030577.001).
  • [ISSN] 0941-1291
  • [Journal-full-title] Surgery today
  • [ISO-abbreviation] Surg. Today
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


89. Ridwelski K, Meyer F, Schmidt U, Lippert H: [Results of surgical treatment in ampullary and pancreatic carcinoma and its prognostic parameters after R0-resection]. Zentralbl Chir; 2005 Aug;130(4):353-61
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Results of surgical treatment in ampullary and pancreatic carcinoma and its prognostic parameters after R0-resection].
  • INTRODUCTION: Resection is currently the only established reasonable therapeutic option with curative potential in pancreatic and ampullary carcinoma.
  • METHODS: Two-hundred-twenty patients with pancreatic and ampullary carcinoma (mean age, 61.4 years; 104 females/116 males) underwent surgery.
  • Histologic investigation revealed 19 carcinomas of the papilla of Vater and 201 ductal pancreatic carcinomas.
  • RESULTS: Hundred-ten patients underwent tumor resection with primary curative intention (50 %): 96 resections of the pancreatic head, 2 total pancreatectomies and 12 left resections of the pancreas.
  • Postoperative letality of curative pancreatic resections was 3.6 % (palliative intervention, 6.7 %; explorative laparotomy, 8.8 %).
  • Five-year survival-rate of carcinoma of the papilla of Vater and pancreatic carcinoma was 73.3 % and 16.2 %, respectively (median survival time was 66.0 and 14.0 months, respectively).
  • CONCLUSION: Resection of pancreatic and ampullary carcinoma according to oncological criteria with tumor-free margins can be considered a treatment option with curative intention and potential.
  • The 5-year survival-rate of 16.2 % in ductal pancreatic carcinoma underlines the demand for the development of effective multimodal therapeutic concepts.
  • Such interventions in patients with pancreatic carcinoma are no reasonable treatment alternative.
  • [MeSH-major] Ampulla of Vater. Carcinoma, Pancreatic Ductal / surgery. Common Bile Duct Neoplasms / surgery. Pancreatectomy. Pancreatic Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Anastomosis, Surgical. Female. Gastroenterostomy. Humans. Male. Middle Aged. Neoplasm Staging. Pancreas / pathology. Postoperative Complications. Prognosis. Survival Analysis. Time Factors

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16103961.001).
  • [ISSN] 0044-409X
  • [Journal-full-title] Zentralblatt für Chirurgie
  • [ISO-abbreviation] Zentralbl Chir
  • [Language] ger
  • [Publication-type] Comparative Study; English Abstract; Evaluation Studies; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


90. Bogoevski D, Chayeb H, Cataldegirmen G, Schurr PG, Kaifi JT, Mann O, Yekebas EF, Izbicki JR: Nodal microinvolvement in patients with carcinoma of the papilla of vater receiving no adjuvant chemotherapy. J Gastrointest Surg; 2008 Nov;12(11):1830-7; discussion 1837-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nodal microinvolvement in patients with carcinoma of the papilla of vater receiving no adjuvant chemotherapy.
  • BACKGROUND: To assess the prognostic significance of nodal microinvolvement in patients with carcinoma of the papilla of Vater.
  • METHODS: From 1993 to 2003 at the University Clinic Hamburg, 777 patients were operated upon pancreatic and periampullary carcinomas.
  • The vast majority of patients were operated upon pancreatic ductal adenocarcinoma (n = 566, 73%), followed by carcinomas of the papilla of Vater (n = 112, 14%), pancreatic neuroendocrine carcinomas (n = 39, 5%), intraductal papillary mucinous neoplasms (n = 33, 4%), and distal bile duct carcinomas (n = 27, 3%).
  • Fresh-frozen tissue sections from 169 lymph nodes (LNs) classified as tumor free by routine histopathology from 57 patients with R0 resected carcinoma of the papilla of Vater who had been spared from adjuvant chemotherapy were immunohistochemically (IHC) examined, using a sensitive IHC assay with the anti-epithelial monoclonal antibody Ber-EP4 for tumor cell detection.
  • CONCLUSIONS: The influence of occult tumor cell dissemination in LNs of patients with histologically proven carcinoma of the papilla of Vater supports the need for further tumor staging through immunohistochemistry.
  • [MeSH-major] Adenocarcinoma / secondary. Adenocarcinoma / surgery. Ampulla of Vater / pathology. Common Bile Duct Neoplasms / pathology. Common Bile Duct Neoplasms / surgery. Lymph Nodes / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biopsy, Needle. Chemotherapy, Adjuvant. Cohort Studies. Female. Humans. Immunohistochemistry. Kaplan-Meier Estimate. Lymph Node Excision. Lymphatic Metastasis. Male. Middle Aged. Multivariate Analysis. Neoplasm Staging. Pancreatic Neoplasms / drug therapy. Pancreatic Neoplasms / mortality. Pancreatic Neoplasms / pathology. Pancreatic Neoplasms / surgery. Probability. Prognosis. Proportional Hazards Models. Retrospective Studies. Risk Assessment. Statistics, Nonparametric. Survival Analysis. Treatment Outcome

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Pathology. 1989 Jan;21(1):11-5 [2474791.001]
  • [Cites] Ann Surg. 1993 Feb;217(2):101-8 [8382467.001]
  • [Cites] Ann Surg. 1998 Oct;228(4):508-17 [9790340.001]
  • [Cites] Scand J Gastroenterol. 1999 Aug;34(8):808-12 [10499482.001]
  • [Cites] Eur J Surg Oncol. 1987 Oct;13(5):409-11 [3311817.001]
  • [Cites] J Hematother. 1994 Fall;3(3):165-73 [7530132.001]
  • [Cites] Lifetime Data Anal. 1995;1(2):195-204 [9385101.001]
  • [Cites] Ann N Y Acad Sci. 1993 Aug 12;690:42-9 [8368769.001]
  • [Cites] HPB (Oxford). 2007;9(2):135-9 [18333129.001]
  • [Cites] Eur J Surg. 1996 Dec;162(12):961-7 [9001878.001]
  • [Cites] J Clin Pathol. 1981 Jul;34(7):779-84 [7021603.001]
  • [Cites] Immunol Today. 1997 Feb;18(2):89-95 [9057360.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1999 Jul 15;44(5):1039-46 [10421536.001]
  • [Cites] Hepatogastroenterology. 2003 Jul-Aug;50(52):928-33 [12845952.001]
  • [Cites] Cancer. 1992 Jul 15;70(2):410-4 [1617591.001]
  • [Cites] Chirurg. 2000 Feb;71(2):196-201 [10734589.001]
  • [Cites] Ann Chir. 2006 May;131(5):322-7 [16615931.001]
  • [Cites] Ann Surg. 1983 Sep;198(3):386-97 [6615059.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2000 Jul 1;47(4):945-53 [10863064.001]
  • [Cites] Surgery. 2001 May;129(5):537-46 [11331445.001]
  • [Cites] Pathologe. 2003 May;24(3):196-203 [12739053.001]
  • [Cites] World J Gastroenterol. 2006 Oct 28;12(40):6515-21 [17072983.001]
  • [Cites] J Clin Oncol. 1994 Sep;12(9):1827-32 [8083707.001]
  • [Cites] Ann Surg. 2004 Dec;240(6):993-1000; discussion 1000-1 [15570205.001]
  • [Cites] Cancer Res. 1987 Jun 1;47(11):2883-91 [3552208.001]
  • [Cites] Cancer Res. 2000 Dec 15;60(24):6836-40 [11156375.001]
  • [Cites] J Clin Pathol. 1990 Mar;43(3):213-9 [1692040.001]
  • [Cites] Nat Rev Cancer. 2004 Jun;4(6):448-56 [15170447.001]
  • [Cites] Cancer Res. 1993 Mar 1;53(5):1027-31 [7679945.001]
  • [Cites] Br J Cancer. 1986 Oct;54(4):631-6 [3535864.001]
  • [Cites] Dis Colon Rectum. 1985 Sep;28(9):664-8 [4053908.001]
  • [Cites] N Engl J Med. 1997 Oct 23;337(17):1188-94 [9337377.001]
  • [Cites] J Natl Cancer Inst. 1993 Mar 17;85(6):493-8 [7680382.001]
  • [Cites] World J Surg Oncol. 2006 Mar 08;4:14 [16524478.001]
  • [Cites] Am J Surg. 1996 Nov;172(5):463-8; discussion 468-9 [8942545.001]
  • [Cites] Ann Thorac Surg. 1994 Nov;58(5):1569-70 [7979715.001]
  • [Cites] Eur J Cancer Clin Oncol. 1987 Feb;23(2):137-47 [2450753.001]
  • [Cites] Z Gastroenterol. 1998 May;36(5):479-81 [9654711.001]
  • [Cites] Arch Surg. 1999 May;134(5):526-32 [10323425.001]
  • [Cites] Lancet. 1990 Jun 30;335(8705):1565-8 [1972494.001]
  • [Cites] Ann Surg. 2005 Jul;242(1):92-100 [15973106.001]
  • [Cites] Br J Cancer. 1992 Sep;66(3):523-7 [1520589.001]
  • [Cites] Science. 1977 Aug 26;197(4306):893-5 [887927.001]
  • (PMID = 18791769.001).
  • [ISSN] 1873-4626
  • [Journal-full-title] Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
  • [ISO-abbreviation] J. Gastrointest. Surg.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


91. Alberts SR, Al-Khatib H, Mahoney MR, Burgart L, Cera PJ, Flynn PJ, Finch TR, Levitt R, Windschitl HE, Knost JA, Tschetter LK: Gemcitabine, 5-fluorouracil, and leucovorin in advanced biliary tract and gallbladder carcinoma: a North Central Cancer Treatment Group phase II trial. Cancer; 2005 Jan 1;103(1):111-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gemcitabine, 5-fluorouracil, and leucovorin in advanced biliary tract and gallbladder carcinoma: a North Central Cancer Treatment Group phase II trial.
  • Patients with biliary tract ACA included 24 with hepatic disease (19 patients had intrahepatic disease and 5 patients had extrahepatic disease) and 4 with disease in the ampulla of Vater.

  • Genetic Alliance. consumer health - Biliary Tract Cancer.
  • MedlinePlus Health Information. consumer health - Gallbladder Cancer.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • Hazardous Substances Data Bank. LEUCOVORIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15558814.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA-15083; United States / NCI NIH HHS / CA / CA-25224; United States / NCI NIH HHS / CA / CA-35101; United States / NCI NIH HHS / CA / CA-35103; United States / NCI NIH HHS / CA / CA-35195; United States / NCI NIH HHS / CA / CA-35415; United States / NCI NIH HHS / CA / CA-35448; United States / NCI NIH HHS / CA / CA-37404; United States / NCI NIH HHS / CA / CA-37417; United States / NCI NIH HHS / CA / CA-52352; United States / NCI NIH HHS / CA / CA-60276; United States / NCI NIH HHS / CA / CA-63826; United States / NCI NIH HHS / CA / CA-63848; United States / NCI NIH HHS / CA / CA-63849
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil
  •  go-up   go-down


92. Komatsu S, Sonoyama T, Ochiai T, Ichikawa D, Ikoma H, Okamura H, Otsuji E: Long-term complete response of multiple hepatic metastases from carcinoma of the papilla of Vater using intrahepatic infusion of 5-FU with low-dose cisplatin following pancreaticoduodenectomy. Int J Clin Oncol; 2008 Dec;13(6):567-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term complete response of multiple hepatic metastases from carcinoma of the papilla of Vater using intrahepatic infusion of 5-FU with low-dose cisplatin following pancreaticoduodenectomy.
  • Of all distant metastases from carcinoma of the papilla of Vater (CPV), the liver is the most frequent site (more than 60%) and should be specifically targeted in the effort to improve the prognosis.
  • [MeSH-major] Ampulla of Vater / pathology. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Common Bile Duct Neoplasms / drug therapy. Liver Neoplasms / drug therapy. Pancreaticoduodenectomy

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Surg. 1998 Jul;228(1):87-94 [9671071.001]
  • [Cites] Ann Oncol. 1998 Jun;9(6):653-6 [9681080.001]
  • [Cites] Ann Surg Oncol. 2003 Dec;10(10):1176-83 [14654474.001]
  • [Cites] J Clin Oncol. 1984 May;2(5):498-504 [6547166.001]
  • [Cites] Cancer. 1996 Oct 15;78(8):1639-45 [8859174.001]
  • [Cites] Cancer. 1998 Jun 15;82(12):2321-5 [9635523.001]
  • [Cites] Am J Pathol. 1954 Sep-Oct;30(5):969-77 [13197542.001]
  • [Cites] N Engl J Med. 1999 Dec 30;341(27):2039-48 [10615075.001]
  • [Cites] Gan To Kagaku Ryoho. 2005 Aug;32(8):1175-7 [16121924.001]
  • [Cites] Eur J Cancer. 1995 Sep;31A(10):1594-8 [7488407.001]
  • (PMID = 19093189.001).
  • [ISSN] 1341-9625
  • [Journal-full-title] International journal of clinical oncology
  • [ISO-abbreviation] Int. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


93. Wu MH, Wu HY: A simple device for closure of a colocutaneous fistula within the laparotomy wound: a case report. Ostomy Wound Manage; 2009 Oct 15;55(10):24-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A simple device made from a silicone, flexi-aid hand exerciser was used to close a colocutaneous fistula within the laparotomy wound of a 50-year old man following surgery of an esophageal carcinoma and a surgical history of Whipple's procedure for adenocarcinoma of the ampulla of Vater.

  • MedlinePlus Health Information. consumer health - Colonic Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19864693.001).
  • [ISSN] 1943-2720
  • [Journal-full-title] Ostomy/wound management
  • [ISO-abbreviation] Ostomy Wound Manage
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


94. Komatsu S, Sonoyama T, Ochiai T, Ichikawa D, Ikoma H, Okamura H, Yamagishi H, Otsuji E: Novel interventional treatment technique for intractable pancreatic fistula due to dehiscence of pancreatico-jejunal anastomosis following pancreaticoduodenectomy. J Hepatobiliary Pancreat Surg; 2008;15(4):453-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Novel interventional treatment technique for intractable pancreatic fistula due to dehiscence of pancreatico-jejunal anastomosis following pancreaticoduodenectomy.
  • Despite recent technological advances in the treatment of hepatobiliary pancreatic disease, intractable external pancreatic fistula is still a major critical complication after pancreaticoduodenectomy, and the treatment strategy is not well defined.
  • A 62-year-old woman underwent pylorus-preserving pancreaticoduodenectomy for carcinoma of the papilla of Vater, with reconstruction by a modified Child's procedure.
  • One year later, she was readmitted to our hospital because of external pancreatic fistula.
  • Both computed tomography and fistulography demonstrated a pancreatic fistula derived from dehiscence of the pancreatico-jejunal anastomosis.
  • The pancreatic fistula persisted for 1 week with conservative management.
  • Therefore, we performed repeated fistulography and cannulation, using two comparatively stiff guidewires introduced into the main pancreatic duct and stenotic anastomosed jejunal lumen, respectively, and we placed an endoprosthesis, using bilateral guidewires to connect the two lumens.
  • Consequently, the pancreatic fistula was successfully closed within a few days.
  • Therefore, it should be considered an effective treatment strategy for persistent pancreatic fistula following pancreaticoduodenectomy that fails to respond to initial conservative management and an endoscopic approach.
  • [MeSH-major] Digestive System Surgical Procedures / methods. Pancreatic Fistula / surgery. Pancreaticoduodenectomy / adverse effects. Prostheses and Implants
  • [MeSH-minor] Ampulla of Vater. Anastomosis, Surgical. Catheterization / methods. Common Bile Duct Neoplasms / surgery. Female. Humans. Middle Aged. Prosthesis Implantation. Radiography, Interventional

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18670851.001).
  • [ISSN] 0944-1166
  • [Journal-full-title] Journal of hepato-biliary-pancreatic surgery
  • [ISO-abbreviation] J Hepatobiliary Pancreat Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


95. Kim K, Chie EK, Jang JY, Kim SW, Oh DY, Im SA, Kim TY, Bang YJ, Ha SW: Role of adjuvant chemoradiotherapy for ampulla of Vater cancer. Int J Radiat Oncol Biol Phys; 2009 Oct 1;75(2):436-41
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Role of adjuvant chemoradiotherapy for ampulla of Vater cancer.
  • PURPOSE: To evaluate the role of adjuvant chemoradiotherapy for ampulla of Vater cancer.
  • METHODS AND MATERIALS: Between January 1991 and December 2002, 118 patients with ampulla of Vater cancer underwent en bloc resection.
  • CONCLUSIONS: Adjuvant chemoradiotherapy may enhance locoregional control and overall survival in patients with ampulla of Vater cancer after curative resection, especially in those with nodal involvement.
  • [MeSH-major] Ampulla of Vater. Common Bile Duct Neoplasms / drug therapy. Common Bile Duct Neoplasms / radiotherapy
  • [MeSH-minor] Adult. Age Factors. Aged. Antimetabolites, Antineoplastic / administration & dosage. Chemotherapy, Adjuvant. Disease-Free Survival. Female. Fluorouracil / administration & dosage. Humans. Lymphatic Irradiation. Lymphatic Metastasis / radiotherapy. Male. Middle Aged. Neoplasm Staging. Proportional Hazards Models. Radiotherapy Dosage. Radiotherapy, Adjuvant. Retrospective Studies. Survival Rate

  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19394162.001).
  • [ISSN] 1879-355X
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; U3P01618RT / Fluorouracil
  •  go-up   go-down


96. Menon KV, Gomez D, Smith AM, Anthoney A, Verbeke CS: Impact of margin status on survival following pancreatoduodenectomy for cancer: the Leeds Pathology Protocol (LEEPP). HPB (Oxford); 2009 Feb;11(1):18-24
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Impact of margin status on survival following pancreatoduodenectomy for cancer: the Leeds Pathology Protocol (LEEPP).
  • BACKGROUND: In a previous study we reported an 85% R1 rate for pancreatic cancer following the use of the rigorous, fully standardized Leeds Pathology Protocol (LEEPP).
  • METHODS: Clinicopathological features, including exact site and multifocality of margin involvement, and survival were collated from a prospective series of 83 pancreatoduodenectomies for pancreatic (n = 27), ampullary (n = 24) and bile duct cancer (n = 32).
  • RESULTS: The R1 rate was high in pancreatic (82%) and bile duct (72%) cancer and significantly lower in ampullary cancer (25%).
  • Margin status correlated with survival in the entire cohort (P = 0.006) and the pancreatic subgroup (P = 0.046).
  • CONCLUSIONS: Margin involvement in pancreatic cancer is a frequent and prognostically significant finding when specimens are assessed using the LEEPP.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Histopathology. 2008 Jun;52(7):787-96 [18081813.001]
  • [Cites] Ann Surg Oncol. 2008 Jun;15(6):1651-60 [18351300.001]
  • [Cites] Arch Surg. 2008 Jan;143(1):75-83; discussion 83 [18209156.001]
  • [Cites] J Gastrointest Surg. 2007 Nov;11(11):1549-55 [17786531.001]
  • [Cites] Ann Surg. 2007 Jul;246(1):52-60 [17592291.001]
  • [Cites] Br J Surg. 2006 Oct;93(10):1232-7 [16804874.001]
  • [Cites] Pancreas. 2006 Jan;32(1):37-43 [16340742.001]
  • [Cites] Gut. 2005 Mar;54(3):385-7 [15710987.001]
  • [Cites] J Hepatobiliary Pancreat Surg. 2004;11(6):402-8 [15619016.001]
  • [Cites] J Gastrointest Surg. 2004 Dec;8(8):935-49; discussion 949-50 [15585381.001]
  • [Cites] Br J Surg. 2004 Nov;91(11):1410-27 [15499648.001]
  • [Cites] Am Surg. 1999 Jul;65(7):618-23; discussion 623-4 [10399969.001]
  • [Cites] Ann Surg. 1998 Jun;227(6):821-31 [9637545.001]
  • [Cites] Ann Surg. 1997 Sep;226(3):248-57; discussion 257-60 [9339931.001]
  • [Cites] Br J Surg. 1996 May;83(5):625-31 [8689203.001]
  • [Cites] Cancer. 1996 Feb 15;77(4):640-5 [8616755.001]
  • [Cites] Ann Surg. 1995 Jun;221(6):721-31; discussion 731-3 [7794076.001]
  • [Cites] Cancer. 1995 Apr 15;75(8):2069-76 [7697596.001]
  • [Cites] Ann Surg. 1995 Jan;221(1):59-66 [7826162.001]
  • [Cites] Cancer. 1993 Oct 1;72(7):2118-23 [8104092.001]
  • [Cites] Ann Surg. 1993 Feb;217(2):144-8 [8094952.001]
  • [Cites] Hepatogastroenterology. 1993 Aug;40(4):384-7 [8406311.001]
  • [Cites] Am J Surg. 1993 Jan;165(1):68-72; discussion 72-3 [8380315.001]
  • [Cites] Ann Surg. 1986 Jan;203(1):77-81 [3942423.001]
  • [Cites] Br J Surg. 2004 May;91(5):586-94 [15122610.001]
  • [Cites] Am Surg. 2004 Mar;70(3):235-40; discussion 240 [15055847.001]
  • [Cites] Eur J Cancer. 2004 Mar;40(4):549-58 [14962722.001]
  • [Cites] Pancreas. 2003 Apr;26(3):243-9 [12657950.001]
  • [Cites] Ann Surg. 2001 Dec;234(6):758-68 [11729382.001]
  • [Cites] Eur J Surg Oncol. 2001 Sep;27(6):549-57 [11520088.001]
  • [Cites] J Gastrointest Surg. 2001 Mar-Apr;5(2):121-30 [11331473.001]
  • [Cites] J Gastrointest Surg. 2000 Nov-Dec;4(6):567-79 [11307091.001]
  • [Cites] Chir Ital. 2000 May-Jun;52(3):263-70 [10932371.001]
  • [CommentIn] HPB (Oxford). 2009 Feb;11(1):2-3 [19590617.001]
  • (PMID = 19590619.001).
  • [ISSN] 1365-182X
  • [Journal-full-title] HPB : the official journal of the International Hepato Pancreato Biliary Association
  • [ISO-abbreviation] HPB (Oxford)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2697870
  • [Keywords] NOTNLM ; cancer / margin / pancreas / resection / survival
  •  go-up   go-down


97. Akatsu T, Aiura K, Takahashi S, Kameyama K, Kitajima M, Kitagawa Y: Recurrent pancreatitis caused by ampullary carcinoma and minor papilla adenoma in familial polyposis: report of a case. Surg Today; 2008;38(5):440-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recurrent pancreatitis caused by ampullary carcinoma and minor papilla adenoma in familial polyposis: report of a case.
  • A 58-year-old man who had undergone total colectomy for FAP 18 years earlier was hospitalized for carcinoma arising from the residual rectum.
  • He had severe diabetes mellitus, but had no symptoms of pancreatic exocrine dysfunction.
  • Upper endoscopy showed multiple duodenal adenomas including carcinoma involving the papilla of Vater.
  • To remove these duodenal adenomas and ampullary carcinoma and prevent recurrent pancreatitis, we performed pancreaticoduodenectomy.
  • On pathologic examination, the major duodenal papilla was completely obstructed by the carcinoma, and the minor papilla was also involved by the adenoma.
  • [MeSH-major] Adenocarcinoma / etiology. Adenoma / etiology. Adenomatous Polyposis Coli / complications. Ampulla of Vater. Common Bile Duct Neoplasms / etiology. Pancreatic Neoplasms / etiology. Pancreatitis / etiology
  • [MeSH-minor] Humans. Male. Middle Aged. Pancreatic Ducts. Pancreaticoduodenectomy. Recurrence